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ABSTRACT
 Since the initial characterization of the human glucose transporter GLUT1, it has been 
observed that the presence of intracellular sugar stimulates the unidirectional rate of sugar uptake 
by a kinetic phenomenon known as trans-acceleration. Both GLUTs 1 and 3 catalyze trans-
acceleration, while both GLUTs 2 and 4 do not. Although the basis for trans-acceleration is 
unknown, potential explanations include the requirement of a modulating cofactor, cellular 
context, or that the behavior is an artifact of imperfect transport measurements. This thesis 
examines whether trans-acceleration is a sequence-specific property intrinsic to the transporter. A 
method for detecting trans-acceleration in mammalian cells at physiologic temperature was 
developed through transport of two different glucose analogs. Homology-scanning mutagenesis 
was employed to exchange transmembrane domains (TMs) of GLUTs 1 and 4, and thereby test 
for accelerated-exchange loss- or gain-of-function. This approach was extended to GLUTs 2 and 
3. The catalytic rates of these chimeric proteins were determined through transport measurements 
and expression measured by cell-surface biotinylation. These studies show that the sequence of 
putative scaffolding domain TM6 is both necessary and sufficient for trans-acceleration in 
scaffolds of GLUT1, GLUT2, and GLUT4. The substitution of TM6 sequence between these 
transporters has no effect on the turnover under exchange conditions, yet profoundly modifies 
turnover in the absence of intracellular sugar. We propose that the sequence-specific interaction of 
TM6 with other TMs structurally restrains relaxation of the empty carrier in GLUTs which 
catalyze trans-acceleration, and that binding of intracellular sugar affects these interactions to 
reduce the overall duration of the transport cycle. In addition, our model suggests that the 
substrate binding constant and rate of carrier relaxation are inter-dependent. In this model, the 
dissociation constant determined by substrate binding and dissociation rates at the endofacial 
sugar binding site must be larger than the equivalent constant at the exofacial site in order for 
trans-acceleration to occur. 
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CHAPTER I
Introduction and Literature Review
Metabolism and Homeostasis
 One of the most basic needs of all life forms is energy in the form of ATP. This 
energy is required for nearly all life-sustaining functions including growth, movement, 
and catabolic and anabolic processes. The generation of ATP is the result of a breakdown 
of nutrients derived from a variety of sources, particularly from dietary intake. At the 
cellular level, some of the simplest inputs for processes to generate ATP are 
monosaccharides, or sugars. Fructose and glucose are the predominant dietary sugars in 
mammals. Overall carbohydrate homeostasis reflects a balance between sugar import, 
utilization, synthesis, secretion and excretion.
Glucose is rapidly converted into ATP by both aerobic and anaerobic pathways. 
This energy may be consumed immediately or stored for later use, in the form of 
glycogen or triglycerides. When external sugar is unavailable, these complex 
carbohydrate and lipid stores can be used to generate glucose through gluconeogenesis. 
A host of environmental factors, including the supply and demand of glucose, impact the 
utilization of aerobic or anaerobic metabolic pathways in the cells and tissues within the 
body. Therefore, glucose homeostasis is an essential cellular and organismal function and 
involves a complex interplay of metabolic, hormonal, and neural pathways.
1
Just as there must be a balance between the consumption, metabolism, and supply 
of nutrients in the body, there must also be a balance between the uptake, reabsorption, 
and output of glucose and other metabolites in the blood, brain, and various organs. This 
is achieved by a diverse set of transporters, mainly the facilitative glucose transporters 
(GLUTs), sodium-linked glucose transporters (SGLTs), and monocarboxylate transporters 
(MCTs), of which the GLUTs and MCTs are part of the Major Facilitator Superfamily 
(MFS).
Integral Membrane Transporters
 While small, non-polar solutes may enter the cell by simple diffusion across the 
plasma membrane, larger or charged molecules require membrane-spanning proteins, 
such as pores, ion channels, or transporters, to gain entry into the cell. This may be 
achieved through passive transport, also known as facilitated diffusion, whereby 
molecules flow down their concentration gradient across the plasma membrane. In 
contrast, molecules may be moved against their concentration gradient through active 
transport. Primary active transport requires the input of ATP, while secondary active 
transport requires the presence of an electrochemical gradient. This allows a molecule to 
be transported against its concentration gradient when it is coupled to the transport of 
another molecule down its concentration gradient. This can occur with both molecules 
moving in the same direction (co-transport or symport) or in opposite directions 
(exchange or antiport). 
2
 Transporters appear to differ fundamentally from ion channels or pores in that 
they must undergo a conformational change in order to translocate substrate across the 
plasma membrane. This occurs after substrate binding at a specific site, which is often 
accessible when the carrier is in either of two conformations: endofacial (cytoplasmic; e1 
conformation) or exofacial (extracellular; e2 conformation). The carrier (whether empty 
or substrate-bound) is in the transitional occluded state (e()) while it undergoes this 
conformational change, as neither substrate binding site is accessible. Although these 
characteristics distinguish membrane transporters from channels and pores, a wide 
variety of active and passive transporters with a multitude of substrates exist. These are 
grouped under two superfamilies: the Major Facilitator Superfamily (MFS) and the ATP-
Binding Cassette (ABC) superfamily, each of which comprises thousands of transporters 
expressed across all organisms (1). 
 As the larger of the two groups, the ABC superfamily is composed of 
transmembrane proteins that transport a diverse set of substrates, including 
macromolecules. Transport by ABC proteins is coupled to the binding of ATP in an 
active-transport mechanism (1). Unlike the ABC transporters, the MFS transporters are 
passive transporters whose substrates are only small molecules. As facilitative carriers, 
they are able to transport a single molecule down its concentration gradient (uniport), or 
couple transport to the concentration gradient of another molecule through symport or 
antiport. There are a variety of MFS transporters, many of which are H+-coupled 
symporters; some function as antiporters of metabolic intermediates and substrates, 
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including nucleosides, phosphates, oxalates, and sugars (2). The largest MFS group is 
that of the sugar porters (SP), comprising over 130 transporters, which transport hexoses 
in a variety of organisms (3). 
 Although all members of the SP family are similar in that they contain either 12 or 
14 membrane spanning domains (TMs) and cytoplasmic N- and C-termini, they vary in 
size, tissue-specific distribution, and specificity for substrate(s). For example, expression 
of the monocarboxylate transporters (MCTs; (4)) in mammalian erythrocytes, neurons, 
and cells of the muscle, liver, and kidney is essential for the export and uptake of the 
critical metabolites pyruvate and lactate. An integral component of blood glucose 
homeostasis includes the reabsorption of glucose from plasma in the small intestine and 
kidney, where a family of sodium-glucose linked transporters (SGLTs; (5)) uses the 
intracellularly-directed Na+ gradient to catalyze the net uphill flow of glucose from the 
lumen to the cytoplasm. However, export of epithelial cell glucose to the interstitium is 
mediated by the solute-linked carrier 2A gene family (SLC2A) of facilitative glucose 
transporters (GLUTs (6)), which accelerate the net downhill flow of glucose across cell 
membranes.
 The GLUTs are classified as uniporters because they are able to transport sugar 
through uptake or export without requiring the presence of sugar at the opposite trans 
side of the membrane. They are also capable of coupling import of one sugar molecule to 
the export of a second sugar molecule (antiport), but unlike some other MFS transporters, 
GLUTs are not obligate antiporters. Only one of the GLUTs (GLUT13 or HMIT, the H+/
4
myoinositol symporter) displays symport, where the movement of one molecule 
(myoinositol) against its concentration gradient is driven by co-transport of another 
molecule down its concentration gradient (in this case, H+). 
GLUT Classes I-III
 To date, fourteen members of the human GLUT family have been identified (7), 
GLUTs 1-14. With the exception of GLUT1, which is known as the basal glucose 
transporter due to its ubiquitous expression, the GLUTs are expressed in a highly tissue-
specific manner (Table 1.1).  The numbering of the GLUTs is mostly based on the advent 
of their discovery and cloning, beginning with the identification of GLUT1 more than 30 
years ago (8), (9). The transporters have been grouped into 3 classes based on sequence 
similarity (10), and to a lesser extent, substrate specificity.
 The Class I transporters, comprising GLUTs 1-4, show 48-63% sequence identity 
with one another. This class of GLUTs has been the most extensively studied and 
characterized, particularly GLUT1, which was first cloned in 1985 (11). While GLUT1 is 
found in all tissues, it is most highly expressed in red blood cells (erythrocytes, (12)), in 
the vascular endothelia at blood-tissue barriers such as the brain, retina, and placenta 
(13), (14), and in CNS astrocytes (15). GLUT2 (16) is critical for glucose transport in 
hepatic metabolic processes, although its detection has been extended to the pancreas and 
small intestine (17). More recently, a role has emerged for GLUT2 in glucose sensing
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Table 1.1  Tissue Specific Expression of Class I-III Human Glucose Transporters 
  (GLUTs) 
  
TRANSPORTER CLASS TISSUE-SPECIFIC EXPRESSION 
GLUT 1 I Ubiquitous; particularly erythrocytes and endothelia, astrocytes 
GLUT 2 I Liver, pancreas, kidney and small intestine 
GLUT 3 I Neurons, leukocytes, sperm, and embryo 
GLUT 4 I Adipocytes and skeletal/cardiac muscle 
GLUT 5 II Intestine, testis, kidney, skeletal muscle, adipose, and brain. 
GLUT 6 III Brain and spleen  
GLUT 7 II Small intestine and colon 
GLUT 8 III Testis, brain, adipose, liver, and spleen 
GLUT 9 II Kidney, liver, placenta, lung, and small intestine 
GLUT 10 III Heart, lung, brain, liver, skeletal muscle, pancreas, placenta and kidney 
GLUT 11 II Heart, skeletal muscle, kidney, adipose, placenta and pancreas 
GLUT 12 III Heart, skeletal muscle, adipose, and prostate 
GLUT13 (HMIT) III Brain 
GLUT 14 (duplicon of 
GLUT3) 
I Testes 
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mechanisms and feeding response (18), (19). The expression of GLUT3 (20) is high in 
neurons (21), where it plays an important role in delivery of glucose to these 
metabolically active brain cells. GLUT14, which is nearly identical (~96%) in sequence 
to GLUT3 and is thought to be a gene duplication, has only been found to be expressed in 
the testis (22). GLUT4 (23), in contrast, is expressed mostly in adipose tissue and skeletal 
muscle, where the majority of the transporter resides in intracellular pools until its 
presence at the cell surface is stimulated by muscle contraction or insulin. 
 The class I transporters transport glucose and galactose, and with the exception of 
GLUT2, also transport dehydroascorbic acid (DHA), the oxidized form of vitamin C 
(23), (24), (25), (26). GLUT2, the only low-affinity Class I glucose transporter (27), 
transports glucosamine with high-affinity and also transports fructose. All Class I 
transporters are also sensitive to the compound cytochalasin B (CCB), which can non-
competitively inhibit transport (28), (29). 
 Unlike Class I, the members of Class II are primarily fructose transporters, and 
mostly are insensitive to inhibition by CCB. Class II transporters comprise GLUTs 5, 7, 
9, and 11, which show 36-40% sequence identity with one another.  GLUT5 (30), (31) is 
primarily responsible for reabsorption of fructose in the small intestine, where it may be 
aided by GLUT7 (32), (33), which is also highly expressed in the testis and prostate. Both 
GLUT9 (34) and GLUT11 (35) have several splice variants that affect their expression. 
Of the two splice variants of GLUT9, GLUT9a is localized to the basolateral membrane 
of kidney proximal tubules, while GLUT9b is localized to the apical membrane (36), 
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(37), (38). Recently, GLUT9 has been shown to transport urate in high capacity, with the 
ability to exchange urate for glucose or fructose (39). Of the three isoforms of GLUT11, 
the first (GLUT11A) is expressed in the kidney and cardiac/skeletal muscle; GLUT11B is 
found in hepatic, adipose, and placental tissue; and GLUT11C is expressed in cardiac/
skeletal muscle and adipocytes (40), (41), (42). Currently, the role of GLUT11 in 
metabolic homeostasis is not well understood.
 The least-characterized GLUTs are also the least similar to one another in 
sequence, with 19-41% sequence conservation. These are the Class III transporters, 
comprising GLUTs 6, 8, 10, 12, and HMIT. The members of Class III are more similar to 
Class I in that they are primarily glucose transporters, although there is recent evidence of 
GLUT8-mediated fructose transport in enterocytes (43). GLUT8 has also been shown to 
transport glucose with high affinity (17), as has GLUT10 for glucose and galactose (44). 
While not all Class III GLUTs have been investigated, GLUT8 has shown sensitivity to 
CCB (45). Some Class III transporters, particularly GLUT6 (46), GLUT8 (45), (17), and 
GLUT12 (47) also contain targeting sequences that keep them sequestered in different 
compartments within the cell, where they may have specific functions. For example, 
GLUT8 has been shown to mediate glucose exit from the endoplasmic reticulum into the 
cytoplasm in neurons (48). Although GLUTs 6 and 8 do not appear to translocate to the 
plasma membrane in response to hormonal stimuli (49), GLUT12 may be another 
insulin-responsive transporter (50). GLUT13 (HMIT) has been shown to be expressed 
primarily in the brain (51), where it transports myoinositol, a critical second messenger 
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molecule and phospholipid precursor. At this point in time, the precise roles of some of 
the class III transporters remain unclear (52). 
GLUT-based Mutations and Disease
 Because one or more of the GLUTs is expressed in every cell in the body, 
mutations to GLUT-encoding genes or factors affecting transporter localization can have 
major consequences for metabolism of certain sugars or proper function and homeostasis 
of different organ systems. 
 For example, mutations to the basal transporter GLUT1 can have severe effects on 
development and brain function. GLUT1-haploinsufficiency, or G1DS (53), is a rare 
autosomal dominant genetic disorder with approximately 100 known cases (54), some of 
which are familial (55), (56). Different mutations in the GLUT1 gene have varying 
effects on the ability of the protein to transport glucose, which is particularly detrimental 
to cerebral glucose supply. Phenotypes of the disorder include high levels of lactic acid, 
causing seizures and delays in development. Some of these effects can be offset by 
lifelong adherence to a ketogenic diet (57), if detected early enough.
 Similarly, Fanconi-Bickel syndrome is present in a small number of individuals 
with autosomal recessive mutations to the GLUT2 gene (58), (59), some of which 
completely abrogate the transport capability of GLUT2. This results in the inability of 
these individuals to ingest simple sugars. Fanconi-Bickel syndrome is characterized by 
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slowed growth, hypoglycemia, enlarged liver, and kidney damage, which may result from 
impaired ability to reabsorb sugar from urine (60).
 More globally, a role for GLUTs as markers for cancer has been under 
investigation for many years, as upregulation of certain GLUTs (61) is necessary for the 
increased metabolism and rapid cell growth characteristic of many cancers (62). GLUT1 
and/or GLUT3 are highly upregulated in several tumor types, including breast, skin, 
ovarian, cervical, kidney, brain, lung, and colorectal cancers (63), (64), (65), (66), (67), 
(68), (69), (70). There is a potential role in cancer metabolism for GLUT12, which was 
identified in mammary and prostate cancer cells (71), (72), and is upregulated in cancer 
lines in response to hormonal stimulation (73). 
 Hormonal control of glucose transport is also central to metabolic disorders. For 
example, diabetes is a chronic metabolic disorder that affects over 300 million people 
worldwide. In type 1 diabetes, a loss of pancreatic β cell mass or function results in 
cessation of insulin production, while in type 2 diabetes, cells become resistant to 
secreted insulin. The effect of either disease state is hyperglycemia, with long-term 
complications such as damage to the cardiovascular tissues, kidneys, and nervous system. 
A role for GLUT4 regulation in type 2 diabetes is still under active investigation, as the 
vast majority of glucose uptake in response to insulin is due to an increase in GLUT4 at 
the plasma membrane in muscle cells (74), (75), (76). Loss of this insulin-stimulated 
GLUT4 translocation is a hallmark of insulin resistance, an early pathology in the 
development of type 2 diabetes (77). Studies in transgenic mice have shown that 
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alterations to GLUT4 (78) or the pathways signaling its trafficking result in higher 
plasma levels of insulin and glucose (79). Knockouts of muscle or adipose cell type-
specific GLUT4 result in defective endocrine signaling, which perturbs the normal 
physiological responses to feeding – namely increased glycogen synthesis and inhibition 
of liver gluconeogenesis – further contributing to insulin resistance and elevated blood 
glucose (80), (81). Such chronic hyperglycemia is damaging to organs and further 
impairs the ability of tissues to maintain glucose homeostasis through normal sensing and 
counter-regulatory responses (72). 
 Manipulation of GLUT4-mediated glucose transport is further linked to metabolic 
disorders through side effects observed with medications. Some of the protease inhibitors 
commonly prescribed to HIV-patients, such as indinavir, have been shown to directly 
interact with GLUT4 (82), (83). Over time, this results in development of metabolic 
syndrome in many of these patients, which is characterized by increased blood glucose 
levels, triglycerides, and cholesterol; abdominal adiposity, hypertension, and risk of type 
2 diabetes and cardiovascular disease (84), (85), (86), (87). There is also an increased 
prevalence for patients with these types of metabolic disorders to show hyperuricemia, 
the condition of elevated levels of uric acid in the blood leading to gout (88). Linking 
plasma urate levels to allelic variance led to the discovery of GLUT9 (89), which was 
recently functionally characterized as a urate transporter (39), (90), expanding the 
importance of GLUT-mediated urate homeostasis in disease (91).
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 Clearly, there are numerous established and potential roles for GLUTs in the 
pathologies of a broad spectrum of metabolic diseases and syndromes. As the gatekeepers 
for cellular hexose entry and exit throughout the body, GLUTs are an integral part of 
metabolic processes, both normal and disordered. As such, GLUTs remain potential 
therapeutic targets, particularly in diabetes and cancer. If manipulation of GLUT 
expression, function, and regulation are to be viable strategies, these processes first must 
be clearly understood through rigorous study.
Common Topology and Motifs
 In order to characterize differences in functional properties of the glucose 
transporters, it is helpful to compare their sequence and structural attributes. Like many 
of the MFS transporters, while they do not share a high degree of sequence conservation 
(25-68%), all of the 14 mammalian GLUTs share similar topology. Hydropathy analysis 
predicts a total of 12 trans-membrane spanning α-helices (TMs) (11), (92), which was 
confirmed by scanning glycosylation mutagenesis (93), FTIR (94) and CD (95) 
spectroscopy analysis. Within the 12 TMs, there is symmetry between TMs 1-6 and TMs 
7-12, which may be the result of gene duplication early in GLUT evolution (96). The first 
6 TMs are connected to the last 6 by a long intracellular loop known as loop 6 (see Figure 
1.1). The length of each GLUT is variable, with an average sequence length of 
approximately 500 amino acids. GLUT1 is 492 residues with a molecular weight of 
~55kDa, while GLUT8 is the smallest (477 residues) and HMIT is the largest, at 648
12
Figure 1.1  Putative topology of human GLUT1
The 12 transmembrane TM domains of the transporter are shown as a cross-section 
through the membrane, with the same coloring scheme as the TMs in Figure 1.2. Both the 
N- and C-termini are cytoplasmic, as is the large loop (loop 6) connecting TMs 6 and 7. 
The single glycosylation site on loop 1 (asn 45) is indicated.
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amino acids. Differences in length tend to result from variations in the length of the N- 
and C-termini and the loops connecting the TMs, while the length of each TM is more 
similar across the GLUT family members. Indeed, the 12 TMs are the regions of the 
protein that have the highest sequence conservation among the GLUTs (10). 
 The regions with the highest degree of sequence divergence among the GLUTs 
are thus the N- and C-termini and loops connecting the TMs, in particular loops 1 and 9 
(10). A single N-linked glycolsylaton site is present in one of these two loops; in Class I 
and II, loop 1 is glycosylated (GLUT1, asn 45; (97)), while Class III transporters are 
glycosylated on loop 9. Although the other GLUTs have not been as extensively 
characterized as GLUT1, the heterogeneous glycosylation of GLUT1 has been linked to 
its transport ability (98). There are several conserved sequence motifs among the GLUTs, 
including PMY (TM4), PESPRY/FLL (loop 6), GRR (loop 8), VPETKG (C-terminus), 
and QQLSGIN (TM7). Transporter selectivity for fructose appears to be due to critical 
hydrophobic residues in TM7, as has been shown in GLUTs 2, 5, 7 (99), 9, and 11 (100).  
 Although GPGPIP/TW (TM10) is also conserved, the class II GLUTs lack the Trp 
residue, which has been shown to be critical for sensitivity to the compounds CCB and 
forskolin, both transport inhibitors of the class I GLUTs (101). Presence of the Trp in 
TM10 may have a direct role in CCB inhibition, as both this motif and sensitivity to CCB 
are absent in the Class II transporters (102). While Class III GLUTs contain the TM10 
Trp, investigation of their inhibitor profiles is incomplete. A different Trp in TM11, which 
is conserved in all GLUTs, is critical for the proper localization and function of GLUT1 
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(103). Several studies investigating the importance of conserved residues GLUT1 and 
GLUT4 have shown loss of glucose transport ability with point mutations in loop 2 
(R92), loop 4 (R153), loop 7 (Y293), loop 8 (RR 333-334; E329), TM10 (P385), and 
loop 10 (E393; R400) (104), (105), (106), (107).
 Although many of the studies referenced above draw from comparative sequence 
analysis across all of the 14 GLUTs, the vast majority of functional characterization has 
focused on the Class I glucose transporters, particularly GLUT1 and GLUT4. This is due 
in part to the earlier discovery and cloning of the Class I members. The abundance and 
ability to purify relatively large amounts of GLUT1 protein from erythrocytes has also 
aided in its characterization. Many efforts have focused on analysis of the surface 
expression and trafficking of GLUT4 in response to insulin, due to its importance in 
diabetic metabolism. More recently, the importance of GLUT3 in brain metabolism has 
emerged, prompting analysis of the cooperative roles of GLUT3 with other transporters, 
such as GLUT1 at the blood-brain barrier and MCTs in lactate transport among astrocytes 
and neurons (108), (109). Although initially characterized as a hepatic glucose 
transporter, GLUT2 has an emerging additional role as a critical glucose sensor in 
counter-regulation, poised to mediate metabolic signaling at the neuronal/endocrine axis 
(110), (111). Though the importance of the Class II and Class III glucose transporters is 
undisputed, their individual functions are less well characterized and are the subject of 
current investigation. Because most of our structural and functional knowledge of glucose 
transporters relies upon analysis of the Class I GLUTs, they are the focus of this work.
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Class I GLUT Tertiary Structure
 Although common putative topology and sequence motifs exist among the 
glucose transporters, a crystal structure for a member of this family has yet to be solved. 
In the absence of such data, it is difficult to predict the spatial arrangement of TMs and 
their interactions during various conformational states of the transport cycle. However, 
structures displaying similar architecture have been solved for several homologous MFS 
bacterial transporters (96), including a cryo-EM structure of the oxalate transporter 
(OxIT (112)), and crystal structures of the lactose permease symporter (LacY (113)) and 
the glycerol-3-phosphate antiporter (GlpT (114)). Through homology-modeling the 
sequences of GLUTs 1, 3, and 4 on these bacterial transporter crystal structures, studies 
have proposed putative models of GLUT tertiary interactions. 
 Analysis of GLUT1 structure has been performed based on both LacY (115) and 
GlpT (116), with the GlpT-based model achieving better statistical scores. These studies 
juxtapose TMs 1, 2, 4, 5, 7, 8, 10, and 11 in a symmetrical arrangement, forming a 
central, water-filled sugar translocation channel coordinated by the scaffolding TMs 3, 6, 
9, and 12 (see Figure 1.2; (116)). The proposed structure for GLUT3 (117) is based on the 
crystal structure of the channel protein MscL (118) and, more loosely, on the low-
resolution structure of the pore aquaporin (119). While this model proposes a similar 
overall architecture in that several TMs are arranged to form a central transport cavity, the 
putative translocation pore is formed by only TMs 5, 7, 9, and 11. 
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Figure 1.2 Threaded model of human GLUT1 based on homology-
modeling with the GlpT crystal structure 
A, Cross-sectional view of the 12 transmembrane (TM) spanning α-helices 
in the plasma membrane, colored corresponding to the color scheme in B, 
based on the homology modeling of GLUT1 on GlpT (Salas-Burgos et al., 
2004). B, Cartoon diagram of the 12 TMs arranged spatially, looking up 
through the transporter from inside the cell, where the cytoplasmic loop 6 
(connecting TMs 6 and 7), N- and C-termini are indicated by blue lines. The 
translocation pore is formed by TMs 1, 4, 7, and 10 (magenta) with TMs 2, 
11, 5, and 8 (blue). The remaining TMs 3, 6, 9, and 12 (green) are positioned 
as scaffolding domains coordinating the arrangement of the TMs involved in 
sugar binding and translocation.
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While the general TM arrangement is somewhat similar to the GLUT1 modeling, there 
are a disparate number of TMs between GLUT3 (12 TMs) and the scaffold proteins 
(MscL has 10 TMs; aquaporin has 6 TMs), neither of which is an MFS transporter. The 
docking studies of GLUT4 (120), (121), however, were also performed based upon the 
GlpT crystal structure. The proposed GLUT4 structure agrees with the spatial 
arrangement of the other GLUT homology models, showing interactions between glucose 
and putative translocation-channel TMs 1, 5, and 11, with helical interactions between 
TMs 1-5 and 2-4, respectively. However, one caveat of the GLUT3 and GLUT4 models 
is that both are partially based on biochemical data obtained for GLUT1, despite 
sequence agreement among the transporters of 63% or less. However, the GLUT4 model 
was extended with molecular dynamics simulations of not only substrates and inhibitors 
common to the Class I GLUTs, but also of GLUT4-specific inhibitors (121). 
 While both the LacY and GlpT structures were crystallized in the endofacial 
conformation, other MFS homologs have been crystallized in the exofacial conformation 
(fucose transporter, FucP; (122)) and an intermediate conformation (multi-drug 
transporter, EmrD; (123)). Further modeling of GLUT1 based on these scaffolds may 
provide insight on helix-packing and TM arrangements in these orientations, with 
implications for modeling the substrate-bound or occluded empty carrier during 
conformational transitions. 
 While the putative topology of GLUT1 has been refined and tested by further 
studies probing the accessibility of regions of the protein by various methods, these data 
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must also be used to assess the homology-threaded structure presented above. Several 
point mutations in GLUT1 shown to be critical to glucose transport based on 
investigation of residues involved G1DS (124), (125) or mutagenic structural studies 
(103), (126), (127), (128), (129) are indeed positioned within the sugar translocation pore 
in the GlpT-based model (116). Exposure of the TM-TM connecting loops has been 
analyzed by scanning glycosylation mutagenesis (93). Exposed lysine residues were 
analyzed by accessibility to proteolytic cleavage and modification by various probes 
(130), revealing that TMs 1 and 8 readily dissociate from the membrane upon being 
released from the rest of the scaffold. Extensive cysteine-scanning mutagenesis studies 
support the putative arrangement of the TMs in the model presented above, particularly 
that TMs 3, 6, 9, and 12 are outer (scaffolding) helices (131), (132), (133), (134), and that 
TM8 is part of the sugar translocation pore (135). However, some of these studies also 
show accessibility in regions that are not predicted to be accessible by the model (136). 
 A study aimed at testing the accuracy of MFS homology modeling compared the 
modeling of GlpT on the crystal structure of LacY to the actual crystal structure of GlpT 
as a proof of concept (137). The results suggest that while the GlpT-based GLUT1 model 
is consistent with overall TM arrangement and topology, it is insufficient to predict 
positioning of individual residues and side chains, and hence interactions among specific 
residues within the TMs and loops. This is not surprising, as GLUT1 sequence identity 
with these bacterial homologs is less than 20%. However, the sequence conservation 
among crystallized MFS proteins (LacY, GlpT, FucP, EmrD) is also only ~30%, yet all 
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solved structures show a similar architecture. In addition, the modeling of GlpT on LacY 
deliberately excluded any experimental evidence to avoid bias (137), whereas the 
modeling of all three GLUT structures attempted to validate and even constrain proposed 
interactions with the available experimental data. In general, these results are in good 
agreement with the homology-modeled structures, with the exception of the putative 
endofacial binding site of the inhibitor CCB in the GLUT1 model (116). 
 While the accuracy and utility of homology-modeled structures can be debated 
from either viewpoint, the reality exists that without a GLUT crystal structure, homology 
modeling and refinement based on additional experimental evidence is the only avenue 
currently available to explore the structure-function relationships in glucose transporters. 
As definitive characterization of GLUT tertiary structure has eluded the field, so too has 
an understanding of interactions between multiple GLUT subunits, and thus the potential 
role of oligomerization in catalytic function.
Class I GLUT Quaternary Structure
 To date, the oligomeric state(s) of GLUT1 have been the most studied. While 
GLUT1 dissociates to a molecular weight consistent with a monomer when resolved on a 
denaturing gel (8), a variety of other studies suggest it exists in a higher order oligomeric 
state. Based on whether or not the samples were exposed to reducing conditions, particle 
sizes consistent with dimers and tetramers have been shown by freeze-fracture electron 
microscopy (138), (139), dynamic light scattering (138), size-exclusion chromatography 
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(140), (141), (142), and co-immunoprecipitation of heterologously-expressed GLUT1-
GLUT4 fusion proteins (143). Based on the observation that GLUT3 appears to exist as a 
functional monomer or dimer ((144), Levine K, DeZutter J, and Carruthers A, in 
preparation), efforts to identify the domain(s) required for GLUT1 oligomerization by 
domain-swapping mutagenesis with GLUT3 implicate GLUT1 TM9 as a tetramerization 
motif (Levine et al., in preparation). The oligomeric state of GLUT1 may complicate 
analysis of its kinetic behavior; for example, studies aimed at defining CCB-binding 
stoichiometry support two fundamentally different oligomerization states, depending on 
whether the transporter is purified in the presence (145), (12) or absence (146), (140), 
(141) of reductant. 
 While studies employing size-exclusion chromatography analysis of the other 
Class I transporters, GLUTs 2 and 4, are ongoing (J. DeZutter and A. Carruthers, 
unpublished), their oligomerization state(s) is not yet known. Aside from the potential 
catalytic advantages of multimeric organization, the relative activity of glucose 
transporters may be affected by either direct regulation or by control of GLUT expression 
at the plasma membrane.
Regulation of Class I GLUT-mediated Transport
 GLUT1 sequence contains several nucleotide-binding motifs (GFSKLGKS111-118, 
a Walker A nucleotide binding motif; KSVLK225-229; and GRRTLHL332-338, a Walker B 
nucleotide binding motif). While depletion of intracellular ATP through metabolic stress 
21
stimulates net sugar uptake, presence of ATP has been shown to decrease both capacity 
and affinity for sugar uptake in red cells (147), (148), an effect that can be competitively 
reversed by AMP and ADP (149). The binding of ATP to GLUT1 displays cooperativity 
(150), where the binding of one molecule of ATP has an effect on the affinity of binding a 
second. As this evidence argues for a direct interaction between ATP and GLUT1, many 
studies have aimed to elucidate the region(s) of the protein involved. Utilizing analysis of 
protection by covalent modification (151) and protease accessibility (152) in the presence 
and absence of ATP, studies have determined that cytoplasmic regions in the N- and C-
termini, loop 6, and the loop connecting TMs 8 and 9 (loop 8) are implicated in ATP 
modulation of the transporter. Further investigation by alanine-scanning mutagenesis 
confirms that two residues within loop 8 are critical for ATP interaction with GLUT1 
(153). 
 This nucleotide-binding motif in loop 8 is conserved within the other Class I 
GLUTs, as well. While the specific regulation by ATP has not been investigated for these 
transporters, ATP has been shown to reduce glucose uptake in insulin-stimulated 
adipocytes, implying regulation of GLUT4-mediated transport (154). GLUT4 has shown 
sensitivity to tyrosine kinase inhibitors (155) and flavonoids (156), such as genistein and 
quercitin, which also block GLUT1 uptake by interacting with the loop 8 ATP-binding 
motif (157). An interaction between ATP and this motif in GLUT4 was modeled in a 
ligand-docking study (158), implying that direct modulation is possible for GLUT4 as 
well. While this phenomenon has not been investigated as thoroughly in GLUTs 2 and 3, 
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intestinal cells expressing GLUT2 also show inhibition of uptake by flavonoids (159). 
These studies raise the possibility that several of the glucose transporters can be regulated 
at putative nucleotide-binding domains by multiple ligands.
 Aside from direct interaction with other molecules or cofactors, the activity of 
GLUTs can be modulated through changes in how much transporter is present at the 
surface. For example, while GLUT3 is expressed at the plasma membrane in the brain, it 
is intracellular in both platelets and white blood cells. In platelets, GLUT3 is sequestered 
in α-granules until it is translocated to the surface upon stimulation by thrombin (160). In 
monocytes and β-lymphocytes, GLUT3 surface expression is triggered by insulin (161), 
(162), (163), which has also been shown to increase GLUT1 at the surface in insulin-
responsive cells (164), (165).
 GLUT4 has long been known as the ‘insulin-sensitive transporter’ due to its rapid 
release from intracellular pools to the plasma membrane upon insulin stimulation (166). 
Under basal conditions, GLUT4 is sequestered in intracellular pools by N-terminal FQQI 
(167), C-terminal dileucine (168), (169), (170), (171) and endosomal targeting 
(TELEYLGP, (172)) motifs. The hormonally-activated, reversible translocation of 
GLUT4 has been extensively studied (173), and it has been shown that insulin acts upon 
the rate of GLUT4 exocytosis through the trafficking pathways mediated by Akt/PI3K 
(phosphatidylinositide-3 kinase) (174) and Rab/GAP (GTPase Activating protein) (175). 
This results in an 8- to 20-fold increase in insulin-stimulated glucose uptake over basal 
conditions (176), (177).
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 Stimulation of other major signaling cascades, such as the protein kinase C (PKC) 
pathway, also contributes to plasma membrane localization of GLUTs. This has been 
shown with a variety of growth factors, which are able to increase surface levels of 
GLUT1 (178), (179). In addition, metabolic stress (i.e. hypoxia, exercise) also has been 
shown to cause an increase in GLUT4 surface expression through the AMP-activated 
protein kinase (AMPK) pathway (180), (181). More recently, this has been extended to 
show that acute metabolic stress increases GLUT1 cell-surface expression in endothelial 
cells (182) in an AMPK-dependent manner (183). Stimulation of transporter recruitment 
to the cell surface by both metabolic stress and insulin are capable of stimulating sugar 
transport up to 50-fold over basal rates (184). 
 While the activity of glucose transporters may be modulated by the extent of their 
expression or binding of external factors, the GLUTs possess intrinsically different 
substrate affinities and transport capabilities as well. These characteristics have been 
studied most extensively in GLUT1, particularly in red cells. Many of the classical 
kinetic assays were first established in erythrocyte experimental systems, but have since 
been extended to analyze differences in substrate transport by other GLUTs in a variety 
of cell types. 
Kinetics of GLUT-mediated Glucose Transport
 Several common experimental methods have been established to perform kinetic 
analysis of GLUT-mediated sugar transport (185), (186), (187); in all three, Vmax and Km 
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can be obtained for both sugar entry and exit under different conditions. The first, zero-
trans (ZT), describes the measurement of unidirectional uptake or efflux of a varied 
concentration of labeled sugar on one side (cis) of the cell, to another side (trans), where 
no sugar is present. For example, zero-trans uptake measures the rate of sugar import 
from the interstitium into a cell that does not contain sugar. In the second type of 
experiment, equilibrium exchange, the total concentration of sugar may be varied, but it 
is kept equal on the cis and trans sides; in this way, the rate of exchange may be 
measured while the system is at equilibrium. The third method, infinite-cis, measures 
sugar moving from a saturating concentration on one side (cis) to the other side where 
sugar is varied to saturating (trans). More commonly, in an infinite-trans experiment, the 
cell is pre-loaded with a saturating amount of sugar inside (trans), and uptake of a 
varying amount of sugar from the outside (cis) is measured. 
 The majority of sugar transport studies have focused on the class I GLUTs, and 
GLUT1 has been the most extensively characterized (188), (189), (190) due to the 
experimental advantage presented by the high expression levels of GLUT1 in 
erythrocytes and the ability to isolate and purify the transporter from these cells.  
Although transport measurements of metabolized sugars are simplified by the slower 
metabolic processes in erythrocytes compared to conventional cell lines, the kinetics of 
red blood cell transport have proven to be complex as well (184). Many systems for 
heterologous expression have been used to add to the characterization of GLUT1-
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mediated sugar transport, such as Xenopus oocytes (191), (192), (134), mammalian cell 
lines (164), (142), (24), (193), and yeast (194), (196).
 Many studies employ both radiolabeled analogs of glucose and specific inhibitors 
in order to measure and stop transport. Two widely used sugar analogs are 2-deoxy-D-
glucose (2-DG) and 3-O-methyl-D-glucose (3-MG) (29). Measurements of unidirectional 
sugar uptake are simplified by use of 2-DG, because it is phosphorylated inside the cell 
by hexokinase into 2-deoxy-D-glucose-6-phosphate (2-DG-6-P) (195), which is no longer 
a substrate for the cell. All Class I GLUTs have been shown to transport 2-DG. In 
contrast, 3-MG is not metabolized, and thus can be transported into and out of the cell 
(196). As previously referenced, the compound CCB is a potent endofacial inhibitor of 
Class I GLUT-mediated transport (Ki(app) ~0.2 µM; (28), (29)), and is often used in 
experimental studies to quench transport measurements. Other commonly used inhibitors 
include phloretin, which is thought to act at both endo- and exofacial sites (Ki(app) ~0.2 
µM; (28)); and maltose, a lower-affinity competitive exofacial inhibitor (Ki(app) ~6 mM; 
(28)). Studies employing these inhibitors and sugar analogs have aimed to characterize 
the transport capacity and affinity among the glucose transporters.
 While physiologic affinity (Km) for substrate varies with both transporter and 
substrate, the affinities for glucose and 2-DG are similar between GLUT1 and GLUT4 
(Km(app) 2-6 mM (197), (198), (199), (144) or 10-14 mM (200)). While the reported 
affinities of GLUT1 and GLUT4 for 3-MG differ in some reports (Km(app) ~20 mM for 
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GLUT1 and ~2-5 mM for GLUT4 (191), (201), (202)), other studies have shown that 
they are similar (Km(app) ~6 mM for both (203); ~4 mM for GLUT1 (204), (205)).
 One of the hallmarks of human erythrocyte GLUT1-mediated transport is 
asymmetry between the rates of sugar uptake and efflux. Both the rate and affinity of D-
glucose and 3-MG exit are ~5- to 10-fold greater than the Vmax and Km for entry under 
zero-trans conditions (206), (207). While the magnitude of asymmetry is larger at lower 
temperatures, it can be measured over the range of 4 to 37°C (207). Despite the presence 
of asymmetry in human GLUT1, the ratio of Vmax : Km is the same under zero-trans exit, 
entry, and equilibrium exchange uptake conditions. Unlike GLUT1, both GLUT2 and 
GLUT4 display symmetrical uptake and exit of 3-MG when endogenously expressed in 
rat hepatocytes (208) or in basal and insulin-stimulated adipocytes (209). Because the 
absolute affinities may vary based on the system in which the transporters are tested, the 
experimental parameters, and the temperature at which the measurements are taken, it is 
important that direct comparisons be performed. 
 While it has been observed that common methods of measuring sugar transport 
may underestimate rates in erythrocytes (210), particularly those of 2-DG transport, there 
exists a complex interplay of variables including the cell system employed, surface 
expression of the transporter, choice and concentration of sugar analog(s), time point of 
measurements, and temperature at which the measurements are performed. Some of the 
complex kinetic characteristics of GLUT1-mediated transport become more or less 
pronounced depending on these variables.
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 While the initial kinetic studies in sheep placenta were the basis for the 
differentiation between transporters and simple channels (211), emerging data of complex 
kinetic behavior in erythrocytes have been incompatible with the most basic models for 
GLUT-mediated substrate transport. Over time, a growing body of experimental evidence 
has led to the development and refinement of several transport models to explain these 
observations.
The Simple Carrier Model
 The most straightforward and oldest model for GLUT-mediated transport is the 
simple carrier (211), (212), (213), (214), which assumes that the basic catalytic unit 
comprises a single GLUT molecule. The simple carrier is capable of presenting a single 
substrate-binding cavity, which exists in either the endofacial (e1) or exofacial (e2) 
conformation (see Figure 1.3). When a single molecule of substrate is bound by the 
carrier in either conformation, the carrier undergoes a transformational change through an 
intermediate, occluded stage (e(S)). The substrate-binding cavity then reorients to face 
the opposite side from which the substrate was bound, and the substrate dissociates from 
the transporter, generating an empty carrier in the opposing conformation. One cycle of 
this unidirectional movement of substrate is known as translocation. In the instance of 
translocation of a sugar molecule into the cell, the empty carrier is now in an endofacial 
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Figure 1.3  The Simple Carrier model for transport
The simple carrier may present 1 of 3 conformations at any instant: e2, exposing 
an exofacial sugar binding site; e(), an intermediate state in which neither surface 
of the carrier exposes a sugar binding site and where a central cavity is occluded 
from extra- and intracellular water; and e1, exposing an endofacial sugar binding 
site. These 3 states reversibly inter-convert as e2 ⇌ e() ⇌ e1. When extracellular 
sugar (So) or intracellular sugar (Si) is complexed to e2, e(), or e1 (denoted as e.S2, 
e(S), or e.S1, respectively), the inter-conversions are termed “translocation.” 
When no sugar is bound, the inter-conversions are termed “relaxation.”
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(e1) conformation. In order to bind a second molecule of sugar on the outside of the cell, 
the substrate-binding cavity must first reorient to the exofacial (e2) state. This can occur 
through one of two pathways. If the carrier remains empty, it must undergo “relaxation,” 
in which it isomerizes from the e1 to the e2 conformation via e(). Alternately, if 
intracellular sugar is present, the e1 conformer can become complexed with another 
molecule of sugar (to form e.S1), undergo reorientation via e(S) to form e.S2, and release 
the bound sugar at the exterior of the cell to regenerate e2. Because this second pathway 
involves translocation of a substrate, it is called “translocation,” not relaxation. However, 
the simple carrier is not compatible with all experimentally observed transport, 
particularly in erythrocytes. Studies have shown that the endofacial inhibitor CCB is able 
to inhibit transport at the same time as the extracellular inhibitor maltose (215). The 
simple carrier model is incompatible with the apparent binding of both endo- and 
exofacial ligands simultaneously.
The Fixed-Site Carrier Model
 An alternate model of the single subunit-based carrier is the fixed-site carrier (see 
Figure 1.4; (262)). This model posits a higher-affinity exofacial binding site and a lower-
affinity endofacial binding site, allowing for the greater Vmax and Km observed for sugar 
exit than entry under saturating extracellular sugar concentrations (206), (216), (217). 
The fixed-site carrier model differs in that the carrier presents both endo- and exofacial 
(e1 and e2) binding sites simultaneously. 
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 Figure 1.4  The Fixed-Site Carrier model for transport
The fixed site carrier simultaneously presents two sugar binding sites, endofacial 
(e1) and exofacial (e2), and a central cavity. The central cavity is large enough to 
permit 2 sugar molecules to pass in opposite directions. Dissociation of sugar 
from e2 to the cavity and subsequent association with e1 is called exchange (top 
cycle). When e1 and e2 are occupied by sugar, exchange of bound sugar with 
cavity sugar is called “geminate exchange” (bottom cycle). 
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This would allow sugar or inhibitors to bind the transporter on both sides at the same time 
and be taken up into a central cavity, where the molecules could exchange past one 
another to cis- and trans- binding sites within the cavity, upon which they would 
dissociate from the carrier and be released to the opposite side of the membrane.
 The fixed-site carrier explains how the Vmax for exchange can be equal for two 
substrates with disparate translocation rates (218). This model is also compatible with the 
observed differences in substrate stereospecificity (219). Despite the partial overlap in 
common substrates (glucose, fructose, and 2-DG) among GLUTs of all three classes, 
there is evidence which suggests that the stereospecificity of the substrate plays an 
important role in its recognition by the transporter. For example, the hexose C1 hydroxyl 
position appears to be most important for glucose-exofacial transporter interactions in 
Class I GLUTs (204), while the C3 and C4 hydroxyl positions may also play a role in 
fructose transport by GLUTs 2 and 5 (220), (221). Evidence suggests differences in the 
endofacial binding site, where the C6 position of the hexose may become increasingly 
important for interactions (222). It has been proposed that the differences in substrate 
specificity indicate the presence of a selectivity filter that is distinct from the sugar 
translocation pore (223).
 The fixed-site carrier model is also consistent with the multiphasic nature of 
transport. Uptake at millisecond time points determined by quench-flow analysis 
indicates that GLUT1-mediated transport in erythrocytes is multiphasic (224). This study 
describes rapid, fast and slow phases of glucose translocation, which are complicated by 
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potential re-binding of substrate at the e1 site, or slow release of substrate into a water-
based compartment formed by the cytosolic domains of the transporter. 
 While both the simple carrier and the fixed site carrier models are consistent with 
the asymmetry observed in GLUT1-mediated transport, neither can explain the low Km 
observed in infinite-cis entry or infinite-trans exit (206), (225), (226). In addition, the 
fixed site carrier model fails to explain data suggesting allosteric or cooperative binding 
of modulators or inhibitors, such as ATP and CCB (227), (228), (229), (150). Although 
ATP has been shown to modulate GLUT1-mediated transport, the precise mechanism is 
unknown. Binding of ATP is thought to affect transport rate and substrate affinity by 
allosteric modulation of intracellular sugar binding sites (230). Interestingly, GLUT1 
binding of endofacial inhibitors (CCB, forskolin) or exofacial inhibitors (maltose) at low 
concentrations has been shown to increase affinity for sugar at the exofacial site (228), 
(229). This cooperativity indicates the presence of non-catalytic sites for allosteric 
modulation of the transporter, leading to the necessary refinement of the fixed-site carrier 
model.
The Modified-Fixed Site Carrier Model
 To address the complex behaviors of allostery and cooperativity observed in red 
cell transport, a hybrid model of the simple and fixed-site carriers has been proposed (see 
Figure 1.5; (228)). In this model, two (or more) functional simple carrier subunits are 
coupled in a functionally anti-parallel fashion. Each subunit may still only present a 
33
Figure 1.5  The Modified Fixed-Site Carrier model for transport
A two-site variant of the simple carrier in which the carrier comprises 2 (or more) 
subunits, which are functionally coupled in an anti-parallel fashion. If one 
subunit presents an e2 site, the adjacent subunit must present an e1 site and vice 
versa, even if only one subunit translocates a sugar molecule (top cycle). If only 
one subunit contains a bound sugar, the unoccupied subunit impedes 
translocation via the occupied subunit because the unoccupied subunit undergoes 
relaxation, which is slower than translocation (as with the simple carrier, Figure 
1.3).
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single substrate binding site at opposite sides of the membrane (e1 or e2, as in the simple 
carrier). However, conformational change of one subunit forces the adjacent subunit to 
undergo the opposite isomerization to the opposite confirmation, regardless of whether it 
is empty or complexed with substrate. Sugar could be translocated in both directions at 
the same time, or unidirectional sugar uptake or efflux could occur with one carrier 
occupied and the other, vacant.
 As additional experimental data is gathered in a variety of systems, further 
refinement of these transport models is expected. However, lack of a crystal structure for 
any of the GLUTs precludes a definitive understanding of the physical mechanism of 
transport. The current models have been developed based on decades of experimental 
evidence, and some have been refined based on the topology and threaded structure 
discussed above. Several models exist due in part to the complex transport behavior 
exhibited by erythrocyte GLUT1, which cannot always be explained by the more 
simplistic models of carrier-mediated sugar transport. However, there are other observed 
kinetic behaviors that are consistent with all three models for transport, yet the basis of 
which are not understood. One such behavior is that of accelerated-exchange transport, or 
trans-acceleration.
Trans-acceleration in Class I GLUTs
 Since the early experimental characterizations of GLUT1-mediated sugar 
transport, it has been reported that a 2- to 10-fold stimulation of unidirectional sugar 
35
uptake is observed in the presence of intracellular sugar (188), (206), (207). This 
stimulation, or acceleration, of uptake when there is sugar in trans has been observed 
with a variety of substrates (glucose, 2-DG, 3-MG) in a variety of cellular environments, 
such as human, avian, dolphin, and rat erythrocytes (231), (148), (232), (233), mouse 
endothelial cells (182), and heterologously expressed GLUT1 in HEK cells (234) and 
Xenopus oocytes (235). Trans-acceleration is also observed for other carrier-mediated 
transport systems such as nucleoside and amino acid transporters, and is one of several 
important functional behaviors that distinguish carriers from channels (186). However, it 
has not been established whether this phenomenon is sequence-based and thus intrinsic to 
GLUT1, whether it is an allosteric modulation of the transporter that requires co-factors, 
whether it is dependent on cellular context, or whether it is simply an artifact of 
experimental conditions used to measure transport. 
 Like asymmetry, trans-acceleration in GLUT1-based systems has been shown to 
be temperature-dependent (207); trans-acceleration is more pronounced at 4°C than at 
physiological temperature. It has been suggested that this is due to the higher prevalence 
of inward-facing carrier (e1) at lower temperatures (207), but this cannot explain trans-
acceleration in the absence of transport asymmetry (e.g. in ATP-free human red cell 
ghosts (236) or in rat erythrocytes (230)).
 The ability to catalyze trans-acceleration has been tested in all the class I GLUTs. 
Human GLUT3 expressed in Xenopus oocytes displays trans-acceleration (237), (24). 
Interestingly, the other Class I transporters, GLUTs 2 and 4, do not display trans-
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acceleration. For example, GLUT2-expressing rat hepatocytes do not show accelerated 
exchange (208). In rat adipocytes stimulated with insulin, where GLUT4 expression is 
very high, trans-acceleration is not observed (203), (177). 
Trans-acceleration in the Context of Transport Models
 While many of the complex behaviors of GLUT-mediated transport are supported 
by one of the prevailing models for transport, trans-acceleration is compatible with all 
three models. In the context of the simple carrier, trans-acceleration is explained by 
assuming that relaxation of the empty carrier is slower than translocation by the 
substrate-complexed carrier. Indeed, relaxation in human erythrocyte GLUT1 proceeds 
50- to 100-fold more slowly than translocation at 4°C (207), (238). In such a case, 
intracellular sugar would permit the carrier to bypass the slower step of relaxation, 
thereby undergoing many more rounds of translocation until equilibrium is reached. At 
ice temperature, a greater proportion of the transporters exist in the e1 conformation, 
assuming the simple carrier hypothesis is correct (207). While this might lead to the 
conclusion that a greater number of opportunities would exist to drive e1 back to e2 via 
translocation in the presence of intracellular sugar, any such affect would be offset by the 
10-fold lower affinity that e1 has for substrate (207). Therefore, the major determinant of 
trans-acceleration via the simple carrier derives from the relative rates of translocation 
and relaxation.
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 For transporters that do not display trans-acceleration (i.e. GLUT4), this would be 
explained by equal rates of relaxation and translocation. In this case, there would be no 
advantage to the presence of intracellular sugar, as the rates of carrier conformational 
change would be equal in the presence or absence of substrate. 
 In the context of the fixed-site carrier, trans-acceleration occurs if the presence of 
a sugar in either the cis- or trans- binding site accelerates the binding and thus exchange 
of another molecule of sugar at the opposite binding site, a process termed geminate 
exchange (239). This model assumes that occupancy of one binding site would affect the 
affinity or binding constant of sugar in the opposite binding site for carriers that display 
trans-acceleration. However, these affinities or binding constants would have to be equal 
in both sugar-binding sites in carriers that do not catalyze trans-acceleration.
 The basis of trans-acceleration can be understood in the context of the modified 
fixed-site carrier by assuming that, as in the simple carrier, relaxation is the rate-limiting 
step in the transport cycle. In this case, the translocation of one molecule of sugar into the 
cell (e.S2 to e.S1) would be as slow as the coupled relaxation of the neighboring empty 
carrier (e1 to e2) in the absence of intracellular sugar. However, sugar inside the cell 
would allow the second subunit to also translocate a molecule of sugar, thereby 
accelerating uptake by the first subunit. Thus the conformational change in one subunit is 
constrained (inhibited or accelerated) by those of the adjacent subunit. Here, the 
assumption would be the same as that of the simple carrier: in transporters that show 
trans-acceleration, the conformational relaxation step would be slower than translocation, 
38
whereas the two rates would be equal in carriers which do not display accelerated 
exchange. 
Trans-Acceleration in Homeostasis
 In order to understand why some transporters might display this kinetic 
phenomenon and others may not, it is helpful to consider the possible advantage of trans-
acceleration. In simulations where the Vmax of sugar uptake and time to equilibration are 
modeled in the presence and absence of trans-acceleration (see Figure 1.6; (240) and A. 
Carruthers, unpublished), it is apparent that the half-time to equilibration is much shorter 
when trans-acceleration is extant. This could be a physiological advantage in situations 
where the amount of sugar is under tight control and a rapid equilibration would be 
desirable, e.g. at blood-tissue barriers such as the brain, placenta, retina, and lactating 
mammary gland. Indeed, such barriers show high expression of either GLUT1 (241), 
(242), (243), (244) and/or GLUT3 (245), (246), both of which are capable of catalyzing 
trans-acceleration. In contrast, in tissues where hormonal control can tune the amount of 
cell-surface transporter in order to affect sugar uptake rates, trans-acceleration would not 
present the same advantage. The liver, pancreas, skeletal muscle, and adipose tissue, 
which are the common sites of GLUT2 and GLUT4 expression (17), (247), are 
responsive to hormonal control. 
 Expression of a combination of transporters that can and cannot catalyze trans-
acceleration could be advantageous for tissues to adapt to sudden metabolic changes. For 
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Figure 1.6  Simulation of the effect of trans-acceleration on half-time to 
compartmental equilibration 
The simulated data for 5 mM sugar (Glc) on the outside, or luminal compartment (cyan; 
S1), taken up in zero-trans into a cell with no intracellular sugar (orange; Si), and no sugar 
present in the abluminal compartment (cyan; S2). As sugar is taken up into the cell (left 
graph) from the luminal compartment (ordinate) over time (abscissa), the half-time to 
equilibration decreases as the Vmax for exchange increases. This is observed when trans-
acceleration is set to increase 2- to 5-fold (Vee=2Vzt to Vee =5Vzt; Vee, Vmax for 
equilibrium exchange; Vzt, Vmax for zero-trans transport) over when no trans-acceleration 
is set (Vee = Vzt). In the second transport step (right graph), the sugar from inside the cell 
(Si) is exported in zero-trans into the abluminal compartment (S2), which is devoid of 
sugar. As sugar equilibrates to S2 (ordinate) over time (abscissa), the half-time to 
equilibration from S1 through the cell to S2 is reduced. When a 5-fold stimulation by 
trans-acceleration is set, the half-time to equilibration is reduced by ~70% (10 sec versus 
30 sec).
cell 
S1 Si S2 
luminal 
compartment 
abluminal 
compartment 
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example, adipocytes and cardiomyocytes express both GLUT1 and GLUT4 (248), (76). 
Although total protein expression levels of GLUT4 are often much higher than that of 
GLUT1 (79), GLUT1 is the predominant glucose transporter at the cell surface during 
basal metabolic states. However, signaling by insulin or exercise induces rapid 
translocation of intracellular GLUT4 (173), (249), where it becomes the primary glucose 
transporter. This would quickly increase the ability to take up more glucose, with less 
emphasis on equilibration; in adipose tissue, for conversion and storage, and in 
cardiomyocytes, to respond to the increased metabolic demands of exercise. 
While other transporter characteristics such as affinity, capacity, and specificity for 
different substrates are critical in the tissue-specific and temporal changes in GLUT 
expression, it is possible that ability to catalyze trans-acceleration is a previously 
unknown factor.
Remaining Questions
 In the absence of a structure to clarify the mechanism of GLUT-mediated glucose 
uptake, evaluating the existing models for GLUT1 structure and transport mechanism 
based on experimental observation is the only way to expand our understanding. The 
proposed models must explain the observed data, and the experimental evidence can be 
used to refine the models further. Through iterative refinement of data interpretation and 
defining the next questions to ask experimentally, we may further elucidate the structure 
and function of glucose transporters. If or when these proteins are crystallized, the solved 
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structures will also be evaluated based on their agreement with the substantial body of 
evidence that has been collected about glucose transport over the last 60 years. The 
dangers of not reconciling transporter structure with the existing body of data on 
transporter biochemistry and behavior are vividly illustrated in the case of the ABC 
transporter MsbA, where an inverted structure was published and later retracted (250), 
(251).
 While the modified fixed-site carrier is consistent with much of the data available 
for GLUT-mediated transport, certain complexities, particularly those of erythrocyte 
transport, are not explained by any of the current models (225), (226), (234). This 
highlights the intrinsic difficulties in modeling the transport cycle based on kinetic data 
alone; the field awaits more detailed knowledge relating transporter structure and 
function.
 Although the kinetic phenomenon of trans-acceleration has been observed since 
the beginning of glucose transporter characterization, its mechanism is unknown. While a 
multitude of GLUT variants and point mutants have been tested for activity, expression, 
substrate and inhibitor specificity or affinity, localization, and structural dynamics, none 
of these has evaluated whether or not trans-acceleration is intrinsic to the carrier. If it is 
not, does trans-acceleration occur based on cellular environment, i.e. in response to a 
modulating co-factor? If trans-acceleration is sequence-based, are the required elements 
related to those determining substrate or inhibitor binding, or oligomerization of carrier 
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subunits? Can the identity of the necessary domain(s) be explained by the putative 
models of GLUT1 structure, or refine the current available models for glucose transport? 
 This thesis attempts to address these questions by evaluating systems and 
methodologies for measuring trans-acceleration, defining the domain(s) that are 
necessary and sufficient for trans-acceleration in Class I glucose transporters, and 
evaluating their potential role in the transport cycle within the current models for GLUT 
structure and transport.
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CHAPTER II
Detecting Changes in Trans-Acceleration of Transport Mediated by Endogenous 
GLUT1 and GLUT4 in 3T3-L1 Fibroblasts and Adipocytes
Abstract
 The human facilitative glucose transporter GLUT1 displays accelerated-exchange 
transport in the presence of intracellular sugar, while the related transporter GLUT4 does 
not. Comparison of these proteins may assist in understanding the basis for this 
phenomenon, known as trans-acceleration. Because the factor(s) governing the ability of 
a glucose transporter to catalyze trans-acceleration may be determined by cellular 
context, a system with endogenous expression of these GLUTs is ideal for comparison.  
Characterization of the 3T3-L1 fibroblast/adipocyte cell line confirmed that while 
GLUT1 is the basal transporter in fibroblasts, GLUT4 expression is significantly 
increased in adipocytes. In order to determine whether catalysis of trans-acceleration is 
intrinsic to GLUT sequence, it is necessary to first establish experimental conditions 
under which trans-acceleration can be measured. Analysis of transport 3T3-L1 cells 
confirmed that fibroblasts show GLUT1-mediated trans-acceleration of sugar uptake. 
However, upon differentiation, trans-acceleration persists in both basal and insulin-
stimulated adipocytes, a characteristic which is not displayed by GLUT4. This implies 
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the presence of a heterogenous population of cell-surface transporters and/or cells in 
various differentiation states. In addition, temporal mapping of the counterflow transient, 
a signature of carrier-mediated transport, was indicative of extremely rapid kinetics. 
Sugar uptake proved to be so rapid (t0.5 ~1-2 seconds) as to preclude accurate, 
reproducible comparisons of GLUT1- and GLUT4-mediated transport in 3T3-L1 cells. 
This study revealed that alternate approaches to transporter expression and methodologies 
to measure trans-acceleration are necessary to analyze sequence-based kinetic differences 
in GLUTs 1 and 4.
Introduction
 Since the very first kinetic characterizations of the ubiquitously expressed human 
GLUT1 glucose transporter in the 1950’s, it has been observed that the presence of sugar 
in trans results in an acceleration of unidirectional sugar uptake or efflux, termed trans-
acceleration (188), (206), (207). This phenomenon results in a 2- to 10-fold stimulation in 
the Vmax for the rate of exchange compared to the Vmax for the rate of zero-trans sugar 
uptake. The ability to catalyze trans-acceleration may present an advantage in certain 
physiological contexts in that it allows the equilibration of sugar on either side of the cell 
membrane to be reached more rapidly (Figure 1.6; (240) and A. Carruthers, unpublished).
 In contrast, the related human isoform GLUT4 does not show trans-acceleration 
in the presence of intracellular sugar. This has been observed experimentally in rat 
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adipocytes (209), (177). Unlike GLUT1, GLUT4 is mainly expressed in adipocytes and 
skeletal muscle. Despite differences in expression patterns, GLUT1 and GLUT4 are 
similar in length (492 and 508 amino acids, respectively) and are both Class I glucose 
transporters. While these transporters show a greater sequence conservation than most of 
the other 12 GLUT isoforms, they still only exhibit 68% sequence identity. Variations in 
sequence are primarily in the N-terminal half of the protein, the intracellular loop 6, and 
the cytoplasmic C-terminus. These disparities between GLUT1 and GLUT4 prompt the 
hypothesis that accelerated-exchange may be sequence-based.
 While a multitude of studies has employed mutations in GLUT1 TM domains, 
loops, and both termini, none has been used specifically to analyze whether trans-
acceleration is intrinsic to GLUT1 sequence. As such, many of these mutations are not 
conservative. Alanine- and cysteine-scanning mutagenesis have been used extensively to 
characterize which region(s) of GLUT1 are exposed to proteolysis or are critical for 
substrate/inhibitor binding (129), (135), (136), (153), (130). Some of these mutations are 
not possible to test because they prevent proper folding, expression, or function of the 
protein. Due to these complexities, an approach using more conservative sequence 
substitutions is desirable. Despite the variations in sequence between GLUTs 1 and 4, the 
TM-domain regions are the most highly conserved in both length and sequence (10). 
Thus the substitution of TM regions among these transporters would increase the 
likelihood of proper folding, TM insertion into the membrane, and functional transport. 
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 As the glucose transporter which was first identified and cloned, more is known 
about the kinetic characteristics of GLUT1 (8), (252) than the other human glucose 
transporters. Due to its potential role in diabetes as an insulin-sensitive transporter, 
GLUT4 kinetics and expression also have been studied thoroughly. The affinities for 2-
DG transport by GLUT1 and GLUT4 in skeletal muscle have been shown to be 
indistinguishable (Km ~10 mM; (200)). While some studies report that GLUT4 has a ~4-
fold higher affinity for 3-MG than GLUT1 (191), (201), (202), other comparisons of Km 
for 3-MG have shown a similar range for both transporters (~4-6 mM; (209), (204), 
(205)). In addition, the ability to induce large amounts of GLUT4 expression at the 
plasma membrane by insulin stimulation provides a tunable expression system that could 
aid in transport measurements.
 Despite the sequence disparity between GLUTs 1 and 4, it is possible that trans-
acceleration is governed by a phenomenon external to the protein. For example, 
interaction with modulating co-factors, perhaps even in specific cellular contexts, may 
play a role. Thus it would be ideal to establish methodologies for measuring the presence 
and absence of trans-acceleration in cells with endogenously expressed transporters. 
 The obvious choice for comparing GLUT1 and GLUT4 kinetics in a system 
where both are expressed would be skeletal muscle or adipose tissue (249), (76). Because 
GLUT1 is the basal transporter used in the majority of tissues, its ability to catalyze trans-
acceleration should be evident in the basal metabolic state, provided it is the dominant 
GLUT isoform expressed. GLUT4 contains targeting sequences that keep the transporter 
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sequestered in intracellular storage compartments under basal conditions (167), (168), 
(169), (170), (171). However, stimulation by insulin and/or exercise affects trafficking 
pathways within the cell. This results in the rapid translocation of GLUT4-containing 
vesicles to the plasma membrane, where GLUT4 becomes the primary transporter (166). 
This would provide a unique opportunity to compare the presence and absence of trans-
acceleration in transport mediated by GLUT1 and GLUT4, respectively, in the same 
system where both are endogenously expressed. 
 Because expression of GLUT1 or GLUT4 can be theoretically controlled by 
cellular differentiation, adipose tissue offers an experimental advantage over skeletal 
muscle for this purpose. Although insulin stimulates both cell types, the greatest amount 
of GLUT4 translocation in muscle cells is observed with a combination of insulin and 
contraction (200), (253). In contrast, high levels of GLUT4 translocation to the cell 
surface in adipocytes only requires the addition of insulin. The murine fibroblast cultured 
cell line 3T3-L1 has been used for decades to study GLUT4 trafficking and insulin 
responsiveness, and is thus well characterized (254), (255), (256), (257).
 While it is the ultimate goal of the study to compare human glucose transporters, 
alignments of murine and human isoforms show high sequence conservation. Mouse 
GLUT1 sequence is 97% homologous to human GLUT1, with a difference of only 17 
amino acids; while mouse GLUT4 is 95% identical to the human isoforms, with 24 
disparate residues. 
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 Here we characterize expression levels of GLUT1 and GLUT4 mRNA in 3T3-L1 
fibroblasts and adipocytes using reverse transcriptase (RT) and quantitative PCR (qPCR), 
and protein expression by Western blot. We then establish parameters for kinetic 
measurements of 3-MG transport by performing time courses and dose-responses. These 
experiments produce transport data that deviate from Michaelis-Menten behavior, 
suggesting that we did not measure initial rates of transport. Changing the inhibitor we 
used to quench transport and shifting our measurements to earlier time points indicated 
that we could measure counterflow, which we mapped over several time points to 
confirm. The slope of the counterflow measured in fibroblasts indicated the presence of 
GLUT1-mediated trans-acceleration. However, trans-acceleration persisted in insulin-
stimulated adipocytes, indicating that either background GLUT1 expression levels were 
too high or a mixed population of fibroblasts and adipocytes precluded the detection of 
GLUT4-mediated loss of trans acceleration. In addition, a time course of 3-MG uptake in 
stimulated adipocytes was even more rapid than transport observed in fibroblasts. These 
data suggest that 3-MG transport in 3T3-L1 cells is too rapid to compare kinetics of 
stimulated adipocytes and basal fibroblasts experimentally, even at ice temperature. 
Experimental Procedures
Materials
 Frozen 3T3-L1 cells of passage 3 were obtained from the laboratory of Dr. 
Michael Czech, Program in Molecular Medicine, University of Massachusetts Medical 
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School, Worcester. DMEM, DPBS, penicillin/streptomycin, trypsin, Bis-Tris gels and 
MES buffer were obtained from Invitrogen. FBS was obtained from HyClone. All 
primers were purchased from Integrated DNA Technologies. RNeasy, Qiashredder and 
One-Step RT-PCR kits were from Qiagen. iScript One-Step PCR kit with SYBR green 
was purchased from BioRad. PVDF membranes were obtained from ThermoFisher. 10% 
bovine serum albumin was from American Bioanalytical. Super Signal Pico West and 
micro-BCA kits were from Pierce. Protease inhibitor cocktail tablets were from Roche. 
[3H]-3-O-methyl-D-glucose was purchased from MP Biomedical. Insulin, SDS, 3-MG, 
maltose, CCB, phloretin, methyl-3-isobutyl xanthine (IBMX), dexamethasone (DMT) 
and all other chemicals were purchased from Sigma.
Solutions
 Growth medium was DMEM containing 10% FBS, 1% penicillin/streptomycin. 
Freezing medium was growth medium containing 5% DMSO. Cell lysis buffer consisted 
of DPBS, 1% SDS plus protease inhibitiors with EDTA. TBS contained 20 mM Tris base, 
135 mM NaCl, pH 7.6. Sample buffer consisted of 0.5 M Tris-Cl, pH 6.8, 40% (v/v) 
glycerol, 8% SDS, bromophenol blue, and 150 mM DTT. Stop solution consisted of 
either 10 µM CCB and 100 µM phloretin or 80 mM maltose, as indicated.
Antibodies
 A custom-made (New England Peptide) affinity-purified rabbit polyclonal 
antibody raised against a peptide corresponding to GLUT1 C-terminal residues 480-492 
was used at 1:10,000 dilution as described previously (152). A goat polyclonal anti-
50
GLUT4 C-terminal antibody (Santa Cruz sc-1608) was used at 1:1,000 dilution. 
Horseradish peroxidase-conjugated goat anti-rabbit and donkey anti-goat secondary 
antibodies (Jackson ImmunoResearch) were used at 1:50,000 and 1:30,000 dilution, 
respectively.
Tissue Culture
 3T3-L1 fibroblasts were prepared by thawing the original vial of P3 cells into 
2x150mm2 plates with growth medium. After 48 hours, these were split at a ratio of 1:4. 
Cells were dissociated from the dish for passage or storage by incubating with 0.5% 
trypsin for 5 min at 37°C, centrifuging for 5 min at 950 rpm, and resuspension in medium 
for growth.
 A fresh vial of 3T3-L1 fibroblasts was thawed each week. These were grown in 
150 mm2 dishes at 37°C, 5% CO2 and fed every 48 hours with growth medium. When 
confluent, fibroblasts were dissociated from the plate by incubation with 0.5% trypsin-
EDTA for 5 minutes and split at 1:4 and/or used for experiments after 4 days of growth 
and feeding. Differentiation into adipocytes was performed as described previously (258). 
Briefly, 0.5 µg/ml insulin, 0.5 mM IBMX and 0.25 µM DMT were added to fibroblasts 
on day 7. Differentiating cells were fed with normal growth medium on day 10 and day 
12. Adipocytes were used for experiments on or after day 14, and the change in cell 
morphology was verified by phase-contrast microscopy prior to all experiments. 
 For transport experiments, all cells were transferred to 12-well plates at least 24 
hours prior to transport measurements. When indicated, adipocytes were stimulated with 
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100 nM insulin during the final 20 minutes of the 2-hour serum starve at 37°C prior to 
performing transport measurements.
Endpoint RT-PCR
 Total RNA was isolated from 3T3-L1 fibroblasts or adipocytes using the RNeasy 
kit and Qiashredder. End point RT-PCR was performed as per the One-Step RT PCR kit 
instructions using mouse GLUT1- and GLUT4-specific primers (see Appendix, Table A2; 
primers were obtained from Dr. Anthony Cura). RT-PCR products were resolved on a 
1.5% agarose gel in TAE buffer. Bands were visualized by ethidium bromide staining 
under UV light on a FujiFilm LAS 3000 and analyzed using FujiFilm MultiGauge 
software. 
Quantitative RT-PCR
 Expression levels of GLUTs 1 and 4 were measured by qPCR using the iScript 
One-Step PCR kit with SYBR green. Reactions were performed according to the kit 
protocol using 100 ng total RNA isolated using the RNeasy kit and Qiashredder, and 
using mouse GLUT1- and GLUT4-specific qPCR primers (see Appendix, Table A2; 
primers were obtained from Dr. Anthony Cura). Samples were run in duplicate on an MJ 
Research PTC-200 Peltier Thermal Cycler with a Chromo4 real time PCR detector 
running Opticon Monitor 3 software (Bio-Rad). Results were analyzed by using the delta-
delta Ct method (259) and normalized to an EIF-1α control.
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Western Blotting
 Cells were trypsinized, pelleted, washed with DPBS, lysed in cell lysis buffer, and 
protein concentration was assessed using a micro-BCA kit. Lysates were normalized for 
total protein concentration and resolved by SDS-PAGE on a 10% Bis-Tris gel in MES 
buffer. Gels were transferred onto PVDF membranes, blocked with 10% bovine serum 
albumin in TBS-T, probed with primary antibody overnight at 4°C, probed with 
secondary antibody for 1 hour at room temperature, and developed using Super Signal 
Pico West Chemiluminescent substrate. Blots were imaged on a FujiFilm LAS-3000 and 
relative band densities were quantitated using ImageJ software.
3-MG Transport and Time Course
 3-MG transport was performed as described previously (234). Briefly, 12-well 
plates of confluent 3T3-L1 cells were serum- and glucose-starved for 2 hours at 37°C in 
FBS- and penicillin/streptomycin-free DMEM lacking glucose. Cells were washed with 
0.5 mL DPBS at 4°C, then exposed to 0.4 mL of uptake solution containing the indicated 
concentration of cold 3-MG plus 2.5 µCi/ml [3H]-3-MG for the indicated time point at 
4°C. Uptake was stopped by addition of 1 mL ice-cold stop solution. Cells were washed 
twice with ice-cold stop solution and extracted with SDS extraction buffer. Total protein 
concentration was analyzed in duplicate using a micro-BCA kit. Each sample was 
counted in duplicate by liquid scintillation spectrometry. Each condition was performed 
in triplicate.
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Zero-Trans, Equilibrium Exchange and Infinite-Trans 3-MG Uptake Measurements
 Zero-trans sugar uptake describes uptake of sugar into cells lacking intracellular 
sugar. This was achieved by using no glucose or sugar analogs during the 2 hour serum-
starve and PBS washes described above. Equilibrium exchange uptake describes equal 
amounts of sugar inside and outside of the cell. This was achieved by pre-loading cells 
with the same amount of 3-MG (5-40 mM) contained in the uptake medium for that 
condition, a concentration which was kept constant throughout the 2 hour serum starve 
and PBS washes prior to uptake. Infinite-trans uptake describes uptake into cells that 
have been pre-loaded with a saturating amount of sugar. This was achieved by pre-
loading the cells with either 40 or 80 mM 3-MG, as indicated, during the 2 hour serum 
starve and PBS washes.
Transport Data Analysis 
 All data analysis was performed using GraphPad Prism (La Jolla, CA, v 5.0). For 
sugar uptake experiments, background counts were subtracted from all samples and 
uptake, v, was normalized to [total protein]/well. [3H]-3-MG uptake (DPM/µg) was then 
converted to mol/µg protein/min by using the measured specific activity of the uptake 
solution. For dose-response experiments, sugar uptake was fitted to the Michaelis Menten 
equation (Equation 2.1):
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by non-linear regression analysis, which yielded the values for Vmax and Km. 
For experiments studying the inhibition of uptake by maltose, sugar uptake was fitted to 
the inhibition equation (Equation 2.2):
by non-linear regression analysis, where yo is the y-intercept ([maltose] = 0) and span is 
the distance between the maximal and minimal values for sugar uptake. The inhibition 
constant (Kiapp) for transport inhibition by maltose was extracted from the fit.
Results
Differentiation and GLUT1/GLUT4 expression in 3T3-L1 fibroblasts and adipocytes 
 In order to assess whether the 3T3-L1 cell line could be used to measure GLUT1- 
and GLUT4-mediated transport, we first had to characterize the changes in expression of 
these transporters during differentiation of fibroblasts into adipocytes. Differential 
interference contrast (DIC) microscopy was used to compare the morphology of live, 
unmodified pre- and post-differentiation cells (Figure 2.1A and B). While 
undifferentiated 3T3-L1 cells have a typical fibroblast morphology, this changes when 
the same cells are examined 1 week after culturing in the presence of IBMX, DMT and 
insulin. The adipocyte morphology (260) is characterized by accumulation of fat droplets
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Figure 2.1  Morphology and expression of GLUT1 and GLUT4 mRNA in 3T3-L1 
fibroblasts and differentiated adipocytes
A, Live fibroblasts were imaged by DIC microscopy at 10x. B, Live adipocytes on day 7 
post-differentiation were visualized using DIC microscopy at 10x. C, Total RNA extracts 
from fibroblasts (F) and adipocytes (A) were used as a template for RT-PCR using 
primers specific to mouse GLUT1 (product size: 515 bp) and GLUT4 (product size: 444 
bp). The products were resolved on a 1.5% agarose gel and visualized using ethidium 
bromide.
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in the cytoplasm, which results from increased triglyceride synthesis after differentiation 
(261).
 Total RNA was extracted from both fibroblasts and differentiated adipocytes and 
screened for GLUT1 and GLUT4 mRNA by RT-PCR (Figure 2.1C). As expected, both 
fibroblasts and adipocytes show expression of GLUT1 and GLUT4 mRNA. The relative 
amount of message was examined using qPCR (Figure 2.2A). Analysis by 
qPCR revealed that GLUT4 mRNA expression was only 40% of GLUT1 mRNA 
expression in fibroblasts. However, upon differentiation into adipocytes, the expression 
of GLUT4 message was increased to 4000% when compared to GLUT1 message. 
 In order to verify that similar changes occurred in protein levels, whole cell 
lysates of both fibroblasts and adipocytes were analyzed by Western blot. When probed 
with a C-terminal anti-GLUT1 antibody (Figure 2.2B), a ~55 kDa band of GLUT1 is 
detected in both fibroblasts and adipocytes, although its expression is more abundant in 
fibroblasts. However, when probed with a C-terminal anti-GLUT4 antibody (Figure 
2.2C), a ~55 kDa GLUT4 band is detected in adipocytes, but not in fibroblasts. The 
combination of morphological changes and increase in GLUT4 mRNA and protein 
expression over GLUT1 confirmed the successful differentiation of 3T3-L1 fibroblasts 
into adipocytes.
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Figure 2.2  Comparative expression of GLUT1 and GLUT4 in 3T3-L1 fibroblasts 
and adipocytes  
A, Quantitative RT-PCR analysis of fibroblast and adipocyte total RNA cell extracts using 
qPCR primers specific to mouse GLUT1 and GLUT4. Results are normalized to GLUT1 
message expression and plotted as relative expression (ordinate) for each cell extract 
(abscissa). Samples were run in duplicate on 2 separate occasions. The significance of the 
difference between GLUT4 (shaded bars) and GLUT1 (empty bars) mRNA relative 
expression was computed using an unpaired, 2-tailed Student’s t-test yielding ** P ≤ 
0.01; *** P ≤ 0.001. B, Western blot analysis of GLUT1 protein expression in whole cell 
lysates fibroblasts and adipocytes using a GLUT1 C-terminal antibody (~55 kDa). C, 
Western blot analysis of GLUT4 protein expression in whole cell lysates from fibroblasts 
and adipocytes using a GLUT4 C-terminal antibody (~55 kDa). 5-20 µg of lysate was 
loaded beside a control of GLUT1 purified from human erythrocytes.
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Initial characterization of 3-MG uptake in fibroblasts
 In order to establish an appropriate time point during the linear phase of uptake 
for future transport experiments, we performed a time course over 10 minutes of 5 mM 3-
MG uptake in fibroblasts at 4°C (Figure 2.3A). Previous experiments in our laboratory 
have indicated that 3-MG transport in other murine cell lines is rapid, even at ice 
temperature (182). In 3T3-L1 fibroblasts, the cells were equilibrated by 2 minutes. To 
make an initial comparison of whether transport rates were stimulated by intracellular 
sugar, we chose a time point of 1 minute and performed dose-responses in cells that were 
either pre-loaded or devoid of intracellular sugar (Figure 2.3B). 
 To examine uptake in the absence of intracellular sugar (zero-trans), fibroblasts 
were depleted of sugar for the 2 hours prior to uptake. To examine transport in the 
presence of intracellular sugar (infinite-trans), cells were pre-loaded with a saturating 
concentration of sugar (80 mM 3-MG). While comparison of 5-40 mM 3-MG uptake 
under zero- and infinite-trans conditions did show a stimulation (trans-acceleration) of 
sugar uptake rates at the 20 mM and 40 mM doses of extracellular 3-MG, the dose-
response of pre-loaded cells was linear. This indicates that either 3MG transport is an 
extremely low affinity process or initial rates were not measured, and the resulting 
transport does not provide accurate values for Vmax or Km. Indeed, when the zero-trans 
uptake data are fitted with the Michaelis-Menten equation (Equation 2.1), the calculated 
Vmax is 219 ± 183 pmol/µg/min and the Km is 133 ± 137 mM. This is much higher than the 
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Km for 3-MG reported in other systems, which is 4-20 mM (204), (205), (192), (201), 
(202). While the calculated Vmax for the infinite-trans dose-response is higher than under 
zero-trans conditions (6960 ± 3420 pmol/µg/min), the Km (2958 ± 14682 mM) is not 
reasonable. 
 These results indicated that an earlier time point was necessary to perform 
accurate dose-responses of 3-MG uptake. While the disparity between intra- and 
extracellular sugar in infinite-trans experiments (80 mM vs 5-40 mM 3-MG) can cause 
changes in cell volume (262), we sought to avoid these complications by ensuring that all 
uptake solutions were osmotically balanced with sucrose, which is not a substrate for 
GLUT-mediated transport. However, the control condition in the time course (Figure 
2.3A) showed increasingly negative counts with time of incubation with cytochalasin B 
(CCB), a commonly used GLUT-specific inhibitor. This implied that the choice of CCB 
for quenching uptake could be causing increased cell permeability and could contribute to 
difficulty with data analysis. This led us to consider whether a different inhibitor, 
maltose, would be a better transport inhibitor to use for these assays.
Comparison of maltose and CCB inhibition of transport
 Maltose is a competitive inhibitor of GLUT-mediated uptake, as it binds at the 
exofacial site (28). When used at high concentrations, it can rapidly inhibit uptake of 
sugar or sugar analogs. We chose to compare inhibition of 3-MG uptake by 80 mM 
maltose or 10 µM CCB (Figure 2.4A). In order to test whether either inhibitor caused 
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leaking of cellular contents over time, we pre-incubated fibroblasts with each inhibitor 
for 0 to 120 seconds prior to adding 5 mM 3-MG uptake, and then processed the cells 
after 1 minute. The 0 second time point indicates that both inhibitor and uptake solution 
were added at the same time. For comparison, uptake was measured in control wells with 
no inhibitor until uptake had proceeded for 1 minute. While this assay was performed at 
4°C, we also included a pre-incubation point at 37°C for comparison. Whereas CCB 
inhibition of 3-MG transport showed a higher background and was variable over the pre-
incubation times tested, maltose showed low background and a very reproducible 
inhibition of 3-MG transport. These data could partially be explained by the 
comparatively higher off-rate of CCB compared to maltose (28). 
 In order to ensure we were using an appropriately high concentration of maltose 
for inhibition in future experiments, we performed a dose-response of maltose inhibition 
of 3-MG transport (Figure 2.4B). We examined the amount of 10 mM 3-MG uptake at 5 
seconds in fibroblasts when simultaneously exposed to 0 to 100 mM maltose. These 
results showed a Ki(app) of ~6 mM for maltose, which is in agreement with what has been 
reported previously (Ki(app) ~6 mM (28)). This confirmed that the use of 80 mM maltose 
was sufficient for transport inhibition.
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Figure 2.3 Initial characterization of 3-MG transport in 3T3-L1 fibroblasts
A, Time course of 5 mM 3-MG zero-trans uptake in fibroblasts at 4°C. Amount of uptake 
of 3[H]-3-MG was normalized to total protein concentration (ordinate) and plotted for the 
length of time of uptake (abscissa). Samples were either incubated with 10 µM CCB 
from the start of the time course (●)	  or stopped with 10 µM CCB at the indicated time 
point (○). Data are plotted as mean ± SEM for n=2 assays. Curves drawn through the data 
were computed by nonlinear regression assuming that uptake is described by Equation 
2.1. B, Dose response of 3-MG uptake at 1 minute in fibroblasts at 4°C. The rate of 
uptake (ordinate) was plotted for uptake of 5-40 mM 3-MG (abscissa) in cells depleted 
of intracellular sugar (zero-trans; (○)) or cells pre-loaded with 80 mM 3-MG (infinite-
trans; (●)). For infinite-trans, 5-40 mM 3-MG uptake solutions were balanced with 
sucrose to 80 mM. Uptake was stopped with 10 µM CCB and 100 µM phloretin. Data are 
plotted as mean ± SEM for n=3 assays. Curves drawn through the data were computed by  
nonlinear regression assuming that uptake is described by Equation 2.1.
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Figure 2.4 Characterization of maltose vs CCB inhibition of 3-MG uptake in 
  fibroblasts 
A, The rate of uptake of 5 mM 3-MG (ordinate) is plotted against the time of pre-
incubation (abscissa) with either 10 µM CCB or 80 mM maltose to inhibit transport, at 
4°C unless otherwise noted. The non-inhibited uptake of 5 mM 3-MG, stopped with 
either CCB or maltose after 1 minute, is shown (Ctrl). All following samples had 
inhibitor added for the time indicated, then 5 mM 3-MG, and samples were aspirated and 
processed after 1 minute. B, The inhibition of 10 mM 3-MG uptake (ordinate) at 5 
seconds in fibroblasts at 4°C is shown for 0-100 mM maltose (abscissa). The curve 
drawn through the data was computed by nonlinear regression assuming that inhibition is 
described by Equation 2.2. The resulting analysis yields parameters of Ki= 5.9 ± 3.4 mM 
with an R2 = 0.8916.
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Characterization of 3-MG transport in fibroblasts using maltose
 Because our previous time course with CCB and the linear infinite-trans results 
had indicated a rapid equilibration, we chose to revisit the time course of 5 mM 3-MG 
zero-trans uptake at shorter time points and using maltose to stop transport (Figure 2.5A). 
When uptake of 3-MG is analyzed over the course of 1 minute, it is apparent that 
equilibration is nearly complete by 10 seconds, which is far faster than our previous dose-
this set of experiments, we chose to compare equilibrium exchange (pre-loading the cells
with 5-20 mM 3-MG, such that intra- and extra-cellular [sugar] were equal) to zero-trans, 
so that the higher concentrations of sugar (40-80 mM) employed in the previous 
experiments could be avoided. While dose-responses under these conditions were no 
longer linear and provided more reasonable values for Km (~26-52 mM), there was no 
stimulation of Vmax with the presence of intracellular sugar. We reasoned that perhaps the 
the time point was still too long and that rapid equilibration was preventing the detection 
of trans-acceleration.
Evaluation of 3-MG transport in fibroblasts at a 2 second time point
 As a proof-of-principle, we chose to compare infinite-trans and zero-trans uptake 
of 10 mM 3-MG at 2 and 5 seconds, respectively (Figure 2.6A). While there is no 
stimulation of uptake with intracellular sugar (40 mM pre-loaded 3-MG) at 5 seconds, 
there is an approximate 2-fold stimulation of uptake observed at 2 seconds when 
intracellular sugar is present. This confirmed that our previous time points were too long 
to measure trans-acceleration. 
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Figure 2.5  Characterization of 3-MG uptake in fibroblasts using modified stop 
  conditions 
A, Time course of 5 mM 3-MG zero-trans uptake in fibroblasts at 4°C. Amount of uptake 
of 3[H]-3-MG was normalized to total protein concentration (ordinate) and plotted for the 
length of time of uptake (abscissa). Samples were stopped with 80 mM maltose at the 
time points indicated. The curve drawn through the data was computed by nonlinear 
regression assuming that uptake is described by Equation 2.1, with R2 = 0.9643. B, Dose 
response of 3-MG uptake at 5 seconds in fibroblasts at 4°C. The rate of uptake (ordinate) 
was plotted for uptake of 5-20 mM 3-MG (abscissa) in cells depleted of intracellular 
sugar (zero-trans; (○)) or cells pre-loaded with 5-20 mM 3-MG (equilibrium-exchange, 
(●)). Uptake was stopped with 80 mM maltose. Data are plotted as mean ± SEM for n=2 
assays. Curves drawn through the data were computed by nonlinear regression assuming 
that uptake is described by Equation 2.1. The resulting analysis yields parameters of Vmax 
= 440.4 ± 32.9 pmol/µg/min, Km = 26.5 ± 3.1 mM, with R2 = 0.9983 for zero-trans 3-MG 
uptake; Vmax = 643.3 ± 654.7 pmol/µg/min, Km = 51.6 ± 68.4 mM, with R2 = 0.9321 for 
equilibrium exchange 3-MG uptake.
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Figure 2.6  Analysis of the effect of intracellular sugar on 3-MG uptake in 
fibroblasts at 2 second uptake measurements 
A, The uptake of 10 mM 3-MG (ordinate) at 2 or 5 seconds (abscissa) in fibroblasts with 
no intracellular sugar (zero-trans; (○)) or pre-loaded with 40 mM 3-MG (infinite-trans; 
(●)). Data are plotted as mean ± SEM for n=2 assays. B, Dose-response of the rate of 
uptake (ordinate) of 5-20 mM 3-MG (abscissa) in fibroblasts with 0 intracellular sugar 
(zero-trans; (○)) or pre-loaded with 5-20 mM 3-MG (equilibrium exchange, (●)). All 
uptake was performed at 4°C and stopped with 80 mM maltose. Curves drawn through 
the data were computed by nonlinear regression assuming that uptake is described by 
Equation 2.1. The resulting analysis yields parameters of Vmax = 150.5 ± 130.8 pmol/µg/
min, Km = 13.5 ± 23.2 mM, with R2 = 0.7431 for zero-trans 3-MG uptake; Vmax = 345.0 ± 
47.5  pmol/µg/min, Km = 6.4 ± 2.4 mM, with R2 = 0.9599 for equilibrium exchange 3-
MG uptake.
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 We then repeated the dose-response of 5-20 mM 3-MG uptake under zero-trans 
(ZT) and equilibrium-exchange (EE) conditions at 2 seconds (Figure 2.6B). This 
experiment showed trans-acceleration at each dose of 3-MG uptake measured, with a 2.3-
fold increase in Vmax (ZT Vmax = 150.5 ± 130.8 pmol/µg/min; EE Vmax = 345.0 ± 47.5 
pmol/µg/min). In addition, the calculated Km for each experiment was within the range of 
reported values (ZT Km = 13.5 ± 23.2 mM; EE Km = 6.4 ± 2.4 mM). These results 
confirmed that we were able to measure GLUT1-mediated trans-acceleration in 
fibroblasts. However, these rapid uptake measurements proved to be difficult to 
reproduce, and prompted us to ask whether we were still underestimating trans-
acceleration at 2 seconds. The ability to detect trans-acceleration at 2 seconds, yet not at 5 
seconds, indicated that we might have been measuring the counterflow transient at 2 
seconds, which would disappear due to equilibration by 5 seconds.
Mapping the counterflow transient in fibroblasts
 While counterflow can occur when trans-acceleration does not, in such a case the 
initial velocity of uptake will be the same as that of zero-trans uptake (Figure 2.7A). 
However, when counterflow is measured in a system where trans-acceleration occurs, this 
will be reflected by an increase in the slope of the initial rate of transport over the slope 
of zero-trans uptake. When we performed uptake of 10 mM 3-MG at 1-second intervals 
between 1 and 5 seconds under infinite-trans and zero-trans conditions (Figure 2.7B), this 
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Figure 2.7 Measuring counterflow of 3-MG uptake in 3T3-L1 fibroblasts and 
  adipocytes
A, Example simulations of counterflow by carriers which do and do not catalyze trans-
acceleration. The amount of uptake represented by accumulated intracellular label (Li; 
ordinate) is graphed over time (abscissa) under zero-trans (black line) and pre-loaded 
conditions where trans-acceleration is allowed (blue line) or is not allowed (red line). B, 
The ratio of intracellular sugar over extracellular sugar (ordinate) is plotted for the first 6 
seconds of 10 mM 3-MG uptake (abscissa) in fibroblasts depleted of intracellular sugar 
(zero-trans; (○)) or pre-loaded with 40 mM 3-MG (infinite-trans; (●)). All uptake was 
performed at 4°C and stopped with 80 mM maltose.
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is exactly what we observed. While the initial time points (1 and 2 seconds) show the 
stimulation of uptake we observe with intracellular sugar, equilibration is reached rapidly 
and the stimulation over zero-trans is undetectable by 3 seconds. In addition, we can see 
from the slope of the fit between 0 and 2 seconds that the initial velocity is much greater 
under infinite-trans conditions, indicative of trans-acceleration.  
 Indeed, the fit of the infinite-trans data indicates that trans-acceleration is even 
underestimated at a 1-second measurement. Because these 1 to 5 second measurements 
were so rapid, we sought to confirm that counterflow was actually occurring and not an 
artifact of the experimental conditions, particularly variations in temperature. To test this,
we compared uptake of 10 mM 3-MG at 1 and 5 seconds for fibroblasts that had been 
pre-incubated on ice for 5-20 minutes prior to performing uptake (Figure 2.8). This 
experiment showed the presence of counterflow at 1 second with no dependence on the 
amount of time at 4°C. In addition, we varied the order in which 1-5 second uptakes were 
performed over several assays, with no change in results. This confirmed that we were 
able to measure the counterflow transient at 1 second of uptake.
Characterization of 3-MG uptake in basal and insulin-stimulated adipocytes
 In order to assess whether we would be able to make comparative measurements 
in adipocytes, we performed a time course of 10 mM 3-MG uptake (Figure 2.9A). This 
was done in both basal (2 hour serum starve) and insulin-stimulated (2 hour serum starve 
with 100 nM insulin in the final 20 minutes) adipocytes to test whether stimulation would 
75
Figure 2.8 Analysis of duration at ice temperature and effect on counterflow 
measurements
The amount of uptake (ordinate) is plotted at 1 and 5 seconds (abscissa) for 10 mM 3-
MG uptake in fibroblasts pre-loaded with 40 mM 3-MG, which were pre-incubated for 
5-20 min at 4°C prior to performing uptake. All uptake was stopped with 80 mM maltose.
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Figure 2.9  Characterization of 3-MG transport in basal and insulin-stimulated 
  3T3-L1 adipocytes
A, Time course of 10 mM 3-MG uptake in basal or insulin-stimulated adipocytes. 
Amount of uptake of 3[H]-3-MG was normalized to total protein concentration (ordinate) 
and plotted for the length of time of uptake (abscissa) for basal (○) or insulin-stimulated 
(●) adipocytes. Data are plotted as mean ± SEM for n=2 assays. Curves drawn through 
the data were computed by nonlinear regression assuming that uptake is described by 
Equation 2.1, with R2 = 0.9643 for the fit of uptake under basal conditions and R2 = 
0.5748 for the fit of uptake under insulin-stimulated conditions. B, Dose response of 3-
MG uptake at 2 seconds in basal adipocytes. The rate of uptake (ordinate) was plotted for 
uptake of 5-20 mM 3-MG (abscissa) in adipocytes depleted of intracellular sugar (zero-
trans; (○)) and adipocytes pre-loaded with 40 mM 3-MG (infinite-trans; (●)). C, Dose 
response of 3-MG uptake at 2 seconds in insulin-stimulated adipocytes. The rate of 
uptake (ordinate) was plotted for uptake of 5-20 mM 3-MG (abscissa) in adipocytes 
depleted of intracellular sugar (zero-trans; (○)) and adipocytes pre-loaded with 40 mM 3-
MG (infinite-trans; (●)). All uptake was performed at 4°C and stopped with 80 mM 
maltose. The lines drawn through data in B and C were computed by nonlinear regression 
analysis assuming that uptake is described by Equation 2.1.
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increase the rate of transport, as expected. Indeed, we observed that over 60 seconds, both 
the amount of uptake and the initial rate at which it occurred was faster in stimulated 
adipocytes. The overall Vmax for uptake is higher in stimulated adipocytes, and the entire 
time course curve is shifted to the left, indicating faster equilibration.
 While this implied that transport would again be too rapid to measure accurately 
in adipocytes, we performed a dose-response of 3-MG uptake at 2 seconds and compared 
this in basal and stimulated adipocytes (Figure 2.9B-C). Indeed, both sets of dose-
responses are linear, indicating that transport at 2 seconds is even more rapid than in 
fibroblasts. Despite an inability to extract meaningful Km and Vmax values from these data, 
the results in both basal and insulin-stimulated adipocytes show that trans-acceleration is 
still present under infinite-trans versus zero-trans conditions.
 To confirm this observation, we wanted to test whether we could measure 
counterflow in adipocytes. When we mapped uptake under infinite-trans conditions over 
1-5 seconds (Figure 2.10), we did indeed observe counterflow in both basal and insulin-
stimulated adipocytes. As we found in the dose-response experiments, the amount of 
uptake in stimulated adipocytes was greater than in basal adipocytes over the first 2 
seconds of uptake. The sharp peak of the counterflow transient and its rapid equilibration 
by 3 seconds is similar to the counterflow observed in fibroblasts, supporting that 
GLUT1-mediated trans-acceleration is operant in these cells.
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Counterflow of 3-MG Uptake in Basal and Stimulated 
3T3-L1 Adipocytes
Time (sec)
D
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Figure 2.10 Counterflow of 3-MG uptake in basal and insulin-stimulated 
adipocytes
Amount of uptake of 3[H]-3-MG was normalized to total protein concentration (ordinate) 
over the first 5 seconds of 10 mM 3-MG uptake (abscissa), which is plotted for 
adipocytes pre-loaded with 40 mM intracellular 3-MG under basal (●) and insulin-
stimulated () conditions. All uptake was performed at 4°C and stopped with 80 mM 
maltose.
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Discussion
 After initial characterization, the 3T3-L1 system appeared ideal for our proof-of-
concept studies. Not only did we see successful differentiation of fibroblasts into 
adipocytes, but the relative expression changes from predominantly GLUT1 to 
predominantly GLUT4 seemed promising for investigating changes in trans-acceleration. 
However, this proved to be more complicated than anticipated.
 Although we successfully measured GLUT1-mediated trans-acceleration in 
fibroblasts, the extremely rapid time points necessary to detect this stimulation were 
difficult to reproduce. This raised the possibility that we would not be able to accurately 
measure transport in insulin-stimulated adipocytes, where we expected to see more rapid 
transport. This assumption was based on experimental evidence in 3T3-L1 adipocytes 
showing that insulin stimulation resulted in both an increase in total membrane protein 
and a 2- to 20-fold stimulation of transport over basal conditions (164), (263). We 
confirmed this in our time course experiment, which showed that 3-MG uptake was 
approximately twice as rapid in stimulated over basal adipocytes. 
 We also were able to measure and map counterflow in fibroblasts. Counterflow 
refers to the transient increase in intracellular accumulation of labeled sugar prior to 
equilibration. This phenomenon is based upon the presence of cold intracellular sugar 
acting as a competitive inhibitor to exit of the initially accumulating labeled sugar, which 
then equilibrates over time.  While the presence of counterflow is merely indicative of 
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carrier-mediated transport (29), (186), the slope of the counterflow can be used to 
determine the presence of trans-acceleration. However, the fit of the experimental 
counterflow data indicated that even at 1 second measurements, we were likely 
underestimating the magnitude of the counterflow transient peak. This further supported 
our concerns that transport in 3T3-L1 cells was extremely rapid and difficult to measure.  
 Despite this technical issue, we were able to use our map of counterflow to show 
GLUT1-mediated trans-acceleration in fibroblasts. By comparing the initial rate of influx 
in zero-trans uptake versus pre-loaded conditions, we observed that the rate of 
counterflow is faster than the rate of zero-trans uptake, showing stimulation of transport. 
The same characteristics were retained in counterflow measurements in both basal and 
insulin-stimulated adipocytes, indicating that trans-acceleration persisted. Indeed, when 
we sought to test for trans-acceleration in adipocytes, we observed accelerated exchange 
uptake under both basal and insulin-stimulated conditions. 
 There could be several reasons for this result. First, performing uptake at sub-5 
second time points introduces higher variability, and less reproducibility. In addition, it is 
possible that stimulation with insulin could increase the amount of GLUT4 at the cell 
surface of the adipocytes, some GLUT1 would still be present in both basal and 
stimulated adipocytes. Although the amount of GLUT1 at the surface of CHO and 3T3-
L1 cells has been shown to increase in response to insulin in some studies (264), (265), 
others show contradictory results (164), (258). In one study, the insulin-induced increase 
in plasma membrane expression of GLUT1 (~6-fold) was accompanied by a greater 
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increase of surface GLUT4 (~17-fold; (263)); another study reported a 90% decrease in 
GLUT1 activity in differentiated adipocytes (266). For our purposes, the critical aspect 
was whether the amount of total GLUT1 at the surface would be significant enough to 
result in a positive read-out for trans-acceleration, which appears to be the case. 
 A third possible explanation would be the presence of a heterogeneous population 
of adipocytes and some undifferentiated fibroblasts. This would likely preclude accurate 
and reproducible measurements of “loss” of trans-acceleration, as a variable number of 
cells would still be utilizing GLUT1 as the primary transporter. Regardless of the 
explanation for the results observed in adipocytes, the 3T3-L1 system proved to exhibit 
transport properties too rapid to be useful as a proof-of-principle model for our study.
 Therefore, we concluded that in order to measure trans-acceleration 
experimentally, we require an experimental system where transport is slowed sufficiently 
to provide reliable, reproducible measurements. This would allow us to ensure the ability 
to measure both gain and loss of trans-acceleration ability above background. In addition, 
in order to compare the effect of sequence differences between GLUT1 and GLUT4, we 
require a cell system where neither is expressed endogenously, such that both transporters 
and mutation(s) to either could be transiently over-expressed. Future studies will focus on 
establishing these parameters and comparing domains of GLUT1 and GLUT4 as they 
pertain to ability to catalyze trans-acceleration.
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CHAPTER III
Sequence Determinants of GLUT1-Mediated Trans-Acceleration: Analysis by 
Homology-Scanning Mutagenesis
Abstract
 The class 1 equilibrative glucose transporters GLUT1 and GLUT4 are structurally 
similar but catalyze distinct modes of transport. GLUT1 exhibits trans-acceleration in 
which the presence of intracellular sugar stimulates the rate of unidirectional sugar 
uptake. GLUT4-mediated uptake is unaffected by intracellular sugar. We devised an 
approach to measure trans-acceleration in transfected HEK cells at physiologic 
temperature by analyzing hetero-exchange uptake of two sugar analogs. Using 
homology-scanning mutagenesis in which domains of GLUT1 are substituted with 
equivalent domains from GLUT4 and vice versa, we show that GLUT1 transmembrane 
domain 6 is both necessary and sufficient for trans-acceleration. In addition, substitution 
of this sequence in GLUTs 1 and 4 alters the catalytic activity of each transporter under 
zero-trans conditions.  Transmembrane domain 6 is not directly involved in GLUT1 
binding of substrate or inhibitors. Rather, this region is part of two putative scaffold 
domains, which coordinate membrane-spanning amphipathic helices that form the sugar 
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translocation pore. We propose that GLUT1 transmembrane domain 6 restrains import 
when intracellular sugar is absent.
Introduction
 The GLUT family of glucose transporters catalyzes tissue-specific facilitative 
monosaccharide transport in mammalian cells (7). GLUT1 mediates sugar uptake in red 
blood cells, smooth muscle and across blood-tissue barriers (12), (267), (268). GLUT4 is 
expressed in adipose tissue, skeletal, and cardiac muscle (269), where it is responsible for 
insulin-stimulated sugar uptake (270), (271).
 While GLUTs 1 and 4 exhibit similar affinities for substrates and antagonists 
(202), (272), their catalytic behaviors are very different. GLUT4 displays kinetic 
symmetry (Vmax and Km for net sugar uptake are indistinguishable from the corresponding 
parameters for net exit (203), while GLUT1 kinetics are asymmetric (Vmax and Km for net 
sugar uptake are significantly lower than the corresponding parameters for net exit 
(185)). In addition, GLUT1 displays a behavior termed trans-acceleration, whereas 
GLUT4 does not (177), (188), (189), (203), (206). 
 Trans-acceleration (also called accelerated-exchange transport) occurs when 
unidirectional uptake of sugar is stimulated by the presence of intracellular sugar or, 
conversely, when unidirectional exit of sugar is stimulated by the presence of 
extracellular sugar (186). Trans-acceleration may provide a metabolic advantage to the 
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cell because it results in a more rapid equilibration of the cytoplasm with extracellular 
sugar. Trans-acceleration is one of several behaviors that distinguishes carrier-mediated- 
from channel-mediated facilitative diffusion systems (273), but the physical basis of 
accelerated exchange transport is unknown. Comparative analysis of GLUTs 1 and 4 
may, therefore, permit definition of the sequence-determinants and thereby the physical 
basis of trans-acceleration.
 GLUTs 1 and 4 are structurally similar, containing cytoplasmic N- and C-termini, 
12 transmembrane spanning α-helices (TMs), and a large intracellular loop connecting 
TMs 6 and 7 (252), (10), (184). In the absence of GLUT crystal structures, our 
understanding of GLUT1 tertiary structure derives largely from scanning cysteine 
mutagenesis (129), (136), (134), (135) and modeling studies (116), (115), which align 
and thread GLUT1 sequence through the crystal structures of Major Facilitator 
Superfamily bacterial transporter homologs GlpT (274) and LacY (113). While these 
homology-based threaded structures provide quite accurate descriptions of transporter 
topography and helix-packing arrangements, they fail to accurately predict helix and 
amino acid side chain orientation within the active sites (137). 
 Some functional domains of GLUT1 have been mapped at low resolution. These 
include components of the GLUT1 nucleotide binding domain (151), (193), (152), 
substrate binding sites (275), (134), inhibitor binding sites (276), (277), allosteric 
modulation sites (213), (230), (229) and oligomerization domains ((142), Levine et al., in 
preparation). However, detailed structures of these domains and the conformational 
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changes associated with transport are not yet available. In addition, analogous modeling 
studies have yet to be extended to GLUT4. Thus, the available data do not yet provide an 
explanation for substrate binding and translocation by GLUTs 1 and 4, or why GLUT1 
catalyzes trans-acceleration but GLUT4 does not.
 This study attempts to investigate the determinants of transporter function using 
homology-scanning mutagenesis of structurally related but functionally different 
members of a transporter family. We engineered GLUT1 and GLUT4 chimeras in which 
we substituted progressively smaller domains of one transporter by the corresponding 
domains of the other transporter. These chimeras exhibit sequence-dependent trans-
acceleration gain- or loss-of-function.
 We observe trans-acceleration in GLUT1-transfected HEK cells but not in cells 
transfected with human GLUT4. Homology-scanning mutagenesis reveals that TM6 of 
GLUT1 is both necessary and sufficient to confer trans-acceleration to the GLUT4 
scaffold. Similarly, the replacement of GLUT1 TM6 with the corresponding region in 
GLUT4 ablates trans-acceleration in the GLUT1 scaffold. These results confirm that 
trans-acceleration is sequence-dependent, requiring a motif within the putative scaffold 
region of GLUT1, rather than in the translocation pore-forming region of the protein. The 
implications of our findings are discussed in the context of the prevailing models for 
GLUT-mediated sugar transport.
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Experimental Procedures
Materials 
 [3H]-2-deoxy-D-glucose was purchased from MP Biomedical. HEK-293 cells 
were purchased from ATCC. DMEM, DPBS, penicillin/streptomycin, Lipofectamine 
2000, DH5α-Subcloning cells, pcDNA 3.1 (+) mammalian expression vector, Bis-Tris 
gels and MES buffer were obtained from Invitrogen. All restriction enzymes and 
associated buffers were obtained from New England Biolabs. All primers were purchased 
from Integrated DNA Technologies. Herculase polymerase, XL1-Blue Competent cells 
and QuikChange Multi Site-Directed Mutagenesis kits were obtained from Stratagene. 
RNeasy, Qiashredder, One-Step RT-PCR, MinElute Gel Purification, PCR Purification, 
and HiSpeed Maxi kits were from Qiagen. iScript One-Step PCR kit with SYBR green 
was purchased from BioRad. PVDF membranes were obtained from ThermoFisher. 10% 
bovine serum albumin was from American Bioanalytical. Super Signal Pico West, 
NeutrAvidin Gel, micro-BCA kits, spin columns and EZ-Link Sulfo-NHS-SS-Biotin were 
from Pierce. Protease inhibitor cocktail tablets were from Roche. Other reagents were 
purchased from Sigma Chemicals.
Solutions 
 Cell lysis buffer consisted of DPBS, 0.5% Triton X-100 plus protease inhibitiors 
with EDTA. TBS contained 20 mM Tris base, 135 mM NaCl, pH 7.6. Biotin lysis and 
column wash buffer comprised TBS, 0.5% Triton X-100 and protease inhibitors with 
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EDTA. Sample buffer consisted of 0.5 M Tris-Cl, pH 6.8, 40% (v/v) glycerol, 8% SDS, 
bromophenol blue, and 150 mM DTT; biotinylation sample buffer did not contain 
bromophenol blue. DPBS-Mg contained 5 mM MgCl2. 2-DG uptake solution contained 
100 µM 2-DG with 2.5 µCi/ml [3H]-2DG in DPBS-Mg. Stop solution consisted of 10 µM 
cytochalasin B and 100 µM phloretin in DPBS-Mg. Triton extraction buffer contained 
0.5% Triton X-100 and 50 µM EDTA in DPBS-Mg. 2-DG/3-MG uptake solution 
consisted of 100 µM 2-DG with 2.5 µCi/ml [3H]-2DG in DPBS-Mg with 40 mM 3-MG.
Antibodies
 A custom-made (New England Peptide) affinity-purified rabbit polyclonal 
antibody raised against a peptide corresponding to GLUT1 C-terminal residues 480-492 
was used at 1:10,000 dilution as described previously (152). A rabbit polyclonal anti-
GLUT4 C-terminal antibody (Sigma G4048) was used at 1:3,000 dilution. A rabbit 
polyclonal anti-myc antibody (AbCam ab9106) was used at 1:5,000 dilution. Horseradish 
peroxidase-conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch) 
was used at 1:50,000 dilution. A rabbit polyclonal anti-Na+,K+-ATPase antibody (Cell 
Signaling Technologies 3010) was used at 1:500 dilution.
Tissue Culture
 HEK-293 cell culture was as previously described previously (195). All 
experiments were performed with confluent cells. Plates were subcultured into 12 well 
plates at a ratio of 1:2-1:4 2-4 days prior to transfection. Passages 4-19 were used for all 
experiments.
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Mutagenesis
 GLUT1- or GLUT4-encoding cDNA was inserted into the EcoRV-Not1 restriction 
sites of pcDNA 3.1 (+). Myc-tagged constructs were made using overlapping primers to 
insert the myc tag in exofacial loop 1, between GLUT1 residues 55-56 or GLUT4 
residues 72-73. All TM-domain chimeras were engineered by designing overlapping 
primers for each region of interest, amplifying each fragment via PCR using Herculase 
polymerase, purifying each fragment with the MinElute Gel Purification kit, joining 
fragments by PCR, and repeating until a full-length insert was obtained. The insert was 
purified by the PCR Purification kit, digested with restriction enzymes, purified by the 
MinElute Gel Purification kit, and inserted into pcDNA 3.1 (+) with the same restriction 
sites. All final constructs were subcloned into either XL1-Blue Competent cells or DH5α-
Subcloning cells, purified using a HiSpeed Maxi kit, and verified by sequencing analysis 
(Davis Sequencing, Davis, CA). All point mutations and amino acid substitutions were 
engineered using QuikChange Multi Site-Directed Mutagenesis kits and were verified by 
sequencing. For a complete list of primers used, see Appendix (Table A1).
Quantitative and End Point Reverse-Transcriptase PCR
 Total RNA was isolated from HEK cells using the RNeasy kit and Qiashredder. 
End point RT-PCR was performed as per the One-Step RT PCR kit instructions using 
GLUT-specific primers. RT-PCR products were resolved on a 1.5% agarose gel and 
visualized by ethidium bromide staining. Expression levels of detected GLUTs were 
measured by quantitative RT-PCR using the iScript One-Step PCR kit with SYBR green. 
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Samples were run in duplicate on an MJ Research PTC-200 Peltier Thermal Cycler with 
a Chromo4 real time PCR detector running Opticon Monitor 3 software (Bio-Rad). 
Results were analyzed by using the delta-delta Ct method (259) and normalized to a 
GAPDH control. For a complete list of primers used, see Appendix (Table A2).
Transient Transfection
 Cells (70-90% confluency) were transfected with 2 µg DNA per well (12 well 
plates) or 5 µg DNA per well (6 well plates), unless otherwise specified. Transfections 
were performed 36-48 hours prior to analysis of sugar uptake or protein expression.
Western Blotting
 Cells were pelleted, washed with DPBS, lysed in cell lysis buffer, and protein 
concentration was assessed using a micro-BCA kit. Lysates were normalized for total 
protein concentration and resolved by SDS-PAGE on a 10% Bis-Tris gel in MES buffer. 
Gels were transferred onto PVDF membranes, blocked with 10% bovine serum albumin 
in TBS-T, probed with primary antibody overnight at 4°C, probed with secondary 
antibody for 1 hour at room temperature, and developed using Super Signal Pico West 
Chemiluminescent substrate. Blots were imaged on a FujiFilm LAS-3000 and relative 
band densities were quantitated using ImageJ software.
Biotinylation
 6-well plates of HEK cells were washed twice with ice-cold DPBS and incubated 
on ice with ice-cold DPBS containing 5 mM EZ-Link Sulfo-NHS-SS-Biotin for 30 min 
with gentle rocking. Reactions were quenched by adjusting each well to 12.5 mM Trizma 
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base. Cells were harvested,  re-suspended in biotin lysis buffer and lysates were bound to 
Neutravidin Gel in spin columns according to kit instructions. Protein concentration was 
determined spectrophotometrically, and normalized loads were analyzed by Western blot 
as described above.
2-deoxy-D-glucose Sugar Uptake
 2-deoxy-D-glucose (2-DG) is an analog of the natural GLUT1 substrate, D-
glucose. At physiologic temperature, cytoplasmic 2-DG is phosphorylated by hexokinase 
to form 2-deoxy-D-glucose-6-phosphate (2-DG-6-P), which is neither metabolized 
further nor is a GLUT1 substrate (195), (278). Imported [3H]-2-DG is therefore trapped 
within the cell as [3H]-2-DG-6-P. 
 2-DG uptake was measured as described previously (234). Briefly, 36-48 hours 
post-transfection, 12-well plates of confluent HEK-293 cells were serum- and glucose-
starved for 2 hours at 37°C in FBS- and penicillin/streptomycin-free DMEM lacking 
glucose. Cells were washed with 0.5 mL DPBS-Mg at 37°C, then exposed to 0.5 mL of 
[3H]-2-DG uptake solution for 0 to 30 min at 37°C. Uptake was stopped by addition of 1 
mL ice-cold stop solution. Cells were washed twice with ice-cold stop solution and 
extracted with Triton extraction buffer. Total protein concentration was analyzed in 
duplicate. Each sample was counted in duplicate by liquid scintillation spectrometry. 
Each condition was performed in triplicate on at least 3 separate assay occasions.
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Zero-Trans and Hetero-Exchange Transport Measurements
 Zero-trans sugar uptake describes uptake of sugar into cells lacking intracellular 
sugar. Hetero-exchange sugar uptake describes uptake of sugar into cells preloaded with a 
different, but transportable sugar (226). Zero-trans uptake of [3H]-2-DG by sugar-
depleted cells was measured as described above with one modification - the transported 
sugar 3-O-methyl-D-glucose (3-MG; 40 mM) was included in the uptake medium. 
Extracellular 3-MG competitively inhibits [3H]-2-DG uptake and thus permits more 
accurate measurement of transport over a 5 minute interval at physiologic temperature 
(37°C). Because 3-MG is not a hexokinase substrate (196), any 3-MG that enters the cells 
during transport or by pre-loading the cells does not compete with intracellular 2-DG for 
interaction with hexokinase. In hetero-exchange uptake, the concentration of 3-MG inside 
and outside of the cell is identical (40 mM). This is accomplished by adding 40 mM 3-
MG to glucose-free DMEM during serum starvation and to DPBS-Mg used in pre-uptake 
washes. This method was developed to measure trans-acceleration in transfected HEK 
cells; analysis of 3T3-L1 fibroblast transport under these conditions did not show trans-
acceleration (Appendix Figure A3.1)
Data Analysis
 All data analysis was performed using GraphPad Prism (La Jolla, CA, v 5.0). For 
sugar uptake experiments, background counts were subtracted from all samples and 
uptake, v, was normalized to [total protein]/well. [3H]-2-DG uptake (DPM/µg) was then 
converted to mol/µg protein/min by using the measured specific activity of the uptake 
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solution. Average uptake in mock-transfected controls was subtracted from the uptake of 
the corresponding transfected samples. For experiments where [3-MG]i was varied, sugar 
uptake, v, was fitted to the following approximation (Equation 3.1):
by non-linear regression analysis, where vb is sugar uptake in the absence of 3-MGi, Emax 
is the stimulation of sugar uptake produced by saturating 3-MGi, [S] is the concentration 
of 3-MGi and KE is that concentration of 3-MGi which stimulates sugar uptake by 50%.
In experiments evaluating whether trans-acceleration is observed, the ratio of hetero-
exchange (HE) uptake:zero-trans uptake (ZT) was computed for each construct. As we 
shall show, this normalizes for experimental variation in transporter cell surface 
expression. When this ratio is significantly greater than 1, trans-acceleration is present. 
The results of paired experiments were analyzed using Student's t-test.
94
Results
GLUT1 and GLUT4 chimeras
 In order to identify GLUT1 domain(s) required for trans-acceleration, we 
swapped specific transmembrane regions of GLUT1 with equivalent GLUT4 sequence. 
This allows us to map the involvement of large regions of the transporter in trans-
acceleration and thereby narrow our focus to smaller sub-domains (Figure 3.1). Chimera 
nomenclature divides the GLUTs into 4 sets of three contiguous TMs (1-3, 4-6, 7-9, 
10-12). A chimera comprising the first half of GLUT1 plus the second half of GLUT4 is 
termed 1144 - GLUT1 TMs 1-3 and 4-6 plus GLUT4 TMs 7-9 and 10-12. If loop 6 
linking TMs 6 and 7 is the focus, this is indicated in parenthesis. Thus, 44(1)11 is GLUT4 
TMs 1-6, GLUT1 loop 6, and GLUT1 TMs 7-12. 1411 is GLUT1 TMs 1-3 plus GLUT4 
TMs 4-6 plus GLUT1 loop 6 and TMs 7-12 (Figure 3.1B).  Mutations involving only 1 or 
2 TMs list the scaffold GLUT with substitutions from the other GLUT in parenthesis, e.g. 
GLUT4 (5,6 G1) is GLUT4 containing GLUT1 TMs 5-6. 
Trans-Acceleration in HEK Cells
 HEK-293 cells were selected for heterologous expression of GLUT1, GLUT4 and 
GLUT1-GLUT4 chimeras because of their very low endogenous expression of human 
GLUTs 1 and 4, as determined by qPCR (Figure 3.2). Net uptake of 100 µM 2-DG 
increases linearly with time (0 – 10 min) in GLUT1-transfected cells (Figure 3.3A). The 
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Figure 3.1 GLUT1/GLUT4 chimeras 
A, Schematic of GLUT topology; trans-membrane domains (1-12) are numbered in 
blocks of 3. Intracellular loop 6 (L6) connects TMs 6-7 and the carboxy-terminus (Ct) is 
cytoplasmic. B, Chimera nomenclature derives from the origin of each block of 3 TMs 
and from the origin of loop 6 (in parentheses). When substitutions smaller than 3 TMs are 
made, the chimera is named by the scaffold protein (GLUT1 or GLUT4) with the 
substituted TM domain(s) in parenthesis (i.e. GLUT4 containing TMs 5-6 of GLUT1 is 
GLUT4 (5,6 G1)).
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Figure 3.2 Analysis of HEK cell endogenous GLUT mRNA expression by qPCR 
HEK cells were screened for the presence of all GLUTs by end-point RT-PCR (Appendix 
Figure A3.1). Quantitative RT-PCR was then used to compare message expression levels. 
Expression relative to GLUT12 message (ordinate) is plotted versus GLUT identity 
(abscissa). The significance of the difference between GLUT12 and other GLUTs was 
computed by an unpaired, 2-tailed Student’s t-test with the following results: 
*** P ≤ 0.005. 
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Figure 3.3 Sugar uptake in HEK cells expressing GLUT1, GLUT4, and 
  myc-tagged GLUTs 
A, Time course of 3[H]-2-DG uptake in control and GLUT1-transfected cells. Ordinate: 
2-DG uptake in dpm per µg total cell protein; abscissa: time in minutes. 2-DG uptake is 
shown in mock-transfected (●) and GLUT1-transfected (○) cells. Lines drawn through 
the points were computed by linear regression. GLUT1-mediated hetero-exchange is 
indicated by the triangle (∆) and the gray rectangle indicates the range of transport 
produced by a 2-3-fold stimulation of transport during hetero-exchange at 5 minutes. B, 
Dose-response of 100 µM 2-DG uptake (ordinate) from medium containing 40 mM 3-
MG into HEK cells pre-loaded with 0-40 mM 3-MG (abcissa) and transfected with 
GLUT1 (○) or GLUT4 (●). Basal uptake by mock-transfected cells was subtracted at 
each 3-MG concentration. Data points represent the mean ± SEM for three separate 
assays. The curve drawn through the GLUT1 data was computed by nonlinear regression 
assuming that uptake is described by equation 3.1. The resulting analysis yields 
parameters of vb = 0.087 ± 0.003 pmol/µg/min; Emax = 0.063 ± 0.002 pmol/µg/min; KE = 
25.8 ± 1.5 mM. The line drawn through the GLUT4 data was computed by linear 
regression. C, Western Blot analysis of total protein levels in GLUT1myc- and 
GLUT4myc-transfected HEK cells. Representative Western blot of whole cell lysates 
from HEK cells transfected with GLUT1myc or GLUT4myc constructs. Lysates were 
resolved by SDS-PAGE, transferred to PVDF membranes and probed with α-myc Ab 
(top), α-GLUT1 C-terminal Ab (middle), or α-GLUT4 C-terminal Ab (bottom). 
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time course of 2-DG uptake is even slower in the presence of competing 3-MG 
(Appendix Figure A3.3). The experiments reported in this study employ a 5-minute 
uptake interval, which provides an ample range of linearity to detect a 2- to 3-fold 
increase in 2-DG uptake during hetero-exchange transport catalyzed by transfected 
GLUTs. In order to characterize differences in sugar uptake in response to intracellular 
sugar, [3H]-2-DG uptake from medium containing 40 mM 3-MG was measured in 
GLUT1- or GLUT4-transfected HEK cells pre-loaded with 0 to 40 mM 3-MG (Figure 
3.3B). GLUT1-transfected HEK cells show a dose-dependent stimulation of 2-DG uptake 
with increasing intracellular [3-MG], while GLUT4-transfected HEK cells do not. This 
confirms that human GLUT1 displays trans-acceleration at 37ºC, whereas human GLUT4 
does not. GLUT1-mediated 2-DG uptake increases in a saturable manner with [3-MG]i, 
showing a maximal stimulation (Emax) of 1.72 ± 0.02-fold with 50% stimulation (KE) at 
25.6 ± 1.5 mM 3-MGi. 40 mM 3-MGi was used in all further hetero-exchange 
experiments.
Modification of GLUT4 to increase surface expression
 The pre-loading experiment (Figure 3.3B) indicates that zero-trans 2-DG uptake 
in GLUT4myc-transfected HEK cells is significantly slower than uptake in GLUT1myc-
transfected cells. Total protein expression levels appear similar by Western blot (Figure 
3.3C), suggesting either that significantly less GLUT4myc is expressed at the cell surface 
or that GLUT4myc has lower intrinsic activity (kcat) than GLUT1myc. We show below 
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that cell surface protein biotinylation analysis indicates that GLUT4myc surface 
expression is less than half that of GLUT1myc. Efforts to increase GLUT4myc surface 
expression by transfecting greater [GLUT4myc] DNA were ineffective (Appendix Figure 
A3.4)
 GLUT4myc surface expression was improved by engineering 3 GLUT4 
mutations known to affect surface expression in a variety of cell types. GLUT4 N- and C-
termini contain internalization (168), (171) and surface-targeting (167), (169) motifs. 
GLUT4myc mutations F5A and LL489-490AA were tested individually and together; 
their surface localization was verified by biotinylation (Appendix Figure A3.5) and their 
function was tested in assays of 100 µM 2-DG uptake under zero-trans conditions (Figure 
3.4A). In these experiments, 2-DG uptake by GLUT4myc is only one quarter of that 
catalyzed by GLUT1myc. 2-DG uptake by GLUT4myc F5A and by GLUT4myc 
LL489-490AA approaches 80% of GLUT1myc-mediated uptake. The triple mutant 
(GLUT4myc F5A/LL489-490AA) catalyzes a level of 2-DG uptake indistinguishable 
from that of GLUT1myc. This mutant (GLUT4myc-3x) was used as the GLUT4 scaffold 
in all further mutational analysis. GLUT1myc typically displays a 1.8 ± 0.15-fold 
stimulation of sugar uptake under hetero-exchange conditions (Table 3.1). However, both 
GLUT4myc and GLUT4myc-3x display no trans-acceleration (Figure 3.4B). This 
confirms that the loop 1 exofacial myc tag and the cell surface-expression mutations 
introduced into GLUT4 do not significantly perturb wild-type exchange-transport 
behavior. 
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Figure 3.4 Sugar transport by GLUT4myc mutants aimed at increasing surface 
  expression   
A, Zero-trans uptake measurements of 100 µM 2-DG in HEK cells (ordinate) transfected 
with GLUT1myc, GLUT4myc, and GLUT4myc mutants (abscissa) engineered to 
increase surface expression (GLUT4 F5A, GLUT4 LL489-490AA, and GLUT4-3x 
(GLUT4 F5A/LL 489-490AA)). Uptake is normalized to zero-trans uptake by 
GLUT1myc transfected cells. B, Uptake measurements (ordinate) of 100 µM 2-DG in the 
presence of 40 mM 3-MG in HEK cells transfected with GLUT1myc, GLUT4myc, or 
GLUT4myc-3x (abscissa) under zero-trans (empty bars) or hetero-exchange (gray bars) 
conditions. Results are shown as mean ± SEM for three separate assays. The significance 
of the difference between control and test conditions was computed by an unpaired, 2-
tailed Student’s t-test analysis yielding the following P values: *** P ≤ 0.001.
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Transport rates are proportional to cell surface GLUT expression
 The absolute rates of GLUT1-mediated zero-trans (ZT) and hetero-exchange (HE) 
2-DG uptake are proportional to the amount of transporter at the cell surface. However, 
transport behavior (GLUT1-mediated trans-acceleration) is unaffected by expression 
level. To illustrate this, HEK cells were transfected with a range of [GLUT1myc DNA], 
and the relationship between cell surface GLUT1myc expression and GLUT1myc-
mediated zero-trans and hetero-exchange transported was investigated (Figure 3.5). 
 Surface expression was quantitated by biotinylation of cell surface protein at 4ºC 
followed by membrane solubilization, streptavidin affinity-purification of labeled 
proteins and quantitation of their GLUT1myc content by immunoblot analysis using α-
myc antibody (Figure 3.5A-B). While the relationship between cell surface expression 
and GLUT1myc-dependent zero-trans or hetero-exchange 2-DG uptake is linear (Figure 
3.5C), the nearly 2-fold increase in hetero-exchange over zero-trans uptake rates remains 
constant at every level of cell surface GLUT1myc observed. We show below that while 
GLUT4 and its engineered variants achieve differing cell surface expression levels, their 
inability to catalyze trans-acceleration is independent of expression level (see Figure 3.4B 
and Figure 3.8).
 Trans-acceleration (or lack thereof) is therefore independent of the amount of 
transporter expressed at the cell surface and is an intrinsic property of the transport 
protein. This is not unexpected. Endothelial cell GLUT1-mediated zero-trans and 
accelerated-exchange 3-MG uptake (the latter being twice as fast as zero-trans uptake) 
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Figure 3.5 The effect of GLUT1myc cell surface expression on transport rates 
  and trans-acceleration  
A, HEK cells were transfected with varying [GLUT1myc DNA]. Two days later, cell
surface proteins were biotinylated, solubilized and affinity purified on streptavidin beads, 
and GLUT1myc was detected by immunoblot analysis using either α-myc Ab or GLUT1 
α-Ct Ab. As a loading control, the α-subunit of the Na+,K+-ATPase was detected using α-
Na+,K+-ATPase Ab. The mobility of molecular weight standards is indicated. The amount 
of GLUT1myc DNA added at transfection is shown above representative blots from an 
experiement. B, Data obtained in the above experiment and from two similar experiments 
were analyzed by densitometry, background corrected, normalized to loading controls, 
and averaged. Ordinate: relative cell surface [GLUT1]; abscissa: µg DNA added at 
transfection. Results are shown as mean ± SEM for three separate assays. The curve is a 
section of a single rectangular hyperbola characterized by K0.5 = 0.47 ± 0.13 µg DNA; 
maximum expression = 1.45 ± 0.12 with expression normalized to unity at 1 µg DNA. C, 
Rate of GLUT1myc-catalyzed zero-trans (●) and hetero-exchange (○) 2-DG uptake as a 
function of cell surface [GLUT1myc] as detected by cell surface biotinylation. Cells were 
transfected with GLUT1myc DNA as in A, and measurements of ZT and HE 2-DG 
uptake or cell surface [GLUT1myc] were made in triplicate on 3 separate occasions. 
Uptake measured in mock transfected cells was subtracted. Results are shown as mean ± 
SEM for three separate assays. The lines drawn through the points were computed by the 
method of least squares and have the following parameters: ZT, slope = 43.7 ± 2.8 fmol/
µg/min/unit biotinylation, y-intercept = 2.6 ± 5.1 fmol/µg/min, R2 = 0.98; HE, slope = 
82.8 ± 8.5 fmol/µg/min/unit biotinylation, y-intercept = 8.8 ± 15.3 fmol/µg/min, R2 = 
0.96.
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are both doubled when endothelial cell surface [GLUT1] is doubled by acute metabolic 
stress (182), (183). Rat erythrocytes express 1,000-fold less GLUT1 than do human 
erythrocytes, but both cells display accelerated-exchange sugar transport (233), (279). 
Rat adipocyte GLUT4-mediated zero-trans and equilibrium exchange 3-MG uptake are 
both increased approximately 12-fold by insulin-induced GLUT4 recruitment to the cell 
surface, but the characteristic GLUT4 kinetic behavior (lack of trans-acceleration) is 
unchanged (209). Provided that heterologous expression of the transporter is sufficient to 
measure its function over background, parental transport, the kinetic behavior of the 
GLUTs (trans-acceleration or lack of trans-acceleration) is independent of cell surface 
expression levels. The measurement of some kinetic constants, such as kcat, does require 
specific knowledge of cell surface expression (see below).
Analysis of half- and quarter-protein domain-chimeras for trans-acceleration
 Zero-trans and hetero-exchange 2-DG transport were measured in HEK cells 
transfected with either GLUT1myc or the half-protein domain chimeras containing 
GLUT1 loop 6 (11(1)44 and 44(1)11). GLUT1 TMs 7-12 are not important for trans-
acceleration (Table 3.1). 2-DG uptake by GLUT1myc and by 11(1)44 is increased under 
hetero-exchange conditions, while transport catalyzed by 44(1)11 is not (Table 3.1). To 
ascertain whether loop 6 sequence is critical, we tested an analogous set of half-domain 
chimeras containing the GLUT4 sequence of loop 6 (Table 3.1). 2-DG uptake by 11(4)44 
or by 11(1)44 is significantly increased under HE conditions but transport by 
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Table 3.1
Zero-Trans and Hetero-Exchange 2-DG Uptake by GLUT1myc-GLUT4myc Chimeras
aChimera bResidues
cZero-Trans 
Uptake (ZT)
fmol/µg/min
dFold-Stimulation 
During Hetero-
Exchange (HE)
HE:ZT
eTrans-
Acceleration
(P value)
GLUT1myc 1-492 117.2 ± 14.9 1.80 ± 0.15 YP ≤ 0.001
GLUT4myc 1-509 42.0 ± 6.8 0.96 ± 0.08 N
GLUT4myc-3x 1-509 77.4 ± 7.4 1.04 ± 0.45 N
44(1)11 G4 1-223G1 208-492 35.4 ± 4.6 0.94 ± 0.17 N
11(1)44 G1 1-266G4 283-509 66.4 ± 7.4 1.90 ± 0.21
Y
P ≤ 0.001
44(4)11 G4 1-282G1 267-492 40.3 ± 9.0 0.96 ± 0.18 N
11(4)44 G1 1-207G4 224-509 35.3 ± 7.3 2.00 ± 0.31
Y
P ≤ 0.01
1444 G1 1-119G4 136-509 103.0 ± 7.0 1.10 ± 0.11 N
4111 G4 1-135G1 120-492 47.3 ± 5.9 1.70 + 0.21
Y
P ≤ 0.01
1411 G1 1-119; 208-492G4 136-223 146.1 ± 10.2 1.00 ± 0.13 N
4144 G4 1-135; 224-509G1 120-207 61.6 ± 8.1 1.80 ± 0.09
Y
P ≤ 0.00001
GLUT4myc (4,5 G1) G4 1-135; 203-509G1 120-186 60.1 ± 4.5 0.65 ± 0.15 N
GLUT4myc (5,6 G1) G4 1-166; 224-509G1 151-207 38.1 ± 3.9 1.90 ± 0.14
Y
P ≤ 0.00001
GLUT4myc (5, G1) G4 1-166; 203-509G1 151-186 53.2 ± 5.7 0.57 ± 0.09 N
GLUT4myc (6, G1) G4 1-203; 224-509G1 187-207 25.8 ± 6.2 1.80 ± 0.23
Y
P ≤ 0.01
GLUT1myc (6, G4) G1 1-186; 208-492G4 203-223 168.3 ± 12.5 1.10 ± 0.11 N
GLUT1myc SIIFI 191-195 
GLTVL
G1 1-190; 196-492
G4 208-212 162.4 ± 7.9 1.30 ± 0.05
Y
P ≤ 0.001
GLUT1myc CIV 202-204 
LVL
G1 1-201; 205-492
G4 218-220 64.1 ± 7.2 2.20 ± 0.18
Y
P ≤ 0.00001
GLUT4myc GLTVL 
208-212 SIIFI
G4 1-207; 213-509
G1 191-195 55.8 ± 4.9 0.59 ± 0.09 N
GLUT4myc LVL 218-220 
CIV
G4 1-217; 221-509
G1 202-204 92.1 ± 5.1 0.97 ± 0.05 N
109
aThe chimeras employed in this study were constructed using two backbones: GLUT1myc (wt 
GLUT1 residues 1-492 with a c-myc epitope (EQKLISEEDL) inserted between residues 55 and 
56) and GLUT4myc-3x (wt GLUT4 residues 1-509 in which F5, L489 and L490 is each 
mutagenized to A, and with a c-myc epitope (EQKLISEEDL) inserted between residues 72 and 
73). All residue numbering ignores the inserted c-myc sequence. Chimera nomenclature is 
described in the Results section and in Figure 1. 
bThe sequence composition of chimeras is described as fusions of GLUT1myc (G1) and 
GLUT4myc-3x (G4) sequence in which G1 and G4 sequence numbering ignores the inserted c-
myc epitope.
cZero-trans uptake (ZT) of 100 µM 2-DG (fmol/µg protein/min) from medium containing 40 mM 
3-MG was measured in transfected HEK cells depleted of intracellular sugar. Values are reported 
as mean ± SEM for a minimum of n = 3 assays and are background-corrected for 2-DG uptake 
measured in non-transfected cells (41 ± 4 fmol/µg protein/min). 
dStimulation of 2-DG uptake observed under hetero-exchange conditions (extra- and intracellular 
[3-MG] = 40 mM) was determined as the ratio of hetero-exchange (HE) 2-DG uptake to ZT 
uptake (fmol/µg/min). Values are reported as mean ± SEM for a minimum of n = 3 assays. 
ZT and HE uptakes were measured for GLUT1myc in every assay. This table reports the 
GLUT1myc data as a global mean ± SEM for a minimum of n=30 assays. The range observed in 
these assays for zero-trans uptake was 39.2 ± 5.36 to 185 ± 18.8 fmol/µg/min. The range 
observed for HE:ZT was 1.48 ± 0.11 to 2.3 ± 0.31
eTrans-acceleration is absent (N) when HE:ZT is not significantly greater than 1. Trans-
acceleration is present (Y) when HE:ZT is significantly greater than 1. Significance was 
determined using an unpaired, 2-tailed student’s t-test.
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44(4)11 or 44(1)11 is not. Cytoplasmic loop 6, therefore, does not contain isoform-
specific sequence that is essential for trans-acceleration. These results allowed us to focus 
on GLUT1 TMs 1-6 for further analysis.
 2-DG uptake by 4111 shows trans-acceleration while uptake by 1444 does not 
(Table 3.1). These data show that isoform-specific sequence in TMs 1-3 is not essential 
for trans-acceleration. In contrast, TMs 4-6 appear essential for trans-acceleration (Table 
3.1). GLUT1myc-mediated 2-DG accelerated-exchange is ablated when GLUT4 TMs 4-6 
are substituted into GLUT1 (1411). Conversely, swapping TMs 4-6 of GLUT1 into a 
GLUT4myc-3x scaffold (4144) produces a gain-of-function chimera characterized by 
robust trans-acceleration (Table 3.1). 
Analysis of TMs 4-6
 We next examined paired TM substitutions in TMs 4-6. We tested for gain-of-
function in GLUT4myc-3x containing either GLUT1 TMs 4-5 (GLUT4 (4,5 G1)) or TMs 
5-6 (GLUT4 (5,6 G1); Table 3.1). Our results show that GLUT4 (4,5 G1) does not show 
exchange stimulation. However, GLUT4 (5,6 G1) displays trans-acceleration gain-of-
function. This result indicates that TMs 5-6 are required for trans-acceleration. Because 
TM5 is also present in the TMs 4-5 chimera, these data suggest either that TM6 alone is 
required for trans-acceleration, or TM6 in combination with TM5 is required. Indeed, 
when we substitute GLUT1 TM6 into GLUT4myc-3x (GLUT4 (6, G1)), we observe a 
trans-acceleration gain-of-function (Table 3.1). Conversely, GLUT1 (6, G4) displays a 
trans-acceleration loss-of-function, indicating that GLUT4 TM6 cannot substitute for 
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GLUT1 TM6. GLUT4 (5, G1) does not show trans-acceleration, indicating that GLUT1 
TM5 alone is insufficient to produce trans-acceleration in GLUT4 (Table 3.1).  Taken 
together, these data confirm that GLUT1 TM6 is both necessary and sufficient for trans-
acceleration. The relative stimulation of HE transport over ZT observed with all the TM-
domain chimeras is summarized in Figure 3.6.
Analysis of transmembrane domain 6 amino-acid substitutions
 Sequence alignment of GLUT1 and GLUT4 TM6 reveals two regions of sequence 
disparity (Figure 3.7). Region A comprises GLUT1 SIIFI191-195, corresponding to GLUT4 
GLTVL208-212. Region B is GLUT1 CIV202-204, corresponding to GLUT4 LVL218-220. We 
chose to exchange the amino acids in Regions A or B between GLUT1 and GLUT4. We 
observe that neither Region A nor B of GLUT1 sequence confers trans-acceleration when 
individually substituted into GLUT4 (Table 3.1).  Similarly, substitution of either Region 
A or B of GLUT4 into GLUT1 does not produce a loss-of-function (Table 3.1). These 
results suggest that all or some of the 8 disparate amino acids within TM6 are required 
for trans-acceleration.
Analysis of kcat/Km for wild-type and TM6 GLUT1 and GLUT4 mutants
 Despite the use of GLUT4myc-3x to increase GLUT4 surface expression, there 
remained consistently lower levels of 2-DG transport among the GLUT4-based chimeras 
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Figure 3.6 Summary of stimulation under hetero-exchange conditions for 
transmembrane domain chimeras
The amount of stimulation observed under hetero-exchange conditions is expressed as a 
ratio of HE:ZT (ordinate), shown for all of the chimeras with TM domain substitutions in 
either GLUT1myc or GLUT4myc scaffolds (abscissa). The global average of HE:ZT for 
GLUT1myc (n=30 assays; Table 3.1) was reported for reference. Trans-acceleration is 
absent when HE:ZT is ≤ 1; a line is drawn to show where HE:ZT is 1. Trans-acceleration 
is present when HE:ZT is significantly above 1. Significance was computed using an 
unpaired, 2-tailed Student’s t-test yielding the following values: ** P ≤ 0.01; *** P ≤ 
0.001; ***** P ≤ 0.00001.
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Figure 3.7 Sequence alignment and conservation of TM6 in GLUTs 
  1 and 4
 
A, Sequence alignment of the trans-acceleration subdomains (cyan background) of 
GLUT1 transmembrane domain 6 (amino acids spanning 191-195-PALLQ-201-203) in 
18 mammals. B, WebLogo plot (http://weblogo.berkeley.edu/) for this alignment. Dolphin 
GLUT1 also displays trans-acceleration (67), but its sequence is not yet known. C, 
Sequence alignment of  the trans-acceleration subdomains (cyan background) of GLUT4 
transmembrane domain 6 (amino acids spanning 208-212-PALLQ-218-220) in 11 
mammals. D, WebLogo plot for this alignment.
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(Table 3.1). This may be related in part to protein stability, as we observe similar amounts 
of message for transfected constructs (Appendix Figure A3.6) but different protein 
expression levels (Appendix Figure A3.7, A3.8). Although we attempted to examine cell 
surface expression by immunofluorescence microscopy (Appendix Figure A3.9), this was 
not quantitative. Due to these differences in chimera expression, we measured relative 
surface GLUT expression by cell-surface biotinylation and used this value to scale zero-
trans uptake rates for constructs of interest.
 Streptavidin pull-downs of biotinylated cell surface proteins confirm the presence 
of transfected myc-tagged GLUTs (Figure 3.8A). The identity of each myc-tagged 
transporter was verified by either anti-GLUT1 or anti-GLUT4 antibodies. Quantitation of 
α-myc signal reveals that GLUT4myc surface expression is 42% ± 2% relative to 
GLUT1myc expression, while surface expression of GLUT4myc-3x is only slightly 
improved (55% ± 18%). GLUT1 (6, G4) shows comparable surface expression to 
GLUT1myc (94% ± 29%), whereas GLUT4 (6, G1) achieves only 17% ± 3% of the 
GLUT1myc level. Scaling the measured zero-trans uptake rate by relative surface 
expression allows us to compare differences in catalytic activity (Figure 3.8B). Adjusted 
rates of zero-trans uptake by GLUT1myc, GLUT4myc, and GLUT4myc-3x are similar 
(Figure 3.8B). However, the trans-acceleration loss-of-function GLUT1 chimera GLUT1 
(6, G4) has an adjusted rate that is 1.5-fold greater than GLUT1myc. In contrast, the 
gain-of-function mutant, GLUT4 (6, G1), has an adjusted zero-trans rate that is lower 
than both wt GLUT4myc and GLUT4myc-3x. However, these differences are not 
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Figure 3.8 Catalytic activity of cell surface GLUT1, GLUT4, and TM6 mutants 
A, Cell surface expression of GLUT1myc, GLUT4myc, GLUT4myc-3x, GLUT1 (6, G4), 
and GLUT4 (6, G1) quantitated by cell surface biotinylation. The streptavidin pull downs 
were probed using α-myc, α-GLUT1, α-GLUT4 and α-Na+,K+-ATPase  (α-subunit) 
antibodies. Average densities of bands detected by α-myc were corrected for density 
observed in mock-transfected cells, normalized to GLUT1myc density and used to 
calculate the data in B and C. B, Adjusted zero-trans 100 µM 2-DG uptake (mol/µg/min, 
ordinate) of GLUT1myc, GLUT1 (6, G4), GLUT4myc, GLUT4myc-3x, and GLUT4 (6, 
G1) (abscissa). Adjusted rates were obtained by scaling the average zero-trans rate of 
each construct by its surface expression relative to GLUT1myc. Results are shown as 
mean ± SEM for three separate assays. An unpaired, 2-tailed Student’s t-test analysis 
yields the following P values: * P ≤ 0.07; **** P ≤ 0.0001. C, Adjusted hetero-exchange 
100 µM 2-DG uptake (mol/µg/min, ordinate) of GLUT1myc, GLUT1 (6, G4), 
GLUT4myc-3x, and GLUT4 (6, G1) (abscissa). Adjusted rates were obtained by scaling 
the average hetero-exchange rate of each construct by its surface expression relative to 
GLUT1myc. Results are shown as mean ± SEM for three separate assays.
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observed when the hetero-exchange rate of uptake is scaled by relative surface expression 
(Figure 3.8C). When intracellular sugar is present, the adjusted rates of GLUT1myc, 
GLUT4myc and both TM6 chimeras are nearly indistinguishable.
Discussion
 Using homology-scanning mutagenesis, we demonstrate that GLUT1 TM domain 
6 is both necessary and sufficient to confer a trans-acceleration gain-of-function to the 
GLUT4 scaffold. Conversely, substituting GLUT4 TM6 into the GLUT1 scaffold ablates 
trans-acceleration. These results establish that trans-acceleration is intrinsic to GLUT1 
sequence, and is not due to modulating co-factors or other cellular contexts. Although 
GLUT1 and GLUT4 TM6 differ by a total of 8 amino acids in two sub-regions, 
homology substitution of either region alone does not materially affect the trans-
acceleration profile of each transporter. This suggests that these sub-domains work in 
concert to affect GLUT1 trans-acceleration of sugar transport.
 The canonical explanation of trans-acceleration centers on two kinetic models for 
carrier-mediated transport: the simple carrier and the fixed-site carrier. The simple carrier 
(Figure 1.3) is proposed to alternate between exofacial and endofacial orientations (212), 
(280), (211), (213). During sugar uptake, an external sugar binds to the exofacial 
orientation, which then undergoes a conformational change to the endofacial state, from 
which the sugar dissociates into cytoplasm. For an additional round of sugar uptake to 
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occur, the endofacial orientation of the carrier must now reorient to the exofacial state. 
Conformational changes (exofacial to endofacial and vice versa) are termed translocation 
when a sugar is bound, and relaxation when no sugar is bound (186). Trans-acceleration 
of sugar uptake occurs when translocation (endofacial to exofacial) is faster than 
relaxation. The absence of trans-acceleration is observed when translocation proceeds at 
the same rate as relaxation. Trans-inhibition would be observed if translocation were 
slower than relaxation.
 The fixed-site carrier model (Figure 1.4) proposes that the carrier exposes 
endofacial and exofacial sugar binding sites simultaneously (262), (185), (281), (282). 
Transport proceeds concurrently in both directions, implying that sugars initially bound at 
exo- or endofacial sites exchange into a central cavity, whence they associate with the 
trans-binding site prior to release into the cytoplasm or interstitium, respectively. Simple 
exchange describes the release of a bound exo- or endofacial sugar into the central cavity 
when the trans-site is unoccupied by sugar. Geminate exchange describes the release of a 
bound exo- or endofacial sugar into the central cavity when the opposite site is occupied 
by sugar (239). Trans-acceleration is observed when geminate exchange is faster than 
simple exchange (239).
 A hybrid model (Figure 1.5) has also been proposed, in which the transporter 
comprises 4 simple carriers arranged in a coupled, anti-parallel configuration. At any 
instant, two subunits (carriers) present exofacial orientations and two subunits present 
endofacial orientations (141). If one exofacial subunit undergoes a reorientation to the 
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endofacial state, the adjacent endofacial subunit must undergo a reorientation to the 
exofacial state. If translocation is faster than relaxation, it is easy to see how intracellular 
sugar could stimulate sugar uptake.
 The current study suggests that GLUT4 TM6 sequence allows equal rates of 
simple carrier relaxation and translocation or equal rates of fixed-site carrier exchange 
and geminate-exchange. In contrast, GLUT1 TM6 sequence inhibits simple carrier 
relaxation but not translocation, or inhibits fixed-site carrier exchange but not geminate-
exchange, thereby allowing intracellular sugar to stimulate unidirectional sugar uptake. 
Whichever kinetic model is correct, the following generalization is consistent with 
experimental evidence. In carriers containing GLUT1 TM6 sequence, an empty 
endofacial sugar-binding site is inhibitory to the rate of uptake. In carriers containing 
GLUT4 TM6 sequence, this inhibition is removed and the rate of uptake is unaffected by 
the presence of intracellular sugar.
 This hypothesis is further supported by the observed differences in kcat/Km ratios 
for GLUT1, GLUT4, and the TM6 chimeras. Vmax/Km for enzyme-catalyzed reactions is 
normally obtained by measuring the rate constant, k, for the reaction at limiting substrate 
concentrations, which is converted to kcat/Km by dividing k by [enzyme]. Vmax/Km is 
obtained from measurements of 2-DG uptake and then normalized to cell surface GLUT 
expression to give kcat/Km. While it is possible that TM6 mutants could alter the affinity 
(~1/Km) of GLUT1 and GLUT4 for substrate, this seems unlikely because TM6 is a 
putative scaffold TM quite distant to the hypothesized GLUT1 substrate-binding cavity 
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(116). Moreover, Km(app) for GLUT1- and GLUT4-mediated sugar uptake is similar for 
both 2-DG (9-10 mM; (200)) and 3-MG (~6 mM; (209)). We therefore hypothesize that 
the observed changes in kcat/Km (Figure 3.8B) largely reflect changes in kcat.
 If TM6 affects the relative rates of simple carrier relaxation and translocation, or 
of fixed-site carrier exchange and geminate-exchange, we predict that the inhibitory 
sequence of GLUT1 TM6 would reduce GLUT4-catalyzed zero-trans uptake. Indeed, we 
observe that kcat/Km for GLUT4 (6, G1) is ~70% lower than that for either wt GLUT4myc 
or the surface-expression mutant GLUT4myc-3x (Figure 3.8B). In contrast, substituting 
GLUT4 TM6 sequence into GLUT1 should increase zero-trans kcat/Km relative to that of 
wt GLUT1, and this is observed. By the same rationale, we would predict that this 
inhibitory sequence would be without effect in the presence of intracellular sugar, as 
relaxation is bypassed with translocation. When we compare the adjusted hetero-
exchange rates of the TM6 chimeras (Figure 3.8C), this is indeed the case.
 GLUT1 TM6 trans-acceleration sub-domains are highly conserved (F194 and 
C202 are 100% conserved among 18 mammalian species; S191 and I193 are 94% 
conserved; see Figure 3.7). A homology-modeled GLUT1 three-dimensional structure 
(116) juxtaposes putative scaffold TMs 6 and 3 with the translocation pore-forming TM1 
(Figure 3.9 A-B). A study by Liu et al., aimed at identifying sequences important for 
ATP-modulation of GLUT1 (235), showed that a point mutation in TM3 (G111A) 
abolishes trans-acceleration of GLUT1 expressed in X. laevis oocytes. We did not 
observe this effect in the TMs 1-3 chimeras because this glycine is conserved between 
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GLUT1 and GLUT4, and is therefore present in both chimeras. While our data suggest 
that G111 alone is not sufficient for trans-acceleration, it does not rule out the possibility 
that G111 makes critical contacts with TM6. The sequence of the membrane-spanning 
region of TM1 is invariant between GLUTs 1 and 4, with the exception of GLUT1 T30 
(Figure 3.9C). This position is conserved in GLUTs 1 and 3 (those carriers showing trans-
acceleration), but not in GLUTs 2 and 4 (carriers lacking trans-acceleration). However, a 
potential role of T30 in trans-acceleration is eliminated by the observation that the 4111 
chimera contains the substitution T30I, yet still displays trans-acceleration. It is tempting 
to speculate that GLUT1 TM6 residues 191-195 and 202-204 interact with partners in 
TM1 and/or TM3 (Figure 3.9C) to stabilize endo- and exofacial orientations of the 
substrate-deficient-carrier, thereby restraining conformational changes between exo- and 
endofacial states (e.g. relaxation). We hypothesize that when sugar binds to exofacial or 
endofacial sites, these interactions are weakened, TM arrangements are destabilized, and 
conformational change is accelerated.
 While the ability to catalyze trans-acceleration has not been studied in all GLUTs, 
exchange transport has been measured in all four of the class I glucose transporters 
(GLUTs 1-4). Human GLUT3 catalyzes trans-acceleration in rat cerebellar granule 
neurons (283) and in transfected HEK cells, while rat liver GLUT2 does not exhibit 
trans-acceleration (208). TM6 sequence comparisons across GLUTs 1 - 4 (Figure 3.9D) 
show that the same 2 sub-domains responsible for trans-acceleration in GLUT1 represent 
the only variable TM6 sequence among all four transporters. 
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 Figure 3.9 Role of TM6 in GLUT1-mediated trans-acceleration.  
Putative glucose transport proteins (GLUT1) homology-modeled structure based on the 
GlpT homology model and visualized using VMD 1.8.5 (© University of Illinois 2006). 
GLUT1 coordinates were obtained from the RCSB Protein Data Bank (entry No. 1SUK). 
A, GLUT1 viewed along the bilayer plane. The limits of the bilayer are indicated by the 
cartoon representations of phospholipids. B, Putative helix packing arrangement viewed 
from the cytoplasmic surface. TMs are numbered and colored as in A. Cytoplasmic loops 
are indicated by solid lines and exofacial loops by dashed lines. C, Putative stacking of 
TMs 6 and 1. TM6 is shown as a ribbon cartoon (cyan) and residues 191-195 and 
201-203 as surface representations (yellow), respectively. TM1 is shown as a surface 
representation (cyan), with residue T30 highlighted (yellow). D, Sequence alignment of 
TM6 from human GLUTs 1, 3, 2 and 4. GLUTs 1 and 3 catalyze trans-acceleration. 
GLUTs 2 and 4 do not. Numbering corresponds to GLUT1 sequence. The areas lacking 
homology are shaded cyan. A putative consensus sequence is indicated.
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Further homology scanning mutagenesis studies extending TM6 substitutions into 
GLUT2 and GLUT3 may reveal whether TM6 plays a central role in trans-acceleration in 
all glucose uniporters.
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CHAPTER IV
Further Characterization of Mutations to TM6 in GLUT1 and the Role of TM6 in 
Class I GLUT-Mediated Trans-Acceleration
Abstract
 The kinetic phenomenon of trans-acceleration has been studied in all four of the 
Class I glucose transporters. Both GLUTs 1 and 3 display accelerated exchange transport, 
whereas both GLUTs 2 and 4 do not. Our previous studies have shown that the putative 
scaffolding domain TM6 is necessary and sufficient for trans-acceleration in GLUTs 1 
and 4. This domain differs in a total of 8 amino acids across 2 sub-regions of the 
sequences, which also represent the most variable regions of TM6 in both GLUTs 2 and 
3. Substitution of these 8 residues show that GLUT2 TM6 sequence causes a trans-
acceleration loss-of-function in GLUT1, and substitution of GLUT3 TM6 sequence 
results in a gain-of-function in GLUT4. These changes in ability to catalyze trans-
acceleration have been associated with changes in kcat/Km of the transporter. Here, we 
show that substitutions to GLUT1 TM6 do not change the intrinsic affinity of the 
transporter for substrate, supporting the hypothesis that changing TM6 sequence changes 
catalytic activity. The GLUT2 and GLUT3 TM6 substitutions in GLUTs 1 and 4 are 
associated with the same patterns of change in zero-trans kcat. In addition, we show that 
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mutation of the GLUT2 TM6 region to GLUT1 or GLUT3 sequence results in a trans-
acceleration gain-of-function. These studies support the hypothesis that the 
conformational changes which rate-limit transport by Class I GLUTs are controlled by 
TM6. 
Introduction
 The mammalian family of glucose transporters (GLUTs) are the primary carriers 
used by cells to transport the sugars required for metabolic processes. Although the 14 
members of this family share a similar putative topology and have overlapping 
specificities for different substrates, they differ in many aspects, including tissue-specific 
expression, kinetic characteristics, and protein sequence (102), (184). Of these, the Class 
I glucose transporters (GLUTs 1-4) have been the most extensively characterized.
 The basal glucose transporter, GLUT1, is expressed in all tissues in the body, 
particularly in red blood cells, the heart, and at blood-tissue barriers (12), (13), (284). 
GLUT1 is a high-affinity glucose transporter with a Km for glucose and 2-deoxy-D-
glucose (2-DG) of ~ 2-6 mM (237), (197), (194), (199), and a Km for 3-O-methyl-D-
glucose (3-MG) of 4-20 mM, depending on experimental conditions (197), (201), (202), 
(209), (204), (205). The kinetics of GLUT1-mediated transport have been the most 
characterized of the GLUTs, as it was the first glucose transporter to be identified and 
cloned. The high levels of GLUT1 expression in erythrocytes have made the red cell a 
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classical model system for studying carrier-mediated glucose transport. Such studies have 
shown that GLUT1-mediated transport is quite complex, displaying rapid, multi-phasic 
kinetics (210), (224), asymmetry in the Vmax and Km for sugar uptake and exit (206), 
(207), and accelerated-exchange transport (also known as trans-acceleration; (188), (207), 
(201), (232)).
 One other Class I transporter, GLUT3, has also been shown to catalyze trans-
acceleration (283). While also present in the testes and in platelets, GLUT3 is highly 
expressed within the brain, particularly in neurons (21). Like GLUT1, GLUT3 is a high-
affinity glucose transporter with an even lower Km for glucose (237), (285). GLUT3 has 
also been shown to be ~5-fold more catalytically active than GLUT1 (283). The brain is 
the organ with the greatest demand for glucose, with brain function in delicate balance 
with glucose supply and delivery. It seems appropriate that GLUTs 1 and 3, glucose 
transporters with high affinity, high turnover, and the ability to rapidly equilibrate sugar 
through trans-acceleration, are the predominant GLUTs expressed at the blood-brain 
barrier and within the brain itself.
 In contrast, the other Class I transporters, GLUTs 2 and 4, do not catalyze trans-
acceleration (208), (177), (201). GLUT2 is mainly expressed in the liver, pancreas, and 
small intestine (16). In addition to its critical role in hormonally regulated sugar 
homeostasis in these tissues, GLUT2 has emerged as a key mediator of glucose sensing 
in the counter-regulatory feedback loop (18). While GLUT2 is the only Class I 
transporter that transports fructose, it is also a low-affinity glucose transpoter (Km ~ 17 
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mM (27), (237), (285)). Studies in rat hepatocytes have shown that GLUT2 displays 
neither asymmetry nor trans-acceleration of glucose (208). Similarly, GLUT4 expression 
is limited to other hormonally-regulated tissues, mainly skeletal/cardiac muscle and 
adipocytes (23). In these cells, the majority of GLUT4 resides in intracellular pools until 
stimulation by insulin (and in muscle cells, contraction) induces a rapid translocation of 
GLUT4 to the plasma membrane (286), (175), (173). Once at the surface, GLUT4 is also 
a high-affinity transporter, with a Km on the order of or lower than that of GLUT1 (200), 
(202), (287); reported GLUT4 affinity for 3-MG ranges from ~2-6 mM (197), (201), 
(202), (209). Like GLUT3, GLUT4 has been shown to display a greater turnover than 
GLUT1 (202), (287), and does not show asymmetry (203). 
 While all four Class I GLUTs transport glucose with high affinity (with the 
exception of GLUT2) and show sensitivity to the specific inhibitor cytochalasin B (CCB) 
(28), (272), (285), their sequence homology is only 48-63% (10). As with sequence 
conservation among all 14 glucose transporters, the most variant regions are the N- and 
C-termini, intracellular loop 6, and the other loops connecting the 12 transmembrane 
(TM) domains. However, our previous studies have shown that 8 disparate amino acids 
within GLUT1 transmembrane domain 6 are necessary and sufficient for trans-
acceleration (288). Because the trans-acceleration profiles of GLUT2 and GLUT3 have 
been determined experimentally, we asked whether conserved sequence motifs in the 
TM6 region could dictate ability or inability to catalyze trans-acceleration. A precursory 
analysis of the TM6 sequences for all four Class 1 transporters (Figure 3.9D) reveals that 
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the significant sequence variations within GLUT2 and GLUT3 TM6 also occur within the 
same 2 sub-regions of 8 amino acids that govern trans-acceleration in GLUT1. 
 In this study, we sought to investigate whether substitution of GLUT1 or GLUT3 
TM6 sequence was able to confer trans-acceleration in GLUT2 and GLUT4, and vice 
versa. We also sought to determine whether increases in 2-DG uptake attributed to trans-
acceleration were due to changes in Km, kcat, or both. We report the affinity of GLUT1 for 
2-DG (Km ~1 mM ) to be unchanged when TM6 is mutated to GLUT4 sequence. 
Competition of 2-DG uptake by 3-MG is also similar between wt GLUT1 and its TM6 
mutant. When we made further substitutions to the TM6 regions of GLUTs 1 and 4 with 
the sequences of GLUTs 2 and 3, we show that GLUT2 TM6 causes a loss-of-function in 
GLUT1, and GLUT3 sequence causes a gain-of-function in GLUT4. These substitutions 
are associated with a modified zero-trans kcat. We then extended the Class I TM6 
sequence substitution analysis to show that mutation of the 8 amino acids to either 
GLUT1 or GLUT3 sequence shows a trans-acceleration gain-of-function in GLUT2.
Experimental Procedures
All materials and procedures used are the same as those reported in Chapter III 
Experimental Procedures, with the following exceptions or additions:
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Mutagenesis
 GLUT1-, GLUT2- or GLUT4-encoding cDNA was inserted into the EcoRV-Not1 
restriction sites of pcDNA 3.1 (+). GLUT3-encoding cDNA was inserted into the BamHI-
Not1 restriction sites of pcDNA 3.1 (+), unless otherwise noted in the legend of Table 4.1. 
Myc-tagged constructs were made using overlapping primers to insert the myc tag in 
exofacial loop 1, between GLUT2 residues 44-45 or GLUT3 residues 49-50. For a 
complete list of primers used, see Appendix (Table A1).
Transient Transfection
 HEK cells (70-90% confluency) were transfected with 2 µg DNA per well (12 
well plates) or 5 µg DNA per well (6 well plates), unless otherwise specified. 
Transfections were performed 36-48 hours prior to analysis of sugar uptake or protein 
expression.
2-deoxy-D-glucose Sugar Uptake
 2-DG uptake was measured as described previously (Chapter III; (234)). Zero-
trans  or hetero-exchange uptake of [3H]-2-DG by sugar-depleted cells was measured as 
described previously (Chapter III; (288)). 
Data Analysis
 For experiments where the uptake of 2-DG in the presence of increasing 
competing [3-MG], sugar uptake, Ki(app), was fitted to the following equation for 
competitive inhibition (Equation 4.1):
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Where yo is the amount of 2-DG uptake in the absence of competing 3-MG and is 
constrained to less than 15 fmol/µg/min, K is the [3-MG] at half-maximal competition of 
2-DG uptake, and span is the difference between the maximum and minimum values for 
2-DG uptake.
 In experiments evaluating whether trans-acceleration is observed, the ratio of 
hetero-exchange (HE) uptake:zero-trans uptake (ZT) was computed for each construct. 
As we have shown previously (288), this normalizes for experimental variation in 
transporter cell surface expression. When this ratio is significantly greater than 1, trans-
acceleration is present. The results of paired experiments were analyzed using Student's t-
test.
Results
Comparison of substrate affinity in GLUT1 and its TM6 mutant
 In order to compare the relative affinities of GLUT1 and GLUT1 containing the 
TM6 sequence of GLUT4 (GLUT1 (6, G4)), a zero-trans dose-response to 2-DG uptake 
was measured (Figure 4.1A). As the experiments testing for changes in trans-acceleration 
relied upon 2-DG uptake, this was the analog chosen to examine the affinity of the 
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GLUT1 TM6 mutant. Analysis of the dose-response by fitting the data to Equation 4.1 
shows that while the Vmax of wt GLUT1 is over 2.5-fold greater than the Vmax for GLUT1
(6, G4), the affinities for 2-DG are within error of one another (Km ~1 mM). It is not 
possible to compare the Km obtained for zero-trans dose responses with a Km under 
equilibrium-exchange conditions for 2-DG, due to the activity of hexokinase on the pre-
loaded 2-DG. Although the affinities for 2-DG uptake were the most critical comparison, 
uptake media in the trans-acceleration experimental format contain 40 mM cold 3-MG as 
a competitive inhibitor of 2-DG uptake. Thus we sought to examine whether the 
competition of 2-DG uptake by increasing [3-MG]o was similar for both transporters. 
Analysis of 3-MG inhibition of 2-DG uptake (Figure 4.1B) yields values for Ki(app) that 
are within the same magnitude for both transporters (wt GLUT1myc Ki(app) = 2.9 ± 9.9 
mM; GLUT1 (6, G4) Ki(app) = 6.8 ± 1.9 mM).
Alignment of Class I transporter transmembrane domain 6 sequence
 TM6 is only 21 amino acids long, according to the most recent putative topology 
of GLUT1 (130). As the sequence conservation among the GLUTs is highest in the TM-
spanning regions, alignment of the putative TM6 sequences across all Class I transporters 
is straightforward (Figure 3.9D). The first 4 residues are invariant (PLLL), with the 
exception of the first 2 residues in GLUT2 (HI), showing 87.5% consensus overall. The
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 Figure 4.1  Characterization of 2-DG transport by GLUT1myc and GLUT1 
 TM6 mutant 
 
A, Dose-response of 2-DG uptake (ordinate) from medium containing 0-1 mM 2-DG 
(abscissa) into HEK cells depleted of intracellular sugar and transfected with 
wtGLUT1myc (○) or GLUT1 (6, G4) (). Curves are drawn using nonlinear regression 
assuming that uptake is described by Equation 2.1, with the following results: wt 
GLUT1myc Vmax = 80.1 ± 37.3 fmol/µg/min, Km = 1.3 ± 0.9 mM with R2 = 0.9630; 
GLUT1(6, G4) Vmax = 29.3 ± 3.2 fmol/µg/min, Km = 0.78 ± 0.2 mM with R2 = 0.9937. 
Data are plotted as mean ± SEM for three separate assays. B, Competition of 2-DG 
uptake (ordinate) from medium containing 0-40 mM cold 3-MG (abscissa) into HEK 
cells pre-loaded with 40 mM 3-MG and transfected with wt GLUT1myc (●) or GLUT1 
(6, G4) (). Curves are drawn using nonlinear regression assuming that inhibition is 
described by Equation 4.1, where yo was constrained to 15 pmoles/µg/min. The resulting 
analysis yielded the following values: wt GLUT1myc Kiapp = 2.9 ± 9.9 mM with R2 = 
0.9264; GLUT1 (6, G4) Ki = 6.8 ± 1.9 mM with R2 = 0.9988. Data are plotted as mean ± 
SEM for two separate assays. In both experiments, uptake was measured at 5 minutes at 
37°C, and basal uptake by mock-transfected cells was subtracted from each data point.
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Figure 4.2  Sequence alignment and conservation of the sub-regions of 
  transmembrane domain 6 in GLUTs 2 and 3
A, Sequence alignment of the GLUT2 regions corresponding to the trans-acceleration 
sub-regions (orange background) of GLUT1 transmembrane domain 6 (human GLUT2 
amino acids spanning 223-227-RAILQ-233-235) in 7 mammals. B, WebLogo plot 
(http://weblogo.berkeley.edu/) for this alignment. C, Sequence alignment of the GLUT3 
regions corresponding to the trans-acceleration sub-regions (orange background) of 
GLUT1 transmembrane domain 6 (human GLUT3 amino acids spanning 189-193-
PAILQ-199-201) in 8 mammals. D, WebLogo plot for this alignment.
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same 8 amino acids which determine GLUT1-GLUT4 changes in trans-acceleration 
represent the most variant sequence in all Class I GLUT TM6 sequence. These are 
distributed across two sub-regions, spanning amino acids 5-9 and 15-17 of the 21 amino 
acid TM6 sequence, which are referred to as A and B, respectively. In sub-region A, there 
are no conserved residues among the transporters which display trans-acceleration 
(GLUTs 1 and 3). There are 3 of 5 residues (60%) conserved between the transporters 
which do not show trans-acceleration (GLUTs 2 and 4). Similarly, in sub-region B, there 
is no similarity between GLUTs 1 and 3, and there is 60% conservation of these 3 
residues among GLUTs 2 and 4. The remainder of TM6 sequence is more highly 
conserved; the 5 residues between the sub-regions A and B are 85% conserved, with 1 
difference each in GLUT3 and GLUT2. The final 4 amino acids of TM6 are 94% 
conserved among the class I GLUTs. With these sequence comparisons in mind, we 
designed Class I TM6 subdomain-swapping chimeras in which only the amino acids of 
sub-regions A and B were exchanged among the transporters. 
 For GLUTs 2 and 3, sequences are known across several mammalian species 
(Figure 4.2). Within TM6, GLUT2 shows 100% conservation of the GLSGV sequence in 
sub-region A, with the exception of human Gly226, which is Ala in 5 other species. Sub-
region B, SLL, is more species-variant, with more than half of the sequences showing 
Cys rather than Ser233. The remaining Leu residues are more conserved (70-85%). In 
GLUT3, TM6 sequence is also more conserved in sub-region A, where the Gly, Thr, and 
Ile of GFTIL are 100% conserved. The Phe190 is Leu in 2 species, while the final Leu is 
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Ile or Val in half of the species examined. In sub-domain B, SAA, the alanines are nearly 
100% conserved (with one exception in chicken GLUT3, which is also the most variant 
of the GLUT2 TM6 species analyzed). However, as in GLUT2, the Ser199 is also a Cys 
in a third of the species. 
Analysis of Class I transmembrane domain 6 substitutions in GLUTs 1 and 4
 As we were able to effect trans-acceleration gain- and loss-of-function by 
substitution of the 8 amino acids comprised by sub-regions A and B in previous studies 
(288), we used the same strategy in comparing the effects of other class I transporter 
sequences (see Table 4.1 for a detailed composition of chimeras). GLUT2 does not 
catalyze trans-acceleration (208). When GLUT2 223GLSGV227/233SLL235 is substituted for 
GLUT1 191SIIFI195/202CIV204 in the mutant GLUT1 (6, G2), we observe a trans-
acceleration loss-of-function (Figure 4.3). 
 Due to previous issues with surface expression of both wtGLUT4 and a triple 
mutant, GLUT4myc-3x (288), we sought to improve surface expression by substitution 
of the C-terminal 32 amino acids of GLUT1, in the construct GLUT4myc-cG1. This also 
simplifies analysis of chimera expression by using the same epitope (GLUT1 C-term) for 
the same antibody across multiple constructs. The C-terminal substitution improved upon 
wtGLUT4myc surface expression in both average zero-trans uptake (86.2 ± 8.4 fmol/µg/
min (Table 4.1) versus 42.0 ± 6.8 fmol/µg/min (Table 3.1)) and cell-surface expression, 
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Table 4.1
Zero-Trans and Hetero-Exchange 2-DG Uptake by GLUT1myc, GLUT4myc, 
GLUT2myc, and GLUT3myc Chimeras
aChimera bResidues
cZero-Trans 
Uptake (ZT)
fmol/µg/min
dFold-Stimulation 
During Hetero-
Exchange (HE)
HE:ZT
eTrans-
Acceleration
(P value)
GLUT1myc 1-492 117.2 ± 14.9 1.80 ± 0.15 YP ≤ 0.001
GLUT4myc-cG1 G4 1-476G1 460-492 86.2 ± 8.4 1.11 ± 0.10 N
GLUT1 (6, G2)
G1 1-190; 196-200; 
204-492
G2 223-227; 233-235
90.8 ± 8.6 1.30 ± 0.17 N
GLUT4 (6, G3)
G4 1-206; 212-216; 
220-476
G3 189-193; 
199-201
G1 460-492
43.4 ± 7.9 1.80 ± 0.10 YP ≤ 0.00001
GLUT2myc-cG1 G2 1-491G1 460-492 80.6 ± 4.4 1.19 ± 0.04
N
GLUT2 (6, G1)
G2 1-222; 228-232; 
236-491
G1 191-195; 
201-203; 460-492
29.7 ± 7.6 2.40 ± 0.13 YP ≤ 0.0001
GLUT2 (6, G3)
G2 1-222; 228-232; 
236-491
G3 189-193; 
199-201
G1 460-492
23.8 ± 4.4 2.43 ± 0.22 YP ≤ 0.001
GLUT3+cG4f G3 1-497G4 497-509 91.2 ± 5.3 2.00 ± 0.10
Y
P ≤ 0.00001
1311+cG4f
G1 1-126; 205-492
G3 125-202
G4 497-509
112.7± 10.1 1.79± 0.10 YP ≤ 0.00001
GLUT3myc-cG1 G3 1-457G1 460-492 111.2 ± 12.1 1.11 ± 0.13 N
GLUT3myc G3 1-497 223.5 ± 7.3198.7 ± 8.5*
0.81 ± 0.20
0.61 ± 0.10* N
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aThe chimeras employed in this study were constructed using four backbones: GLUT1myc (wt 
GLUT1 residues 1-492 with a c-myc epitope (EQKLISEEDL) inserted between residues 55 and 
56); GLUT4myc-cG1 (wt GLUT4 residues 1-476, in which F5 is mutagenized to A and the C-
terminal 32 amino acids of GLUT1 are substituted for the C-terminus of GLUT4; and where a c-
myc epitope (EQKLISEEDL) is inserted between residues 72 and 73); GLUT2myc-cG1 (wt 
GLUT2 residues 1-491 in which the C-terminal 32 amino acids of GLUT1 are substituted for the 
C-terminus of GLUT2; and where a c-myc epitope (EQKLISEEDL) is inserted between residues 
44 and 45); and GLUT3 (wt GLUT3 residues 1-497 with a c-myc epitope (EQKLISEEDL) 
inserted between residues 49 and 50). All residue numbering ignores the inserted c-myc sequence. 
Chimera nomenclature is described in the Results section and in Chapter III. 
bThe sequence composition of chimeras is described as fusions of GLUT1 (G1), GLUT2 (G2), 
GLUT3 (G3), and/or and GLUT4 (G4) sequence in which GLUT sequence numbering ignores 
the inserted c-myc epitope.
cZero-trans uptake (ZT) of 100 µM 2-DG (fmol/µg protein/min) from medium containing 40 mM 
3-MG was measured in transfected HEK cells depleted of intracellular sugar. Values are reported 
as mean ± SEM for a minimum of n = 3 assays unless noted, and are background-corrected for 2-
DG uptake measured in non-transfected cells (41 ± 4 fmol/µg protein/min). 
dStimulation of 2-DG uptake observed under hetero-exchange conditions (extra- and intracellular 
[3-MG] = 40 mM) was determined as the ratio of hetero-exchange (HE) 2-DG uptake to ZT 
uptake (fmol/mg/min). Values are reported as mean ± SEM for a minimum of n = 3 assays. 
ZT and HE uptakes were measured for GLUT1myc in every assay. This table reports the 
GLUT1myc data as a global mean ± SEM for a minimum of n=30 assays. The range observed in 
these assays for zero-trans uptake was 39.2 ± 5.36 to 185 ± 18.8 fmol/µg/min. The range 
observed for HE:ZT was 1.48 ± 0.11 to 2.3 ± 0.31
eTrans-acceleration is absent (N) when HE:ZT is not significantly greater than 1. Trans-
acceleration is present (Y) when HE:ZT is significantly greater than 1. Significance was 
determined using an unpaired, 2-tailed student’s t-test.
fConstructs were designed and made by Dr. K. Levine and Dr. J. DeZutter. Both inserts were put 
in the same vector (pcDNA 3.1 (+)) as the other chimeras listed, while using 5’HindIII and 
3’XHOI sites. GLUT3+cG4 and 1311+cG4 represent a fusion of the C-terminal 13 amino acids 
of GLUT4 on the intact GLUT3 sequence or the chimera 1311 rather than a C-terminal 
substitution. Sequence range of TMs 4-6 substituted in 1311 differs slightly from TMs 4-6 of 
other chimeras reported in this study due to source of GLUT1 topology (for 1311, alignment 
reported in Joost and Thorens, 2001 was used; other chimeras use alignment reported in Blodgett 
et al., 2008).
*Both ZT and HE uptake were performed at 2 min instead of 5. The GLUT1myc-mediated ZT 
uptake at 2 min was 77.1 ± 10.3 fmol/µg/min in the same experiment. Each wtGLUT3myc 
experiment was performed n=1.
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but was within a similar range of the GLUT4myc-3x mutant in both transport (86.2 ± 8.4 
fmol/µg/min (Table 4.1) versus 77.4 ± 7.4 fmol/µg/min (Table 3.1)) and surface 
expression (Figure 4.4B). The surface expression of GLUT4myc-cG1 is still less than 
that of wtGLUT1myc. Upon characterization, we observe that this C-terminal 
substitution is without effect on trans-acceleration; GLUT4myc-cG1 does not display 
accelerated exchange (Figure 4.3 and Table 4.1). This is expected, as we have previously 
shown that the C-terminal half of the protein is not involved in trans-acceleration (288). 
However, when we substitute the sequence of GLUT3 (189GFTIL193/199SAA201 for 
GLUT4 208GLTVL212/218LVL220), which displays trans-acceleration, into the GLUT4myc-
cG1 scaffold (GLUT4 (6, G3)), we observe a trans-acceleration gain-of-function (Figure 
4.3).
Analysis of kcat/Km for Class I TM6 GLUT1 and GLUT4 mutants
 In order to characterize whether the GLUT2 and GLUT3 sequence substitutions 
within TM6 cause changes to kcat, it was necessary to measure relative surface expression 
of each transporter and scale the rates of uptake, as we have done previously (288). 
Biotinylated cell-surface transporters were pulled down and affinity-purified on 
streptavidin columns. Western blotting analysis with both α-myc and α-GLUT1 C-
terminal antibodies (Figure 4.4A) shows that GLUT1myc exhibits the highest level of 
surface expression. Quantitation of the α-myc bands by densitometry (Figure 4.4B) 
reveals that the surface expression of the GLUT2 TM6 mutant of GLUT1 is 62 ± 5% 
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 Figure 4.3  Comparison of transport by GLUTs 1 and 4 containing GLUTs 2-3 
TM6 sequence substitutions 
Normalized uptake of 100 µM 2-DG/40 mM 3-MG (ordinate) under zero-trans (ZT, 0 
mM 3-MGi; empty bars) or hetro-exchange (HE, 40 mM 3MGi; shaded bars) conditions 
into HEK cells transfected with GLUT1myc, GLUT4myc containing the C-terminal 32 
amino acids of GLUT1 (GLUT4-cG1), GLUT1myc containing the TM6 sequence of 
GLUT2 (GLUT1 (6, G2)), or GLUT4myc-cG1 containing the TM6 sequence of GLUT3 
(GLUT4 (6, G3)) (abscissa). The value for normalized uptake was obtained by 
normalizing HE uptake to ZT for each transfected construct. Uptake was measured at 5 
minutes at 37°C, and basal uptake by mock-transfected cells was subtracted from each 
data point. Data are plotted as mean ± SEM for four separate assays. An unpaired, 2-
tailed Student’s t-test yields the following P value: ***** P ≤ 0.00001.
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Figure 4.4  Cell-surface expression of GLUT1, GLUT4-cG1, and mutations to 
TM6 
A, HEK cells were transfected with the construct indicated. Two days later, cell surface 
proteins were biotinylated, solubilized and affinity-purified on streptavidin beads. 
Transfected constructs were detected by α-myc and α-GLUT1 C-terminal antibodies. As 
a loading control, the α-subunit of the Na+,K+-ATPase was detected with α-Na+,K+-
ATPase (α−subunit). The mobility of molecular weight standards is indicated. 
Transfected constructs that were investigated in additional experiments are shown in 
bold. B, Data obtained in the above experiment and two similar experiments were 
analyzed by densitometry, background corrected, normalized to loading controls, and 
averaged. The average density of α-myc bands normalized to GLUT1myc (ordinate) is 
plotted for the constructs of interest (abscissa). Data are plotted as mean ± SEM for three 
separate assays. The significance between the expression of each TM6 mutant relative to 
its scaffold was computed by an unpaired, 2-tailed Student’s t-test yielding the following 
P values: ** P ≤ 0.01; *** P ≤ 0.001.
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relative to GLUT1myc. While the GLUT1 C-terminal substitution in GLUT4myc was 
made to increase its expression, GLUT4myc-cG1 displayed only 52 ± 5% of GLUT1myc
expression. The GLUT3 TM6 substitution in this GLUT4 scaffold showed even lower 
expression, at 25 ± 2% of GLUT1myc expression.
 Using the relative surface expression to scale the zero-trans and hetero-exchange 
rates of transport (Table 4.1), we are able to uncover differences in the kcat of transporters 
mutated in TM6. Upon examining differences in zero-trans rates of uptake (Figure 4.5A), 
we observe that the kcat of GLUT1 (6, G2) shows a 2.3 ± 0.5-fold increase over that of wt 
GLUT1myc. In contrast, the kcat of the gain-of-function mutant, GLUT4 (6, G3), is 
reduced 5.6 ± 3.1-fold from that of GLUT4myc-cG1. However, when the rates obtained 
from hetero-exchange uptake are scaled by the same relative surface expression values, 
no significant difference in kcat is observed among the transporters (Figure 4.5B).
Analysis of GLUT1 domain 6 substitutions in GLUT2
 Although our studies have not characterized the kinetics of transport by the other 
Class I GLUTs, we sought to examine whether TM6 is operant in the trans-acceleration 
profiles of GLUT2 and GLUT3. First, we had to establish whether we could observe the 
expected wild-type behavior of each transporter in the experimental system we 
established based on GLUTs 1 and 4. Due to concerns with the ability to express 
sufficient wtGLUT2 at the surface (289), we performed the same 32-amino acid 
exchange with GLUT1 C-terminal sequence that was used with GLUT4 above. 
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Figure 4.5  Catalytic activity of cell surface GLUT1, GLUT4-cG1, and 
  GLUTs 2-3 TM6 mutants
A, Adjusted zero-trans 100 µM 2DG/40 mM 3-MG uptake (ordinate) into HEK cells 
transfected with GLUT1myc, GLUT1 (6, G2), GLUT4myc-cG1 and GLUT4 (6, G3) 
(abscissa). B, Adjusted hetero-exchange uptake of 100 µM 2DG/40 mM 3-MG uptake 
(ordinate) into HEK cells transfected with GLUT1myc, GLUT1 (6, G2), GLUT4myc-
cG1 and GLUT4 (6, G3) (abscissa). Adjusted rates were obtained by scaling the 
average zero-trans or hetero-exchange rate of each construct by its surface expression 
relative to GLUT1myc (Figure 4.4B). Data are plotted as mean ± SEM for n=3 assays. 
An unpaired, 2-tailed Student’s t-test yields the following P values: *** P ≤ 0.001; 
***** P ≤ 0.00001
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Figure 4.6  Comparison of transport by GLUT2-cG1 containing GLUT1 and 
  GLUT3 TM6 sequence substitutions
Normalized uptake of 100 µM 2-DG/40 mM 3-MG (ordinate) under zero-trans (ZT, 
0 mM 3-MGi; empty bars) or hetro-exchange (HE, 40 mM 3-MGi; shaded bars) 
conditions into HEK cells transfected with GLUT1myc, GLUT2myc containing the 
C-terminal 32 amino acids of GLUT1 (GLUT2-cG1), GLUT2-cG1 containing the 
TM6 sequence of GLUT1 (GLUT2 (6, G1)), or GLUT2-cG1 containing the TM6 
sequence of GLUT3 (GLUT2 (6, G3)) (abscissa). The value for normalized uptake 
was obtained by normalizing HE uptake to ZT for each transfected construct. Uptake 
was measured at 5 minutes at 37°C, and basal uptake by mock-transfected cells was 
subtracted from each data point. Data are plotted as mean ± SEM for n=3 assays. An 
unpaired, 2-tailed Student’s t-test yields the following P values: *** P ≤ 0.001; 
***** P ≤ 0.00001.
N
or
m
al
iz
ed
 U
pt
ak
e 
(%
)
GL
UT
1 Z
T
GL
UT
1 H
E
GL
UT
2-c
G1
 ZT
GL
UT
2-c
G1
 H
E
GL
UT
2 (
6, 
G1
) Z
T
GL
UT
2 (
6, 
G1
) H
E
GL
UT
2 (
6, 
G3
) Z
T
GL
UT
2 (
6, 
G3
) H
E
0
100
200
300
*************
Normalized Uptake of GLUT2-cG1 Containing
TM6 Sequence of GLUT1/GLUT3
150
When we tested GLUT2myc-cG1, as expected, we observed no trans-acceleration (Figure 
4.6 and Table 4.1). Using the same chimeric strategies employed in earlier experiments, 
we substituted the TM6 sequence of GLUT1 191SIIFI195/202CIV204 or GLUT3 
189GFTIL193/199SAA201 into GLUT2 sub-regions A and B sequence (GLUT2 
223GLSGV227/233SLL235). Upon testing these chimeras, we observe that substitutions of 
TM6 sub-regions from both GLUT1 and GLUT3 cause a trans-acceleration gain-of-
function in GLUT2myc-cG1 (Figure 4.6).
Analysis of trans-acceleration in GLUT3
 In earlier studies aimed at elucidating regions of GLUT1 involved in trans-
acceleration, we had tested two existing constructs in the laboratory containing 
substitutions of GLUT3 TMs 4-6 sequence in GLUT1 with an addition of the final C-
terminal 13 amino acids of GLUT4 (1311+cG4), and complete GLUT3 sequence with an 
addition of the final C-terminal 13 amino acids of GLUT4, used as an epitope tag 
(GLUT3+cG4). Both of these constructs displayed trans-acceleration under standard HE 
versus ZT transport analysis (Figure 4.7 and Table 4.1). Based on the above results in 
GLUT2, we sought to test whether substitutions of GLUT2 and GLUT4 sequences into 
GLUT3 TM6 would result in a loss-of-function. However, when these constructs were 
engineered, they were based upon a new GLUT3 scaffold containing both the myc tag 
and a substitution of the C-terminal GLUT1 32 amino acids, for the sake of consistency 
with previous GLUT2- and GLUT4-based scaffolds. Unexpectedly, GLUT3myc-cG1 
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Figure 4.7  Comparison of transport by GLUT3+cG4 and GLUT1+cG4 
  containing GLUT3 TMs4-6 sequence substitution
Normalized uptake of 100 µM 2-DG/40 mM 3-MG (ordinate) under zero-trans (ZT, 0 
mM 3-MGi; empty bars) or hetro-exchange (HE, 40 mM 3-MGi; shaded bars) 
conditions into HEK cells transfected with GLUT1myc, GLUT3 with the addition of 
the C-terminal 13 residues of GLUT4 (GLUT3+cG4), GLUT1myc containing the C-
terminal addition of GLUT4 and TMs 4-6 sequence of GLUT3 (1311+cG4) (abscissa). 
The value for normalized uptake was obtained by normalizing HE uptake to ZT for 
each transfected construct. Uptake was measured at 5 minutes at 37°C, and basal 
uptake by mock-transfected cells was subtracted from each data point. Data are plotted 
as mean ± SEM for n=3 assays. An unpaired, 2-tailed Student’s t-test yields the 
following P value: ***** P ≤ 0.00001.
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does not display trans-acceleration in the same conditions under which GLUT3+cG4 
showed trans-acceleration (Figure 4.8A). We reasoned that the only major difference in 
these constructs was the C-terminal sequence, and that it would be best to proceed with a 
wt GLUT3 sequence in future experiments. However, the wt GLUT3myc construct still 
does not show trans-acceleration in our experimental system (Figure 4.8B). We tested this 
construct under normal assay conditions (5 min uptake) and also at a shorter time point (2 
min). This implies that the experimental methods developed for measuring trans-
acceleration in a GLUT1-based system are inadequate to measure the more rapid kinetics 
observed with GLUT3-mediated transport.
Discussion
 Taken together, the similarities in Class I glucose transporter substrate specificity 
and differences in both affinities and sequence conservation raise several questions. First, 
although we have shown that TM6 sequence is critical for trans-acceleration in GLUTs 1 
and 4, we have hypothesized that this is due to a modification in kcat of the transporter 
during zero-trans sugar uptake. While this is supported by experimental data reporting 
values for kcat/Km , it assumes that modifications to TM6 do not affect the affinity of the 
transporter for substrate. Despite data from other studies reporting that residues within 
TM7 and nearby loops are involved in GLUT substrate specificity (199), (99), (100), 
clearly there exists a range of operational affinities for a single substrate among different
153
N
or
m
al
iz
ed
 U
pt
ak
e 
(%
)
GL
UT
1 Z
T
GL
UT
1 H
E
GL
UT
3-c
G1
 ZT
GL
UT
3-c
G1
 H
E
0
50
100
150
200
250
**
Normalized Uptake of GLUT3-cG1 at 5 min 
N
or
m
al
iz
ed
 U
pt
ak
e 
(%
)
GL
UT
1 Z
T
GL
UT
1 H
E
GL
UT
3 Z
T (
5 m
in)
GL
UT
3 H
E (
5 m
in)
GL
UT
3 Z
T (
2 m
in)
GL
UT
3 H
E (
2 m
in)
0
50
100
150
200
250
Normalized Uptake of wt GLUT3myc 
at 5 min and 2 min
**
A
B
154
Figure 4.8  Comparison of transport by GLUT3myc containing GLUT1 or wt 
  C-terminal sequence
A, Normalized uptake of 100 mM 2-DG/40 mM 3-MG (ordinate) under zero-trans (ZT, 0 
mM 3-MGi; empty bars) or hetro-exchange (HE, 40 mM 3-MGi; shaded bars) conditions 
into HEK cells transfected with GLUT1myc or GLUT3myc containing the C-terminal 32 
amino acids of GLUT1 (GLUT3-cG1) (abscissa). Data are plotted as mean ± SEM for 
n=3 assays. An unpaired, 2-tailed Student’s t-test yields the following P value: ** P ≤ 
0.01. B, Normalized uptake of 100 mM 2-DG/40 mM 3-MG (ordinate) under zero-trans 
(ZT, 0 mM 3-MGi; empty bars) or hetro-exchange (HE, 40 mM 3-MGi; shaded bars) 
conditions into HEK cells transfected with GLUT1myc or wt GLUT3myc (abscissa). 
Uptake was measured for the time indicated at 37°C, and basal uptake by mock-
transfected cells was subtracted from each data point. The value for normalized uptake 
was obtained by normalizing HE uptake to ZT for each transfected construct.
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transporters. In order to confirm that kcat is changed by substitutions of TM6 sequence, it 
required investigation of whether the Km remained unaffected by these changes.
 Second, if the 8 disparate amino acids between GLUTs 1 and 4 represent the only 
major variation in TM6 sequence among the Class I GLUTs, can substitution of the 
sequences from GLUTs 2 and 3 cause associated trans-acceleration loss- and gain-of-
function in GLUT1 and GLUT4, respectively? If so, is the same change in zero-trans kcat 
observed for these substitutions? In addition, can the inverse substitutions of GLUTs 1 
and 4 sequence into GLUTs 2 and 3 result in commensurate trans-acceleration gain- and 
loss-of-function? 
 In this study, we sought to further characterize mutations to TM6 within the Class 
I glucose transporters. First, we showed that the Km for substrate (2-DG) of the GLUT1 
TM6 mutant was similar to that of wt GLUT1. To complement these data, we confirmed 
that the Ki(app) for inhibition of 2-DG uptake was also similar for the competing sugar (3-
MG) used in our studies. Together, these results establish that the catalytic changes 
observed in previous studies (288) are indeed due to TM6-mediated alterations to kcat of 
the transporter, and are not due to changes in carrier affinity for substrate. 
 However, analysis of the dose-response showed a greater Vmax for wt GLUT1 than 
GLUT1 (6, G4), which is unexpected. Previous studies have indicated that the zero-trans 
Vmax of GLUT1 (6, G4) is higher than wt GLUT1 (Table 3.1), which agrees with the 
faster zero-trans turnover observed with this mutant (Figure 3.8B). While it remains 
formally possible that the surface expression of GLUT1 (6, G4) was significantly lower 
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in the 2-DG dose-response experiment, the surface expression of this construct has been 
similar to that of wt GLUT1 in previous studies (Figure 3.8A). Thus the apparent 
differences in Vmax could be further explored with additional experiments that test higher 
concentrations of substrate to ensure that the system saturates, and analysis of 3-MG 
uptake in order to obtain more accurate kinetic measurements.
 We then extended this analysis of TM6 function in GLUT1 and GLUT4 trans-
acceleration and kcat properties by analyzing the substitution of TM6 sequence from the 
other two Class I GLUTs. A substitution of 8 residues from TM6 of GLUT2, which does 
not catalyze trans-acceleration, results in a loss-of-function in GLUT1. This is 
accompanied by an increase of the zero-trans kcat in GLUT1 (6, G2). This same pattern is 
observed with the zero-trans kcat changes in the GLUT4 TM6 mutant of GLUT1 (GLUT1 
(6, G4); Figure 3.8B). However, a substitution of 8 amino acids from TM6 of GLUT3, 
which does catalyze trans-acceleration, results in a gain-of-function in GLUT4. With the 
GLUT4 (6, G3) mutant, we observe a similar decrease in kcat to what we see with the 
GLUT1 TM6 mutant of GLUT4 (GLUT4 (6, G1); Figure 3.8B). 
 In our previous study, we explained the observed differences in zero-trans kcat by 
hypothesizing that TM6 sequence is able to affect catalytic rate by slowing 
conformational changes (e.g. relaxation) in the empty carrier. This could be explained by 
TM6 interacting with residues in proximally arranged transmembrane domains, 
potentially TMs 1 and 3. The strength of interactions between TM6 and other TMs would 
be influenced by the sequence of these 8 amino acids within TM6, and inhibitory 
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sequence would slow the conformational change from e1 to e2. This would explain the 
basis for how trans-acceleration could occur. Binding of an intracellular sugar to e1 could 
cause a structural rearrangement that would weaken the interaction(s) between TM6 and 
other TM(s), allowing e1 to e2 relaxation to progress at the same rate of translocation of 
substrate-bound e2 to e1, causing stimulation of uptake by intracellular sugar. If this were 
the case, one would expect the substitutions in TM6 sequence to be without effect on kcat 
under hetero-exchange conditions, since intracellular sugar is present. This is indeed what 
we observe for all 4 mutations to TM6 in GLUT1 and GLUT4.
 In seeking to extend the analysis of TM6 in trans-acceleration profiles of the other 
Class I transporters, we were able to show that substitution of the two sub-regions from 
GLUT1 or GLUT3 TM6 sequence into GLUT2 resulted in a trans-acceleration gain-of-
function. This supports our hypothesis that TM6 plays a role in trans-acceleration outside 
of GLUTs 1 and 4. However, we did not test whether these modifications to GLUT2 TM6 
sequence resulted in the same changes in kcat pattern observed with the GLUT1 and 
GLUT4 TM6 mutants. Establishing whether the kcat of GLUT2 is affected in the same 
way would further support a role for TM6 in carrier-associated conformational changes in 
the transport cycle.
 In turn, further analysis of GLUT3 is required to determine whether TM6 plays a 
critical role in all Class I transporters. While we were not able to measure trans-
acceleration in wt GLUT3 or GLUT3 containing the C-terminus of GLUT1, we did 
observe trans-acceleration by both full-length GLUT3 with the fusion of the 13 C-
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terminal amino acids of GLUT4, and by GLUT1 containing the TMs 4-6 sequence of 
GLUT3. We hypothesize that the underlying problem may be one of catalytic rate versus 
ability to measure initial rates. Other studies have shown that GLUT3 has a higher 
turnover than any of the other Class I GLUTs, including GLUT1 (290). This is confirmed 
by our zero-trans uptake measurements; GLUT3 shows nearly a 2-fold faster rate of 
uptake than GLUT1 at 5 minutes. We reasoned that perhaps we were attempting to 
characterize kinetics at a time point beyond the window of initial rates. The trans-
acceleration profile was unchanged at the faster time point of 2 minutes. However, the 
rate of basal uptake by GLUT3myc at 2 minutes (Table 4.1) was still ~1.7-fold faster than 
the average GLUT1myc-mediated rate of uptake at 5 minutes. 
 This supports our experimental observations that GLUT3-based kinetics appear to 
be more rapid and thus would require fine-tuning of experimental conditions. At the very 
least, time courses of 2-DG/3-MG uptake at 37°C and dose-responses would have to be 
performed in order to assess the best window for characterization of GLUT3-mediated 
trans-acceleration. The report which established GLUT3-mediated trans-acceleration in 
rat neurons (283) did so at a lower temperature, because transport was too rapid to 
measure accurately at 37°C. Although we employed an excess of 3-MG in our uptakes in 
order to slow uptake at 37°C through competitive inhibition, this may be insufficient for 
measurements of GLUT3-based transport. 
 Interestingly, the C-terminal substitutions in GLUT3 appeared to have an affect 
on the basal rate of zero-trans uptake at 5 minutes. While wt GLUT3myc showed nearly a 
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2-fold increase in Vmax over GLUT1myc, we did not observe this increased rate in 
GLUT3-cG1, whose Vmax was similar to that of wt GLUT1myc (Table 4.1). Indeed, we 
observed this lower Vmax with GLUT3+cG4 as well. The C-termini of GLUTs 1-4 are 
highly variant in sequence and length (Figure 4.9); the C-terminus of GLUT3 is 6 
residues longer than GLUT1. Our observations are supported by studies examining the 
effect of C-terminal sequence on the transport function of GLUT1. Deletion of the C-
terminal 37 amino acids has shown that transport is ablated. With this deletion, the carrier 
is locked in the e1 conformation, implying a role for the C-terminus in transport-
associated conformational changes. (291). Truncations greater than the final 24 C-
terminal residues (468-492) showed similar Km but decreased Vmax in GLUT1, as did 
point mutations at G466E and F467L. However, the point mutant R468L showed a lower 
Km (107).
 Additional studies have tested substitutions of other Class I GLUT C-terminal 
sequences. Analysis of GLUT1 containing the GLUT2 C-terminus showed a ~3.8-fold 
increase in Km and a ~4.3-fold increase in Vmax (289), which are more characteristic of 
GLUT2 than GLUT1 (292). Similarly, a chimera containing the C-terminus of GLUT4 in 
GLUT1 displayed both lower Vmax and Km under equilibrium exchange conditions, which 
are more characteristic of GLUT4-mediated transport (293). The inverse substitution 
(GLUT1 C-terminus in GLUT4) had the inverse effect; a 3- to 5-fold increase in Km was 
observed (294). Both of these GLUT1/GLUT4 C-terminal chimeras showed increased 
turnover rates relative to the wild-type scaffold transporter (293). These results certainly
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GLUT1 K G R T F D E I A S G F R Q G G A S Q S D K T P E E L F H P L G A D S Q V
GLUT2 K G K S F E E I A A E F Q K K S G S A H R P K A A V E M K F L G A T E T V
GLUT3 R G R T F E D I T R A F E G Q A H G A D R S G K D G V M E M N S I E P A K E T T T N V
GLUT4 R G R T F D Q I S A A F H R T P S L L E Q E V K P S T E L E Y L G P D E N D
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Figure 4.9  Alignment of C-terminal sequences of Class I GLUTs
The C-terminal sequence of GLUTs 1-4 is aligned, with the numbering corresponding to 
GLUT1 residues shown on top. The C-terminal sequence of GLUT3 is longer than the 
other Class I GLUTs. Residues which contain basic (blue) or acidic (red) side chains are 
colored accordingly. Phenylalanies (yellow) and prolines (green) are also indicated.
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establish a role for the C-terminal sequence of GLUTs to affect both the turnover and 
affinity for substrate, which would in turn affect the ability to measure other kinetic 
parameters. 
 Previously, Dauterieve et al. showed that substituting the C-terminus of GLUT4 
into the murine isoform of GLUT1 resulted in a loss of accelerated-exchange when the 
chimera was expressed in Xenopus oocytes (293). However, they did not observe a gain-
of-function with the inverse substitution in mouse GLUT4. In direct contradiction of 
these results, we have shown that the C-terminus is not involved in trans-acceleration in 
human GLUTs 1, 2, and 4 ((288) and Figure 4.6). Although we were able to detect trans-
acceleration in GLUT3+cG4, but not with GLUT3-cG1, we hypothesize that this 
difference is due to the experimental parameters not having been optimized for GLUT3.  
Regardless, until procedures are adjusted which allow detection of trans-acceleration in 
wt GLUT3, evaluating the GLUT3-based constructs containing TM6 substitutions of 
GLUTs 2 and 4 sequence is of limited value.
 Despite the Class I mutagenesis resulting in trans-acceleration loss- and gain-of-
function chimeras, no obvious ‘trans-acceleration motif’ is evident upon sequence 
comparison. While analysis of the Class I sequence conservation among mammals could 
provide some insight as to which residues of the disparate TM6 sequence could be the 
most critical in mediating trans-acceleration behavior, it is difficult to draw any 
conclusions without testing the trans-acceleration profile of each species variant. For 
example, the differences in ability to catalyze accelerated-exchange have been reported 
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for the rat isoform of GLUT2 and the rat and mouse isoforms of GLUT3 (208), (283), 
(182). Thus while we can deduce from our results that human GLUT2 also does not 
display trans-acceleration and sequence variation between rat and human GLUT2 is 
without effect, we cannot yet make the same claim for human GLUT3. Once more data in 
different species or heterologous expression systems is obtained, then perhaps such 
sequence comparisons can become more predictive rather than correlative. Although our 
understanding and characterization of trans-acceleration in the Class I glucose 
transporters remains incomplete, the results presented in this study expand the importance 
of TM6 in accelerated-exchange transport. The relation of specific GLUT sequence to 
distinct function is a key to identifying critical motifs in modes of substrate transport 
kinetics and conformational changes during the carrier cycle.
163
CHAPTER V
Conclusions and Future Directions
 Despite over 50 years of kinetic characterization of the human basal glucose 
transporter GLUT1, the phenomenon of accelerated-exchange transport has remained 
unexplained. Possible explanations have included that the observation of trans-
acceleration is an artifact of transport measurement methods, or that this behavior is 
contingent upon cell type and/or modulating cofactors. This thesis offers evidence that 
the ability to catalyze trans-acceleration is a sequence-based, intrinsic quality of glucose 
transporters. 
 In addition, the identification of GLUT1 TM6 as both necessary and sufficient for 
trans-acceleration provides insight into the mechanism of this kinetic phenomenon. We 
hypothesize that the sequence of TM6 affects trans-acceleration through interaction with 
other TM(s) within GLUT1 to alter the rate of relaxation of the carrier in the absence of 
intracellular sugar. When these potential interactions are strong, conformational 
relaxation of the empty carrier (e1 to e2) would be restrained, influencing the rate of zero-
trans sugar entry. However, when intracellular sugar is bound, the conformation of e.S1 
might weaken these TM6-mediated interactions through rearrangement of the substrate-
bound TMs. This would allow translocation to proceed at a faster rate than relaxation. 
Conversely, in transporters containing a TM6 sequence that does not display strong 
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interactions with other TMs, relaxation may proceed at an unimpeded rate equal to that of 
translocation. Thus intracellular sugar would have no effect on these interactions, and 
trans-acceleration would not be observed.
 The TM6 region of the transporter is distinct from those domains implicated thus 
far in interactions with inhibitors, substrates, modulating factors, or other GLUT 
subunits.  As a putative scaffolding domain coordinating the arrangement of the TMs 
forming the sugar translocation pore, TM6 is likely critical for conformational changes 
during the transport cycle. Studies examining the accessibility of TMs by proteolysis 
((130), K. Lloyd and A. Carruthers, unpublished) and covalent modification (78) have 
shown that TM6 is one of the least exposed transmembrane segments of GLUT1, both in 
the presence and absence of substrate. This supports its hypothetical scaffolding role, as 
nearly all of TM6 appears to be buried in the membrane in more than one conformational 
state. This is in direct contrast to the other TMs which are thought to form the sugar 
translocation pore; TMs 1, 2, 4, 5, 7, and 8 are accessible to proteolytic cleavage by 
varying degrees. Transmembrane domains 1 and 8 readily dissociate from the membrane 
upon cleavage, while putative scaffolding domains 6, 3, 9, and 12 display no accessibility 
(with the exception of 1 site in TM3; (130)).
 An extensive cysteine-scanning mutagenesis study of the residues within TM6 
identifies several residues that appear to be crucial for proper transporter function (78). 
This is in contrast to the same analysis of putative scaffolding helix 12, where scanning 
Cys-mutagenesis produced no transport-deficient mutations (133). The cysteine 
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substitutions in TM6 that significantly perturbed or ablated transport function were those 
at positions Ile192, Pro196, Gln200, Gly201, Leu204, and Pro205. Interestingly, with the 
exception of Ile192, these residues are distinct from those we identified to be critical for 
trans-acceleration. Although the I192C mutation resulted in ~80% reduction of transport 
capability over the C-less GLUT1 scaffold transporter, mutation to another residue in the 
trans-acceleration region (S191C) caused a doubling of 2-DG uptake.  It is interesting 
that single Cys mutations at each of these two sites appear to have a profound but 
opposite impact on transporter function, while our substitution of this entire sub-region 
(sub-region A: GLUT1 SIIFI 191-195) was insufficient to cause gain- or loss- of 
accelerated exchange (288). This is likely due to our use of conservative substitutions of 
actual TM6 sequence from other Class I transporters, as opposed to the strategy 
employed in the non-conservative Cys substitutions in a Cys-less transporter scaffold. 
This implies that the transport-deficient Cys-mutants tested by Makepeace and Mueckler 
have defective scaffolding interactions distinct from those we hypothesize to be important 
in trans-acceleration. All of the conservative substitutions we made in TM6 of the Class I 
GLUTs continued to transport sugar. This argues for interactions between residues of 
TM6 and those of other TMs to have different roles in stabilization, coordination, and 
conformational change of the carrier during the transport cycle.
 In order to better understand the role of TM6 in such structural changes, it will be 
necessary to identify which TM(s) interact with different region(s) of TM6. 
Unfortunately, the current threaded model of GLUT1 on GlpT (116) did not report 
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pairings of TM6 residues with those of other proximally placed TMs, explicitly because 
no functional significance had been ascribed to the scaffolding TMs at the time the model 
was published. However, GLUT1 accelerated-exchange loss-of-function has been 
observed in GLUT1 mutants examined in other studies where TM6 has not been changed. 
When Liu et al. examined mutations to the nucleotide-binding motif in TM3, although 
this did not affect ATP interaction with GLUT1, the point mutant Gly111Ala failed to 
show trans-acceleration (235). While we have systematically ruled out a direct role for 
TM3 in trans-acceleration in GLUT1, this study implies the existence of critical 
contact(s) between TM6 and TM3. According to the current threaded model, TM3, along 
with TM1, are the domains located nearest to TM6 (116). We hypothesize that we did not 
observe changes in trans-acceleration capability with TM1 substitutions because of our 
strategy of exchanging GLUT1 and GLUT4 sequence. The conservation of TM1 
sequence between GLUT1 and GLUT4 is high (81% across 31 amino acids). Thus, if 
critical contacts for TM6 exist within this domain, they were likely maintained in our 
chimeras and we were able to observe gain- and loss-of-function with only changes to 
TM6 sequence. 
 Although the sequence conservation between GLUT1 and GLUT4 is lower in 
TM3 (40% across 20 amino acids), it is possible that if critical contacts exist, they were 
either maintained in our chimeras by conserved residues, or that similar motifs (i.e. 
hydrophobic residues) are permitted in contact positions. According to the low-resolution 
TM arrangement model proposed by the extensive Cys-scanning mutagenesis of 
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Makepeace and Mueckler, TM5 may be positioned to make critical contacts with TM6 as 
well (134). Transmembrane domain 5 is also highly conserved between GLUT1 and 
GLUT4 (74% across 31 amino acids), so it is not surprising that our substitutions of TM5 
sequence, alone or in combination with TM6 sequence, did not result in a change of 
accelerated exchange behavior in the scaffold protein.
 One of the next steps toward expanding the role of TM6 in GLUT-mediated trans-
acceleration would be to further characterize TM6 substitutions in GLUTs 2 and 3. While 
we have shown that GLUT1 or GLUT3 TM6 sequence causes a gain-of-function in a 
GLUT2 scaffold, we have not examined whether this elicits the same decrease in zero-
trans kcat we observed with the same sequence substitutions in GLUT4. While this could 
be examined experimentally in a similar manner, one caveat is the presence of the 
GLUT1 C-terminus in the GLUT2 chimera. While we have shown that the C-terminus 
has no direct role in trans-acceleration, several studies (293), (294), (289), (107), (291) 
conclude that changing C-terminal sequence can affect the affinity and turnover of the 
transporter. Unfortunately, modification to the C-terminus is one of the methods we 
began to utilize to increase surface expression of the chimeras. 
 One of the greatest challenges presented by these GLUT chimeras has been 
variation in surface expression and thus low levels of zero-trans sugar uptake, which 
complicates analysis of additional kinetic parameters. While some of the C-terminal 
substitutions aided expression, as in the case of GLUT2-cG1 and GLUT4-cG1 chimeras, 
we also observe that C-terminal GLUT1 substitutions have an effect on GLUT3- and 
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GLUT4-based turnover (Table 4.1). We have hypothesized that our inability to detect 
trans-acceleration in either wt GLUT3 or GLUT3-cG1 is due to a high turnover rate. This 
increase in turnover is inferred from the greater zero-trans Vmax of uptake for both 
constructs, which we found was decreased in full-length GLUT3 fused with the C-
terminus of GLUT4 (Table 4.1). In this construct, we are able to detect trans-acceleration.
 When analyzing GLUT4-cG1, it is evident that the zero-trans kcat (Figure 4.5) is 
~3-fold greater than that of GLUT1. This is in contrast to the GLUT4 and GLUT4-3X 
constructs, which displayed a kcat similar to GLUT1 (Figure 3.8). However, another study 
comparing C-terminal substitutions characterized GLUT1 as having a ~2-fold higher 
turnover than GLUT4, while a GLUT4-cG1 mutant was ~50% faster than GLUT1 (293). 
The disagreement in relative turnover between the studies may be due to differences in 
heterologous expression system (HEK cells versus Xenopus oocytes), substrate (2-DG 
versus 3-MG), or method for measuring surface expression (cell-surface biotinylation 
versus radiolabel incorporation and immunoprecipitation of membrane proteins). Such C-
terminal substitutions add a layer of complexity in comparing turnover in the mutant 
transporters. Despite this, our analysis of changes in relative zero-trans kcat shows the 
same pattern for TM6 substitutions, regardless of whether the chimera contains an altered 
C-terminus. However, future studies may aim to address improvement in chimera surface 
expression through some other means that is without effect on transporter turnover or 
affinity.
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 Because the accurate measurement of transporter at the plasma membrane is 
critical for determination of turnover, our studies would be strengthened by using an 
orthogonal approach for cell-surface quantitation. Several possibilities exist; while 
immunofluorescence (IF) microscopy proved to be merely qualitative (Appendix Figure 
A3.6), confocal microscopy may be able to provide better quantitative imaging. However, 
the same technical issues complicating traditional IF microscopy would likely extend to 
analysis by confocal microscopy. 
 The antibodies currently available for GLUT1 and GLUT4 utilize intracellular 
epitopes, requiring exofacial tags for antibody staining, which may increase the 
possibility of non-specific staining. Although the exclusive detection of surface-tagged 
proteins should be possible by avoiding detergent in treatment of the cells, fixation of 
cells by agents such as formaldehyde or methanol may result in some permeability. This 
increases the risk of signal from non-surface transporter present in vesicles or other 
intracellular compartments. In addition, these techniques are complicated by the 
relatively small size and high density of HEK cells, which grow in multiple adherent 
layers as they reach confluency. While seeding a lower population of cells yields better 
antibody staining and imaging, transfection efficiency declines precipitously when cells 
are below ~90% confluency. Thus the number of cells expressing transfected chimeras is 
very low (~10%) in cells at densities optimized for imaging, and does not accurately 
reflect the transfection efficiency or surface expression extant when transport 
determinations are made.
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 Another approach for transporter surface quantitation would be analysis by flow 
cytometry. While this technique has the same requirement for exofacially tagged proteins, 
the challenges of cell permeation and population density are overcome. Antibody staining 
can be performed on live cells without fixative, and confluent transfected cells may be 
dissociated from adherent layers by addition of non-proteolytic agents for single-cell 
analysis of a suspension. However, the effect of such treatment on long-term cell viability  
and transporter surface expression is not known. Another advantage of this technique is 
that calibration beads have been made with a determined number of IgG binding sites1, 
which permit a direct correlation of fluorescence intensity and amount of bound 
secondary antibody. Thus a standard curve of bound antibody can be established and used 
to calculate number of cell-surface transporters. This may enable more quantitative rather 
than relative assessment of GLUT chimeras at the surface, which would either support or 
further refine our conclusions regarding TM6 sequence and changes in zero-trans 
turnover of the transporter.
 Extension of this work to further investigate TM6 sequence in carrier turnover 
and interactions with other TMs would provide more information to evaluate the current 
models for transport, all of which are consistent with trans-acceleration. However, once 
we determined that substitutions in TM6 did not affect affinity for sugar uptake (Chapter 
IV), we were able to constrain parameters in a mathematical simulation of the transport 
cycle based on the simple carrier. In the case of trans-acceleration, this would extend to 
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1 http://www.bangslabs.com/sites/default/7iles/bangs/docs/pdf/PDS%20814%20Web.pdf
the modified-fixed site carrier as well, as both models offer the same basis for an 
explanation of accelerated-exchange. We did not simulate fixed-site carrier-based 
geminate exchange because this would require, at minimum, additional measurements of 
substrate exit to approximate the affinity of the second binding site. These we could not 
perform with 2-DG, and we have not analyzed TM6 mutant transport of 3-MG alone. 
However, we are able to gain insights into the transport cycle based on evaluating 
predictions of the simple carrier.
Model Predictions and Implications
 In using this mathematical model based on the simple carrier (Figure 5.1 and 
Table 5.1) to examine the transport cycle, arbitrary values were used as inputs, as some of 
these parameters cannot be measured or were not undertaken in the present study. This 
allows examination of the relationships between variables affecting different steps in the 
cycle. However, this model is constrained to reflect our experimentally observed affinity 
for zero-trans uptake of 2-DG (Kzt21 ≈ 0.5-1 mM) and the consistently observed 
magnitude for trans-acceleration under exchange conditions (~1.8- to 2.5-fold).
In order to examine a scenario describing a transporter with characteristics like GLUT4, 
parameters must be adjusted to reflect the absence of trans-acceleration and the presence 
of symmetric transport (Table 5.2). This is accomplished by setting relaxation rates equal 
to translocation rates (Roo = R12 = R21 = Ree), and by requiring that uptake and efflux 
capacities are equal (R21 = R12). When we set these parameters, we observe that the  
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Figure 5.1 King-Altman diagram of the simple carrier transport cycle 
The empty carrier in the exofacial conformation (e2) becomes complexed with substrate S 
(e.S2) in a way described by a dissociation constant (K2) determined as the ratio of the 
rate of dissociation of a substrate from the eS2 complex (b-2) divided by the second order 
rate constant for S2 and e2 association (b2). Once interstitial substrate is bound, 
translocation of substrate occurs and is described by the conformational change of e.S2 to 
e.S1. This is a reversible conformational change – the forward or reverse reactions are 
described by the first order rate constants (k1 or k-1, respectively). Substrate dissociation 
from e.S1 into the cytoplasm yields the empty endofacial carrier (e1), and is described by 
the dissociation constant K1, which is the ratio of the rate of dissociation of substrate 
from the e.S1 complex (b-1) divided by the second order rate constant for substrate-e1 
association (b1). In order for the carrier to import another extracellular substrate, e1 must 
relax back to the e2 state in a reaction described by the first-order rate constant, k0.  
Relaxation is also reversible; e2 can relax to the e1 state via the rate constant, k-0.
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Table 5.1 Definition of Model Constants and Formulas
Parameter Definition Formula
R21 Translocation during uptake (e.S2 to e.S1)
€ 
k0 + k−1
(k0 • k−1)
!
R12 Translocation during efflux (e.S1 to e.S2)
€ 
k−0 + k1
(k−0 • k1)
!
Ree Relaxation (e2 to e1)
€ 
k1 + k−1
(k1 • k−1)
!
Roo Relaxation (e1 to e2)
€ 
k0 + k−0
(k0 • k−0)
!
K Michaelis constant
€ 
K1 •
k0
k1
!
Kzt21 Zero-trans uptake constant
€ 
K • RooR21
Kzt12 Zero-trans efflux constant
€ 
K • RooR12
Kee Carrier isomerization constant
€ 
K • RooRee
If transport is symmetrical (GLUT4), R21=R12. If transport is asymmetrical (GLUT1), R12<R21.
If trans-acceleration occurs, Roo>R21 and R21>R12>Ree.
In the absence of trans-acceleration, k0, k-0 > k0, k-0 when trans-acceleration is not observed.
Velocity constants are computed as 
€ 
1
R ! ; e.g . 
€ 
V ZT 21= 1R21
!
For a passive transporter, the relationship 
 
€ 
Vzt21
Kzt21
=
Vzt12
Kzt12
=
Vee
Kee
 must be satisfied because 
€ 
R12 + R21 = Roo + Ree !
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The relative magnitude of the relaxation rates (k0 and k-0) are constrained through the following 
relationships:
Table 5.2 Parameters Illustrating a System without Trans-Acceleration or 
Asymmetry 
Parameter Value Parameter Value
k0 20 min-1 Kzt21 0.67 mM
k-0 20 min-1 Kzt12 0.67 mM
k1 20 min-1 Kee 0.67 mM
k-1 20 min-1 Vzt21 10 mM L-1min-1
b1 30 mM-1min-1 Vzt12 10 mM L-1min-1
b-1 20 min-1 Vee 10 mM L-1min-1
b2 30 mM-1min-1 R21 0.1 min mM-1L-1
b-2 20 min-1 R12 0.1 min mM-1L-1
K1 0.67 mM Ree 0.1 min mM-1L-1
K2 0.67 mM Roo 0.1 min mM-1L-1
Y 20 K 0.67 mM
175
Where Y is a constant of equality relating translocation, relaxation and binding rates defined as:
(Equation 5.1)
Rearrangement of the terms solves for the rate of relaxation (k-0) as dependent on Y and the ratio 
of substrate binding rates inside and outside the cell:
(Equation 5.2)
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intracellular and extracellular dissociation constants (K2 and K1) must be equal in order 
for the rate constant for relaxation (k-0) to be equal to the rates of the other transitions (k0, 
k1, k-1). Even though the rates of substrate binding (b1 and b2) may be slower than the 
rates of dissociation (b-1 and b-2), their ratios must remain the same in order to model a 
system without trans-acceleration or asymmetry. 
 In contrast, GLUT1 displays both trans-acceleration and asymmetry. In this 
scenario (Table 5.3), trans-acceleration is reflected as a slower rate of relaxation (1/Roo) 
than either uptake or exit (1/R21, 1/R12). In this case, we have modeled a 2.5-fold 
stimulation of uptake under exchange conditions versus zero-trans conditions (Vee = 2.5 
Vzt21), which is within the range of trans-acceleration we have observed experimentally. 
To accomplish trans-acceleration and asymmetry (Vzt21 < Vzt12 < Vee), it is required that 
Ree < R12 < R21 < Roo and k-0 < k0, and K1 must be greater than the extracellular binding 
constant, K2. If the dissociation of bound substrate from e.S2 and e.S1 occurs at the same 
rate, this requires that the rate of substrate binding to e1 is slower than binding to e2 (b1 < 
b2). If the rate of substrate binding is equal at both surfaces, then the rate of dissociation 
must be faster on the inside (b-1 > b-2). Adjusting the intracellular substrate dissociation 
constant K1 to be two times greater than K2 is the only way that forces the rate of 
relaxation to be slower, as defined in Equation 5.2.
 The main conclusion of this model is the unexpected finding that the rates of 
binding and relaxation appear to be inter-dependent. When relaxation and translocation 
rates are equal, the asymmetry of binding is lost. This is particularly interesting in the 
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Table 5.3 Parameters Illustrating a System with Trans-Acceleration and 
  Asymmetry 
Parameter Value Parameter Value
k0 5 min-1 Kzt21 0.67 mM
k-0 10 min-1 Kzt12 1 mM
k1 20 min-1 Kee 1.5 mM
k-1 20 min-1 Vzt21 4 mM L-1min-1
b1 30 mM-1min-1 Vzt12 6.67 mM L-1min-1
b-1 60 min-1 Vee 10 mM L-1min-1
b2 20 mM-1min-1 R21 0.25 min mM-1L-1
b-2 20 min-1 R12 0.15 min mM-1L-1
K1 2 mM Ree 0.1 min mM-1L-1
K2 1 mM Roo 0.3 min mM-1L-1
Y 15 K 0.5 mM
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context of the role we have defined for TM6 in trans-acceleration. While we have 
presented our hypothesis that TM6 affects the relaxation rate of the empty carrier through 
interactions with other proximal transmembrane domains, TM6 must also affect substrate 
binding, presumably by altering the rate at which e1 and e2 become available for
substrate. Although TM6 is a putative scaffolding domain and unlikely to bind substrate 
directly, the interactions of TM6 with other TMs may impact the exposed regions of the
TMs forming the sugar translocation pore. This would in turn influence rates of substrate 
binding or dissociation, and could explain why changes to TM6 sequence that equalize 
isomerization rates of the inward- and outward-facing unliganded carrier also allow equal 
substrate binding rates on both sides of the membrane. In contrast, if transporters 
displaying trans-acceleration are more structurally constrained by the sequence of TM6, 
this would slow both relaxation of the empty carrier and affect the availability of 
substrate binding sites. According to our model, both of these conditions must occur in 
accelerated-exchange transport.
 In order to test this hypothesis definitively, it will be necessary to obtain 
additional experimental transport measurements, particularly those for exit (R12) and a 
comparison of the affinity constants under zero-trans (Kzt12 and Kzt21) and exchange 
conditions (Kee). This requires use of a sugar analog other than 2-DG, which is 
metabolically trapped inside the cell and thus precludes measurement of exit or exchange 
parameters. Ideally, 3-MG would be used to further test the predictions of this model in a 
system expressing GLUT1, GLUT4, and the TM6 substitution chimeras of each. These 
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experiments may prove more technically challenging, as transport of 3-MG is extremely 
rapid. Reliable measurements of initial transport rates must be performed at ice 
temperature, and may require cells with a larger equilibration volume than HEKs. In 
addition, variable surface expression of these chimeras would also complicate detailed 
kinetic analysis. This argues for the development of stably transfected cell lines for each 
construct, which would then require careful establishment of parameters for comparing 3-
MG transport kinetics, such as time courses and dose-responses.
 Many studies have focused on mutations of GLUT transmembrane domains in the 
sugar translocation pathway to examine their potential roles in substrate interaction, 
affinity and specificity. In contrast, the work present in this thesis examines a novel role 
for a scaffolding domain in affecting intrinsic rates of the transport cycle. Although the 8 
TMs of the sugar translocation pore are coordinated by 4 scaffolding TMs, none of these 
scaffolding TMs has been previously assigned a role in transporter function. The 
importance of scaffolding domain sequence in modulating GLUT characteristics is 
supported by work from this laboratory showing that the scaffolding TM9 is critical for 
oligomerization of the transporter (Levine et al., in preparation). These studies clearly 
show that the range of operational activity among the GLUTs is determined by distinct 
regions of the protein, implying that different kinetic qualities of a transporter can be 
tuned separately from others. 
 Although the elucidation of such structure-function relationships is interesting to 
the characterization of glucose transporters, there are broader implications for the study 
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of other transport proteins as well. For example, the monocarboxylate transporters 
(MCTs) are critical for the symport of lactate and H+ in a multitude of tissues (4). While 
not all of the MCTs have been well-characterized, both MCT1 and MCT4 have shown 
trans-acceleration on the same orders of magnitude presented in this work (1.5- to 2.5-
fold stimulation; (43), (295)). The accelerated-exchange observed by MCTs 1 and 4 can 
be stimulated by either substrate, lactate or H+. This is thought to occur through allosteric 
modulation of the affinity in the second catalytic site upon binding of the first substrate. 
While we do not argue a substrate-based allosteric modulation of binding site affinity in 
our above model, it is interesting that the current model for MCT accelerated-exchange 
also explains this phenomenon by both an impeded relaxation of the empty carrier and a 
change in substrate binding (4). 
 Although MCTs are also members of the Major Facilitator Superfamily of 
transporters, their sequence homology to other members is also quite divergent (i.e. 
MCT shows 10-15% sequence identity with GlpT and LacY). However, the same 
argument for assumption of similar transmembrane domain arrangement and topology in 
the MFS-based GLUT modeling studies can be extended to MCTs as well. In fact, like 
GLUTs 1 and 3, a putative structure for MCT1 has also been proposed by homology 
modeling on the GlpT crystal structure (296). Transmembrane domain 6, along with 
TM3, is also a putative scaffolding domain in MCT1 (297). These two scaffolding 
domains have been hypothesized to interact with the MCT1-associated cofactor basigin 
(CD147; (297)). Basigin acts as a chaperone to assist MCT1 localization to the plasma 
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membrane (298), but its continued interaction with MCT1 and MCT4 is also important 
for transport activity (299). It is tempting to speculate that this cofactor may affect MCT 
conformational changes by coordinating scaffolding domains of the transporter.
 It would be interesting to determine which of the other MCTs display accelerated 
exchange transport, in addition to completing this analysis in the Class II and III GLUTs. 
While TM6 may not be operant in trans-acceleration among all these transporter 
isoforms, it is possible that a symmetric or homologous scaffolding domain is critical for 
this behavior. Further sequence comparisons among transporters that catalyze trans-
acceleration may add to the understanding of interactions between TMs and their impact 
on the carrier transport cycle. Furthermore, extending this analysis to include comparing 
endogenous expression patterns of trans-accelerating carriers may yield additional 
insights. For example, MCTs also exhibit tissue-specific distribution. While both MCT1 
and MCT4 display accelerated-exchange, MCT1, like GLUT1, is a basally expressed 
transporter with high levels detected in erythrocytes and oxidative muscle cells. MCT4, 
however, is expressed mostly in glycolytic cells of the heart and muscle (300). While not 
enough information is currently available, the continued characterization of differences in 
transporter kinetics and distribution will provide insight into the adaptive advantages of 
the distinct expression of transporter isoforms. While the variety of transporter substrate 
specificity, affinity, and catalytic efficiency are critical to the global homeostasis of 
metabolites, capacity for accelerated-exchange transport may be as well.
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 The physiological significance of trans-acceleration could be analyzed further 
through genetic manipulation of a model organism. For example, the loss-of-function 
GLUT1 (6, G4) mutant transporter could be expressed in transgenic mice, particularly in 
tissues where rapid equilibration is hypothesized to be critical (e.g. muscle cells, or 
endothelial barriers in the brain, retina, placenta, or lactating mammary gland). Possible 
phenotypes would include decreased function at these sites, such as impaired muscle 
contraction or endurance, seizures, loss of consciousness, impaired vision, retardation of 
fetal growth, or decreased milk production. Such in vivo studies would only serve to 
underscore both the importance of rapid equilibration in global glucose homeostasis, and 
the related expression and function of transporters which catalyze trans-acceleration.
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APPENDIX
Table A1 Primers Used in Molecular Cloning and Mutant Construct Creation
Construct Primer(s) 
WT GLUT1 
5’FWD EcoRV
CGATATCATGGAGCCCAGCAGCAAG
WT GLUT1 
3’REV Not1
AGCGGCCGCTCATCACACTTGGGAATC
GLUT1 myc 
5’FWD
GAGCAAAAGCTTATTTCTGAAGAGGACTTGCTGCCCACCACGCT
CACC
GLUT1 myc 
3’REV
CAAGTCCTCTTCAGAAATAAGCTTTTGCTCGATGCTCTCCCCATA
GCG
WT GLUT4 5’FWD EcoRV CGATATCATGCCGTCGGGCTTC
WT GLUT4 3’REV Not1 AGCGGCCGCTCATCAGTCGTTCTCATC 
GLUT4 myc 5’FWD GAGCAAAAGCTTATTTCTGAAGAGGACTTGCCTCCAGGCACCCT
CACC
GLUT4 myc 3’REV CAAGTCCTCTTCAGAAATAAGCTTTTGCTCGATGGAGCTGGGTCC
CTC
GLUT4 F5A Quick Change 
5’FWD
GCAGATATGCCGTCGGGCGCCCAACAGATAGGCTCCGAAGATGG
G
GLUT4 LL489/490AA
Quick Change 
5’FWD
CCTTCCACCGGACACCCTCTGCTGCAGAGCAGGAGGTGAAACCC
GLUT4 F5A 
5’FWD EcoRV
CGATATCATGCCGTCGGGCGCC
11(1)44 5’FWD CTGGAGCTGTTCCGCTCCCCCACCCA
WT GLUT1 5’FWD EcoRV
11(1)44 3’REV GATCAGGGGCTGCCGGTGGGTGGGG
WT GLUT4 3’REV Not1
11(4)44 5’FWD TGCATCGTGCTGCCCTTCTGCCCCGA
WT GLUT1 5’FWD EcoRV
11(4)44 3’REV GAGGTAGCGGGGGCTCTCGGGGCAG
WT GLUT4 3’REV Not1
44(1)11 5’FWD CTGGTCCTGCTGCCCTTCTGTCCCGA
GLUT4 F5A 5’FWD EcoRV
44(1)11 3’REV CAGGAAGCGGGGACTCTCGGGACAG
WT GLUT1 3’REV Not1
44(6)11 5’FWD CTCCAGCTCCTGGGCAGCCGTGCCT
GLUT4 F5A 5’FWD EcoRV
44(6)11 3’REV GAGGATGGGCTGGCGGTAGGCACGG 
WT GLUT1 3’REV Not1
1444 5’FWD TCGAAACTGGGCAAGTCCTTTGAAAT
WT GLUT1 5’FWD EcoRV
1444 3’REV TCGTCCAAGGATGAGCATTTCAAAGG
WT GLUT4 3’REV Not1
4111 5’FWD GCCAATGCTGCTGCCTCCTATGAGAT
GLUT4 F5A 5’FWD EcoRV
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4111 3’REV GCGGCCCAGGATCAGCATCTCATAG
WT GLUT1 3’REV Not1
1411 5’FWD WT GLUT1 5’FWD EcoRV 
1444 5’FWD
44(1)11 5’FWD
1411 3’REV 1444 3’REV
44(1)11 3’REV
WT GLUT1 3’REV Not1
4144 5’FWD GLUT4 F5A 5’FWD EcoRV
4111 5’FWD
11(4)44 5’FWD
4144 3’REV 4111 3’REV
11(4)44 3’REV
WT GLUT4 3’REV Not1
G4 (4/5) 5’FWD GLUT4 F5A 5’FWD EcoRV
4111 5’FWD
ATGGGCAACAAGGACCTGTGGCCAC
G4 (4/5) 3’REV 4111 3’REV
TGTGAGGCCCAGGAGCAGTGGCCAC
WT GLUT4 3’REV Not1
G4 (5/6) 5’FWD GLUT4 F5A 5’FWD EcoRV
GTGGGGGAGATTGCTCCCACTGCCC
11(4)44 5’FWD
G4 (5/6) 3’REV GCCCAGGGCCCCACGAAGGGCAGTG
11(4)44 3’REV
WT GLUT4 3’REV Not1
G4 (5) 5’FWD GLUT4 F5A 5’FWD EcoRV
G4 (5/6) 5’FWD
G4 (4/5) 5’FWD
G4 (5) 3’REV G4 (5/6) 3’REV
G4 (4/5) 3’REV
WT GLUT4 3’REV Not1
G4 (6) 5’FWD GLUT4 F5A 5’FWD EcoRV
CTGGGCACTGCCAGCCTGTGGCCCC
11(4)44  5’FWD
G4 (6) 3’REV GATGATGCTCAGCAGCAGGGGCCAC
11(4)44 3’REV
WT GLUT4 3’REV Not1
G1 (6) 5’FWD WT GLUT1 5’FWD EcoRV
G4 (4/5) FWD
44(1)11 5’FWD
G1 (6) 3’REV G4 (4/5) 3’REV
44(1)11 3’REV
WT GLUT1 3’REV Not1
GLUT1 SIIFI 191-195 GLTVL
Quick Change 5’FWD
TGGCCCCTGCTGCTGGGCCTCACAGTGCTACCGGCCCTGCTG
GLUT1 CIV 202-204 LVL
Quick Change 5’FWD
CCGGCCCTGCTGCAGCTGGTCCTGCTGCCCTTCTGTCCC
GLUT4 GLTVL 208-212 SIIFI
Quick Change 5’FWD
TGGCCACTGCTCCTGAGCATCATCTTCATCCCTGCCCTCCTGCAG
C 
GLUT4 LVL 218-220 CIV
Quick Change 5’FWD
CCTGCCCTCCTGCAGTGCATCGTGCTGCCCTTCTGTCCC  
GLUT2
5’FWD EcoRV
CGATATCATGACAGAAGATAAGGTC 
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GLUT2
3‘REV Not1
AGCGGCCGCTCATTACACAGTCTCTGT  
GLUT2 myc
3’REV
CAAGTCCTCTTCAGAAATAAGCTTTTGCTCATGTCTATAGTGAGA
GLUT2 myc
5’FWD
GAGCAAAAGCTTATTTCTGAAGAGGACTTGGTTTTGGGTGTTCC
ACTG
GLUT2 cG1
5’FWD
ACCAAAGGAAAGTCTTTTGAGGAGATCGCTTCCGGCTT 
GLUT2 cG1
3‘REV Not1
AAGCCGGAAGCGATCTCCTCAAAAGACTTTCCTTTGGT 
WT GLUT3
5’FWD BamH1
CGGATCCATGGGGACACAGAAGGTC
WT GLUT3
3‘REV Not1
AGCGGCCGCTCATTAGACATTGGTGGT
GLUT3 myc
3‘REV 
CAAGTCCTCTTCAGAAATAAGCTTTTGCTCCTTGTCCGTCAAAGT  
GLUT3 myc
5’FWD
GAGCAAAAGCTTATTTCTGAAGAGGACTTGGGAAATGCCCCACC
CTCT
GLUT3 cG1
5’FWD
ACCCGTGGCAGGACTTTTGAGGAGATCGCTTCCGGCTT 
GLUT3 cG1
3‘REV Not1
AAGCCGGAAGCGATCTCCTCAAAAGTCCTGCCACGGGT 
GLUT2 GLSGV 223-227 
SIIFI/SLL 233-235 CIV
5‘FWD EcoRV
AGCATCATCTTCATCAGGGCTATTCTACAATGCATCGTGCTCTTTT
TCTGTCCAGAA 
GLUT2 GLSGV 223-227 
SIIFI/SLL 233-235 CIV
3‘REV Not1
CACGATGCATTGTAGAATAGCCCTGATGAAGATGATGCTAAGCAG
GATGTGCCA
GLUT2 GLSGV 223-227 
GFTIL/SLL 233-235 SAA
5‘FWD EcoRV
GGTTTTACCATCCTTAGGGCTATTCTACAAAGTGCAGCCCTCTTTT
TCTGTCCAGAA
GLUT2 GLSGV 223-227 
GFTIL/SLL 233-235 SAA
3‘REV Not1
GGCTGCACTTTGTAGAATAGCCCTAAGGATGGTAAAACCAAGCA
GGATGTGCCA 
GLUT3 GFTIL 189-193 
GLSGV/SAA 199-201 SLL
5‘FWD BamHI
GGCCTGTCTGGTGTGCCAGCAATTTTGCAGTCTCTGCTACTTCCA
TTTTGCCCTGAA  
GLUT3 GFTIL 189-193 
GLSGV/SAA 199-201 SLL 
3‘REV Not1
TAGCAGAGACTGCAAAATTGCTGGCACACCAGACAGGCCCAGTA
GCAGCGGCCA
GLUT3 GFTIL 189-193 
GLTVL/SAA 199-201 LVL
5‘FWD BamHI
GGCCTCACAGTGCTACCAGCAATTTTGCAGCTGGTCCTGCTTCCA
TTTTGCCCTGAA 
GLUT3 GFTIL 189-193 
GLTVL/SAA 199-201 LVL
3‘REV Not1
CAGGACCAGCTGCAAAATTGCTGGTAGCACTGTGAGGCCCAGTA
GCAGCGGCCA   
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Table A2 Primers Used in Genomic/RT-PCR and Q-PCR GLUT Screens 
Mouse GLUT1 RT 5’FWD GAACCTGTTGGCCTTTGTGGC
Mouse GLUT1 RT 3’REV GCTGGCGGTAGGCGGGTGAGCG
Mouse GLUT4 RT 5’FWD TGCAACGTGGCTGGGTAGGC
Mouse GLUT4 RT 3’REV AGGGAGTACTGTGAGAGCCAG
Mouse GLUT1 Q 5’FWD AGCCCTGCTACAGTGTAT
Mouse GLUT1 Q 3’REV AGGTCTCGGGTCACATC
Mouse EIF1α CAACATCGTCGTAATCGGACA
Mouse EIF1α  GCTTAAGACCCAGGCGTACTT
Human GLUT Genomic/RT- and Q-PCR Primers
GLUT1 RT 5’FWD GCGGAATTCAATGCTGATGA
GLUT1 RT 3’REV TCTTGGCCCGGTTCTCCTCG 
GLUT2 RT 5’FWD TACCTTTACATCAAGTTAGA 
GLUT2 RT 3’REV TAGAATAGGCTGTCGGTAGC
GLUT3 RT 5’FWD CTGCGGACTCTGCACAGGTT 
GLUT3 RT 3’REV TTTCTGTTAATGAGCAAAAA
GLUT4 RT 5’FWD CCCCGCCCGGCAGCCATGGC
GLUT4 RT 3’REV AGAGAGGGTGTCCGGTGGAA
GLUT5 RT 5’FWD AGGCTGACGCTTGTGCTTGC
GLUT5 RT 3’REV TGCCAAATTTATTCACCAAG  
GLUT6 RT 5’FWD AGGGGCGGAGCCTGGCCGGT      
GLUT6 RT 3’REV AGACCAGGGCATACCCAAAG
GLUT7 RT 5’FWD AAAGGGGACCCTGCTGATCA 
GLUT7 RT 3’REV CCGGGTTGCCCAAGATGGCC
GLUT8 RT 5’FWD CGCGCCCCGCGGCCGCCGCG
GLUT8 RT 3’REV AGGCTCAGCTTGCGCCCGGC
GLUT9 RT 5’FWD GGTTTGGTCATTGAGCACCT 
GLUT9 RT 3’REV CTGGCCCACTGCAGAAAGAG 
GLUT10 RT 5’FWD CTGGAGACTCTGGCCTGCTG 
GLUT10 RT 3’REV CCAGTTGAAGCTGTTGCAGA
GLUT11 RT 5’FWD GTGTGAGCATGAACATCCAG
210
GLUT11 RT 3’REV GGGAGGCGAGCTGGAGCGCC
GLUT12 RT 5’FWD TAACTTCTAGCATGAACTGG
GLUT12 RT 3’REV TATAAACATAACAACAAAAA 
GLUT13 RT 5’FWD CAGGTGTGAAAATGAAACCA  
GLUT13 RT 3’REV ATACTCTGCTGTGTGTAAAA
GLUT1 Q 5’FWD ATCGTGGCCATCTTTGGCTTTGTG 
GLUT1 Q 3’REV CTGGAAGCACATGCCCACAATGAA 
GLUT3 Q 5’FWD AGCTCTCTGGGATCAATGCTGTGT  
GLUT3 Q 3’REV ATGGTGGCATAGATGGGCTCTTGA 
GLUT4 Q 5’FWD AAGAATCCCTGCAGCCTGGTAGAA
GLUT4 Q 3’REV CCACGGCCAAACCACAACACATAA  
GLUT6 Q 5’FWD GCTCGGCAATTTCAGCTTTGGGTA 
GLUT6 Q 3’REV  TGGGATTTGGTCAGATGCAGGTCA 
GLUT8 Q 5’FWD AGGGTTTATTCCCATCACTGCCCA    
GLUT8 Q 3’REV TGAGCCCAAGGAAGTAGCCAGAAA
GLUT9 Q 5’FWD TTCTGGCCATCATCGCCTCTTTCT
GLUT9 Q 3’REV GTTGACGGTGCCTGCAATGATGAA 
GLUT10 Q 5’FWD AAGAGACGGTTCACCCTGAGCTTT
GLUT10 Q 3’REV TCCAGAATTTCCAGGCAGACGGAT
GAPDH Q 5’FWD GAAGGTGAAGGTCGGAGTC 
GAPDH Q 3’REV GAAGATGGTGATGGGATTTC
GLUT1MYC 114 Q 5’FWD GGTGATCGAGGAGTTCTACAACCAGA
GLUT1MYC 278 Q 3’REV ACAGAGAAGGAGCCAATCATGC 
GLUT4MYC 158 Q 5’FWD AACAGAGCTACAATGAGACGTGGCTG 
GLUT4MYC 355 Q 3’REV TCCTTCCAAGCCACTGAGAGATGA 
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Table A3 Calculated Product Size of Human GLUT-Specific Genomic Primers 
in PCR Screening of Genomic DNA and RT-PCR Screening of 
RNA 
GLUT Genomic DNA
Product Size (bp)
RT-PCR
Product Size (bp)
mRNA
Detection
1 990 400 Y
2 652 184
3 862/850 242 Y
4 657 223 Y
5 802 259
6 817 267 ?
7 1107 275
8 609/998 248 Y
9 3145 422
10 882 343 Y
11 758 210
12 4824 142 ?
13 4379/386 265
14 1130 173 ?
All product sizes indicated are based on primers reported in Appendix Table A2. For transporters with 
extremely faint product bands (Appendix Figure A3.1) or inability to verify primers via genomic DNA PCR 
screening, specific qPCR primers were designed (Table A2) and these transporters were included in qPCR 
analysis of HEK endogenous transporter expression (Figure 3.2).
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Table A4 Calculated Molecular Weight and Isoelectric Point of Chimeras
Construct Calculated MW (Da) Calculated PI
GLUT1 54084 8.93
GLUT1myc 54787 6.47
GLUT4 55269 8.43
GLUT4myc 55973 5.75
GLUT4myc-3x 55812 5.75
44(1)11 56114 5.94
11(1)44 55204 7.65
44(4)11 55877 6.05
11(4)44 54968 8.19
1444 54728 8.33
4111 56353 5.94
1411 55030 8.55
4144 56052 5.75
GLUT4 (4,5 G1) 55972 5.75
GLUT4 (5,6 G1) 55957 5.75
GLUT4 (5, G1) 55877 5.75
GLUT4 (6, G1) 55892 5.75
GLUT1 (6, G4) 55189 8.48
Molecular weight and isoelectric point were calculated for each chimera sequence using the Bioinformatics 
Resource Portal ExPASy calculator (http://web.expasy.org/compute_pi/).
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Zero Trans vs Hetero-Exchange Uptake of 
100 µM 2-DG in 3T3-L1 Fibroblasts 
D
PM
/µ
g
10
 m
M 
ZT
10
 m
M 
HE
20
 m
M 
ZT
20
 m
M 
HE
40
 m
M 
ZT
40
 m
M 
HE
0
5
10
15
20
A
B
Time Course of 100 µM 2-DG Uptake 
in 3T3-L1 Fibroblasts 
0 2 4 6 8 10
0
10
20
30
40
50
D
PM
/µ
g
Time (min)
214
Figure A3.1 Analysis of hetero-exchange uptake in 3T3-L1 Fibroblasts 
A, Time course of 100 µM 2-DG uptake in 3T3-L1 fibroblasts at 37ºC. Amount of uptake 
of 3[H]-2-DG was corrected for background, normalized to total protein concentration 
(ordinate) and plotted for the length of time of uptake (abscissa). Data are plotted as 
mean ± SEM for n=2 assays. Curves drawn through the data were computed by nonlinear 
regression assuming that uptake is described by Equation 2.1, with R2 = 0.9577. B, 
Comparison of zero-trans and hetero-exchange uptake of 100 µM 2-DG from medium 
containing 10-40 mM 3-MG, normalized to total protein concentration (ordinate) in 
fibroblasts pre-loaded with 10-40 mM 3-MG (abscissa). Data are plotted as mean ± SEM 
for n=2 assays. Uptake was performed at 3 minutes at 37ºC.
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Figure A3.2 Primer verification and RT-PCR screen of GLUTs expressed in HEK 
cells 
A, Genomic primers against all 14 GLUTs were designed such that a PCR screen of HEK 
genomic DNA would yield products of a large size for verification (Appendix Table A2). 
Genomic DNA was prepared according to the Qiagen Genomic DNA Purification kit and 
1 µg DNA per reaction was analyzed by PCR using both Taq (top panel) and Vent 
(bottom panel) polymerases. Products were resolved on a 1.5% ethidium bromide gel and 
visualized by UV light. Target product size bands are boxed in red. B, The same primers 
verified in A were used to analyze HEK mRNA in an RT-PCR screen for smaller size 
products indicative of message (Table A2). HEK mRNA was isolated and prepared 
according to the Qiagen RNeasy kit. RT-PCR was performed according to the Qiagen 
One-Step RT-PCR kit using 1 µg RNA per reaction. Products were resolved on a 1.5% 
ethidium bromide gel and visualized by UV light. Target product size bands are boxed in 
red. In cases where large intron-exon spacing complicated the design of genomic primers, 
multiple primers were tested (i.e. GLUT13). Any RT-PCR products detected in B were 
then screened by qPCR (Figure 3.2). In the case where a genomic primer could not be 
verified or detected in RT-PCR screens (i.e. GLUT12), this transporter was included in 
the qPCR analysis.
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Time Course of 100 µM 2-DG/40 mM 3-MG Hetero-Exchange 
Uptake in GLUT1-Transfected HEK Cells
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Figure A3.3 Time course of 2-DG/3-MG uptake under hetero-exchange 
  conditions 
Uptake of 100 µM 2-DG from medium containing 40 mM 3-MG in GLUT1-transfected 
HEK cells pre-loaded with 40 mM 3-MG. Uptake was corrected for background, mock-
subtracted and normalized to total protein concentration (ordinate), and plotted for the 
length of time of uptake (abscissa). Lines drawn through the data were computed by 
linear regression. Data are plotted as mean ± SEM for n=3 assays. 
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Zero-trans Uptake of 100 µM 2DG in HEK Cells 
Transfected with Increasing [GLUT4myc]
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Figure A3.4 Sugar uptake in HEK cells transfected with increasing [GLUT4] 
 
Zero-trans uptake of 100 µM 2-DG was corrected for background, mock-subtracted, 
normalized to total protein concentration (ordinate) and plotted for HEK cells transfected 
with 1, 2, 4, or 10 µg [GLUT4myc] DNA (abscissa). For reference, the standard amount 
of [GLUT1myc] transfected in all assays (2 µg) was included. Data are plotted as mean ± 
SEM for n=2 assays. 
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Figure A3.5 Verification of cell-surface expression of transporters with 3 
mutations to GLUT4 localization motifs 
HEK cells were either mock-transfected (M) or transfected with GLUT1myc (G1), 
GLUT4myc (G4), or 3 of the surface expression mutants of GLUT4myc (F5A, 
LL489-490AA (LL), or both mutations (2x)). Cells were biotinylated at 4ºC, and surface-
labeled proteins were affinity-purified on streptavidin beads. Lysates were resolved by 
SDS-PAGE and blotted with anti-myc antibody (A). Both anti-GLUT1 C-terminal 
antibody (B) and anti-GLUT4 C-terminal antibody (C) were used to verify identity of the 
construct. Mobility of molecular weight standards is indicated.
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Figure A3.6 Relative expression of myc-tagged transfected construct mRNA by 
qPCR 
Primers designed against both GLUT transporter sequence and the incorporated myc tag 
(Appendix Table A2) were used to analyze the relative amount of transfected message in 
RNA isolated from HEK cells transfected with 2 µg of DNA. RNA was prepared 
according to the Qiagen RNeasy kit and qPCR was performed according to the BioRad 
SYBRgreen qPCR kit. Relative expression normalized to GLUT1 (ordinate) is plotted for 
each of the main constructs used for TM6 comparisons (abscissa). Results are plotted as 
mean ± SEM for n=3 assays. 
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Figure A3.7 Variations in chimera protein expression detected by Western 
blot 
HEK cells were transfected with the constructs indicated and whole cell lysates were 
extracted and resolved by SDS-PAGE. Western blots were dually probed with anti-myc 
antibody (A) and GAPDH antibody as a loading control. The identity of all chimeras was 
also verified by blotting with anti-C-terminal antibodies for GLUT1 and GLUT4. 
Mobility of molecular weight markers is indicated. B, Bands from A were quantitated by 
densitometry. C, HEK cells transfected with the constructs indicated were biotinylated at 
4ºC. Cell-surface proteins were pulled down on streptavidin columns and resolved by 
SDS-PAGE. Cell surface expression of chimeras was detected by blotting with anti-myc 
antibody. Variations in apparent molecular weight of each construct correlate with 
variations in calculated molecular weight and isoelectric point, as determined by 
sequence-based calculations (Appendix Table A4). 
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Figure A3.8 Variations in chimera expression detected by sugar transport 
Zero-trans uptake of 100 µM 2-DG was performed at 5 minutes at 37ºC in HEK cells 
transfected with the constructs indicated (abscissa). Amount of uptake was mock-
subtracted, corrected for background, normalized to total protein content, and normalized 
to uptake by GLUT1myc (ordinate). 
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Figure A3.9 Immunofluorescence microscopy of permeabilized HEK cells 
expressing myc-tagged GLUT1 
Two fields of view at 100x (A, B) representative of areas which showed positive staining 
for GLUT1myc in transfected HEK cells. Cells were fixed with 4% formaldehyde at 4ºC, 
permeabilized with 0.5% Triton X-100 with 1%FBS, and incubated overnight with anti-
myc antibody (9E10 at 1:1000). An alexa 488-conjugated secondary antibody was used to 
detect anti-myc signal (green). Cells were mounted with Vetcashield containing DAPI 
staining (blue) for nuclear localization. Mock-transfected cells showed no alexa 488-
associated signal. Non-permeabilizing modifications to detect only surface myc-tagged 
transporters showed either no staining or diffuse non-specific staining.
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